

DL

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau




(43) International Publication Date
17 June 2004 (17.06.2004)

PCT

(10) International Publication Number
WO 2004/050899 A2

- (51) International Patent Classification⁷: **C12Q**
- (21) International Application Number:
PCT/US2003/038733
- (22) International Filing Date: 3 December 2003 (03.12.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/430,761 3 December 2002 (03.12.2002) US
60/487,474 15 July 2003 (15.07.2003) US
60/517,039 4 November 2003 (04.11.2003) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:
US 60/487,474 (CIP)
Filed on 15 July 2003 (15.07.2003)
US 60/430,761 (CIP)
Filed on 3 December 2002 (03.12.2002)
US 60/517,039 (CIP)
Filed on 4 November 2003 (04.11.2003)
- (71) Applicant (for all designated States except US): **AR-CHEMIX CORPORATION** [US/US]; One Hampshire Street, Cambridge, MA 02139 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **KEEFE, Anthony** [US/US]; 9 Bellis Circle #6, Cambridge, MA 02141 (US). **WILSON, Charles** [US/US]; 229 Lexington Road,
- (54) Title: **METHOD FOR *IN VITRO* SELECTION OF 2'-SUBSTITUTED NUCLEIC ACIDS**
- (74) Agent: **ELRIFI, Ivor, R.**; Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P., C., One Financial Center, Boston, MA 02111 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/050899 A2



(57) Abstract: Materials and methods are provided for producing aptamer therapeutics having modified nucleotide triphosphates incorporated into their sequence. The aptamers produced by the methods of the invention have increased stability and half life.

BEST AVAILABLE COPY

METHOD FOR *IN VITRO* SELECTION OF 2'-SUBSTITUTED NUCLEIC ACIDS

FIELD OF THE INVENTION

[0001] The invention relates generally to the field of nucleic acids and more particularly to aptamers, and methods for selecting aptamers, incorporating modified nucleotides. The invention further relates to materials and methods for enzymatically producing pools of randomized oligonucleotides having modified nucleotides from which, *e.g.*, aptamers to a specific target can be selected.

BACKGROUND OF THE INVENTION

[0002] Aptamers are nucleic acid molecules having specific binding affinity to molecules through interactions other than classic Watson-Crick base pairing.

[0003] Aptamers, like peptides generated by phage display or monoclonal antibodies (MAbs), are capable of specifically binding to selected targets and, through binding, block their targets' ability to function. Created by an *in vitro* selection process from pools of random sequence oligonucleotides (Fig. 1), aptamers have been generated for over 100 proteins including growth factors, transcription factors, enzymes, immunoglobulins, and receptors. A typical aptamer is 10-15 kDa in size (30-45 nucleotides), binds its target with sub-nanomolar affinity, and discriminates against closely related targets (*e.g.*, will typically not bind other proteins from the same gene family). A series of structural studies have shown that aptamers are capable of using the same types of binding interactions (hydrogen bonding, electrostatic complementarity, hydrophobic contacts, steric exclusion, *etc*) that drive affinity and specificity in antibody-antigen complexes.

[0004] Aptamers have a number of desirable characteristics for use as therapeutics (and diagnostics) including high specificity and affinity, biological efficacy, and excellent pharmacokinetic properties. In addition, they offer specific competitive advantages over antibodies and other protein biologics, for example:

[0005] 1) Speed and control. Aptamers are produced by an entirely *in vitro* process, allowing for the rapid generation of initial (therapeutic) leads. *In vitro* selection allows the specificity and affinity of the aptamer to be tightly controlled and allows the generation of leads against both toxic and non-immunogenic targets.

[0006] 2) Toxicity and Immunogenicity. Aptamers as a class have demonstrated little or no toxicity or immunogenicity. In chronic dosing of rats or woodchucks with high levels of aptamer (10 mg/kg daily for 90 days), no toxicity is observed by any clinical, cellular, or biochemical measure. Whereas the efficacy of many monoclonal antibodies can be severely limited by immune response to antibodies themselves, it is extremely difficult to elicit antibodies to aptamers (most likely because aptamers cannot be presented by T-cells via the MHC and the immune response is generally trained not to recognize nucleic acid fragments).

[0007] 3) Administration. Whereas all currently approved antibody therapeutics are administered by intravenous infusion (typically over 2-4 hours), aptamers can be administered by subcutaneous injection. This difference is primarily due to the comparatively low solubility and thus large volumes necessary for most therapeutic MABs. With good solubility (>150 mg/ml) and comparatively low molecular weight (aptamer: 10-50 kDa; antibody: 150 kDa), a weekly dose of aptamer may be delivered by injection in a volume of less than 0.5 ml. Aptamer bioavailability via subcutaneous administration is >80% in monkey studies (Tucker *et al.*, J. Chromatography B. 732: 203-12, 1999). In addition, the small size of aptamers allows them to penetrate into areas of conformational constrictions that do not allow for antibodies or antibody fragments to penetrate, presenting yet another advantage of aptamer-based therapeutics or prophylaxis.

[0008] 4) Scalability and cost. Therapeutic aptamers are chemically synthesized and consequently can be readily scaled as needed to meet production demand. Whereas difficulties in scaling production are currently limiting the availability of some biologics and the capital cost of a large-scale protein production plant is enormous, a single large-scale synthesizer can produce upwards of 100 kg oligonucleotide per year and requires a relatively

modest initial investment. The current cost of goods for aptamer synthesis at the kilogram scale is estimated at \$500/g, comparable to that for highly optimized antibodies. Continuing improvements in process development are expected to lower the cost of goods to < \$100/g in five years.

[0009] 5) Stability. Therapeutic aptamers are chemically robust. They are intrinsically adapted to regain activity following exposure to heat, denaturants, *etc.* and can be stored for extended periods (>1 yr) at room temperature as lyophilized powders. In contrast, antibodies must be stored refrigerated.

[0010] Given the advantages of aptamers as therapeutic agents, it would be beneficial to have materials and methods to prolong or increase the stability of aptamer therapeutics *in vivo*. The present invention provides materials and methods to meet these and other needs.

BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Figure 1 is a schematic representation of the *in vitro* aptamer selection (SELEX™) process from pools of random sequence oligonucleotides.

[0012] Figure 2 shows a 2'-O-methyl (2'-OMe) modified nucleotide, where "B" is a purine or pyrimidine base.

[0013] Figure 3A is a graph of VEGF-binding by three 2'-OMe VEGF aptamers: ARC224, ARC245 and ARC259; Figure 3B shows the sequences and putative secondary structures of these aptamers.

[0014] Figure 4 is a graph of the VEGF-binding by various 2'-OH G variants of ARC224 and ARC225

[0015] Figure 5 is a graph of ARC224 binding to VEGF in HUVEC.

[0016] Figure 6 is a graph of ARC224 binding to VEGF before and after autoclaving, in the presence or absence of EDTA.

[0017] Figures 7A and 7B are graphs of the stability of ARC224 and ARC226, respectively, when incubated at 37 °C in rat plasma.

[0018] Figure 8 is a graph of dRmY SELEX™ Round 6 sequences binding to IgE.

[0019] Figure 9 is a graph of dRmY SELEX™ Round 6 sequences binding to thrombin.

[0020] Figure 10 is a graph of dRmY SELEX™ Round 6 sequences binding to VEGF.

[0021] Figure 11A is a degradation plot of an all 2'-OMe oligonucleotide with 3'-idT, in 95% rat plasma (citrated) at 37 °C, and Figure 11B is a degradation plot of the corresponding dRmY oligonucleotide in 95% rat plasma at 37 °C.

[0022] Figure 12 is a graph of rGmH h-IgE binding clones (Round 6).

[0023] Figure 13A is a graph of round 12 pools for rRmY pool PDGF-BB selection, and Figure 13B is a graph of Round 10 pools for rGmH pool PDGF-BB selection.

[0024] Figure 14 is a graph of dRmY SELEX™ Round 6, 7, 8 and unselected sequences binding to IL-23.

[0025] Figure 15 is a graph of dRmY SELEX™ Round 6, 7 and unselected sequences binding to PDGF-BB.

SUMMARY OF THE INVENTION

[0026] The present invention provides materials and methods to produce oligonucleotides of increased stability by transcription under the conditions specified herein which promote the incorporation of modified nucleotides into the oligonucleotide. These modified oligonucleotides can be, for example, aptamers, antisense molecules, RNAi molecules, siRNA molecules, or ribozymes. Preferably, the oligonucleotide is an aptamer.

[0027] In one embodiment, the present invention provides an improved SELEX™ method ("2'-OMe SELEX™") that uses randomized pools of oligonucleotides incorporating modified nucleotides from which aptamers to a specific target can be selected.

[0028] In one embodiment, the present invention provides methods that use modified enzymes to incorporate modified nucleotides into oligonucleotides under a given set of transcription conditions.

[0029] In one embodiment, the present invention provides methods that use a mutated polymerase. In one embodiment, the mutated polymerase is a T7 RNA polymerase. In one embodiment, a T7 RNA polymerase modified by having a mutation at position 639 (from a tyrosine residue to a phenylalanine residue "Y639F") and at position 784 (from a histidine residue to an alanine residue "H784A") is used in various transcription reaction conditions which result in the incorporation of modified nucleotides into the oligonucleotides of the invention.

[0030] In another embodiment, a T7 RNA polymerase modified with a mutation at position

639 (from a tyrosine residue to a phenylalanine residue) is used in various transcription reaction conditions which result in the incorporation of modified nucleotides into the oligonucleotides of the invention.

[0031] In another embodiment, a T7 RNA polymerase modified with a mutation at position 784 (from a histidine residue to an alanine residue) is used in various transcription reaction conditions which result in the incorporation of modified nucleotides into the aptamers of the invention.

[0032] In one embodiment, the present invention provides various transcription reaction mixtures that increase the incorporation of modified nucleotides by the modified enzymes of the invention.

[0033] In one embodiment, manganese ions are added to the transcription reaction mixture to increase the incorporation of modified nucleotides by the modified enzymes of the invention.

[0034] In another embodiment, 2'-OH GTP is added to the transcription mixture to increase the incorporation of modified nucleotides by the modified enzymes of the invention.

[0035] In another embodiment, polyethylene glycol, PEG, is added to the transcription mixture to increase the incorporation of modified nucleotides by the modified enzymes of the invention.

[0036] In another embodiment, GMP (or any substituted guanosine) is added to the transcription mixture to increase the incorporation of modified nucleotides by the modified enzymes of the invention.

[0037] In one embodiment, a leader sequence incorporated into the 5' end of the fixed region (preferably 20-25 nucleotides in length) at the 5' end of a template oligonucleotide is used to increase the incorporation of modified nucleotides by the modified enzymes of the invention. Preferably, the leader sequence is greater than about 10 nucleotides in length.

[0038] In one embodiment, a leader sequence that is composed of up to 100% (inclusive) purine nucleotides is used.

[0039] In another embodiment, a leader sequence at least 6 nucleotides long that is composed of up to 100% (inclusive) purine nucleotides is used.

[0040] In another embodiment, a leader sequence at least 8 nucleotides long that is

composed of up to 100% (inclusive) purine nucleotides is used.

[0041] In another embodiment, a leader sequence at least 10 nucleotides long that is composed of up to 100% (inclusive) purine nucleotides is used.

[0042] In another embodiment, a leader sequence at least 12 nucleotides long that is composed of up to 100% (inclusive) purine nucleotides is used.

[0043] In another embodiment, a leader sequence at least 14 nucleotides long that is composed of up to 100% (inclusive) purine nucleotides is used.

[0044] In one embodiment, the present invention provides aptamer therapeutics having modified nucleotides incorporated into their sequence.

[0045] In one embodiment, the present invention provides for the use of aptamer therapeutics having modified nucleotides incorporated into their sequence.

[0046] In one embodiment, the present invention provides various compositions of nucleotides for transcription for the selection of aptamers with the SELEXTM process. In one embodiment, the present invention provides combinations of 2'-OH, 2'-F, 2'-deoxy, and 2'-OMe modifications of the ATP, GTP, CTP, TTP, and UTP nucleotides. In another embodiment, the present invention provides combinations of 2'-OH, 2'-F, 2'-deoxy, 2'-OMe, 2'-NH₂, and 2'-methoxyethyl modifications of the ATP, GTP, CTP, TTP, and UTP nucleotides. In one embodiment, the present invention provides 5⁶ combinations of 2'-OH, 2'-F, 2'-deoxy, 2'-OMe, 2'-NH₂, and 2'-methoxyethyl modifications the ATP, GTP, CTP, TTP, and UTP nucleotides.

[0047] The invention relates to a method for identifying nucleic acid ligands to a target molecule, where the ligands include modified nucleotides, by: a) preparing a transcription reaction mixture comprising a mutated polymerase, one or more 2'-modified nucleotide triphosphates (NTPs), magnesium ions and one or more oligonucleotide transcription templates; b) preparing a candidate mixture of single-stranded nucleic acids by transcribing the one or more oligonucleotide transcription templates under conditions whereby the mutated polymerase incorporates at least one of the one or more modified nucleotides into each nucleic acid of the candidate mixture, wherein each nucleic acid of the candidate mixture comprises a 2'-modified nucleotide selected from the group consisting of a 2'-position modified pyrimidine and a 2'-position modified purine; c) contacting the candidate mixture with the target molecule; d) partitioning the nucleic acids having an increased

affinity to the target molecule relative to the candidate mixture from the remainder of the candidate mixture; and e) amplifying the increased affinity nucleic acids, in vitro, to yield a ligand-enriched mixture of nucleic acids.

[0048] The 2'-position modified pyrimidines and 2'-position modified purines include 2'-OH, 2'-deoxy, 2'-O-methyl, 2'-NH₂, 2'-F, and 2'-methoxy ethyl modifications. Preferably, the 2'-modified nucleotides are 2'-O-methyl or 2'-F nucleotides.

[0049] In some embodiments, the mutated polymerase is a mutated T7 RNA polymerase, such as a T7 RNA polymerase having a mutation at position 639 from a tyrosine residue to a phenylalanine residue (Y639F); a T7 RNA polymerase having a mutation at position 784 from a histidine residue to an alanine residue (H784A); a T7 RNA polymerase having a mutation at position 639 from a tyrosine residue to a phenylalanine residue and a mutation at position 784 from a histidine residue to an alanine residue (Y639F/H784A).

[0050] In some embodiments, the oligonucleotide transcription template includes a leader sequence incorporated into the 5' end of a fixed region at the 5' end of the oligonucleotide transcription template. The leader sequence, for example, is an all-purine leader sequence. The leader sequence, for example, can be at least 6 nucleotides long; at least 8 nucleotides long; at least 10 nucleotides long; at least 12 nucleotides long; or at least 14 nucleotides long.

[0051] In some embodiments, the transcription reaction mixture also includes manganese ions. For example, the concentration of magnesium ions is between 3.0 and 3.5 times greater than the concentration of manganese ions.

[0052] In some embodiments of the transcription reaction mixture, each NTP is present at a concentration of 0.5 mM, the concentration of magnesium ions is 5.0 mM, and the concentration of manganese ions is 1.5 mM. In other embodiments of the transcription reaction mixture each NTP is present at a concentration of 1.0 mM, the concentration of magnesium ions is 6.5 mM, and the concentration of manganese ions is 2.0 mM. In other embodiments of the transcription reaction mixture each NTP is present at a concentration of 2.0 mM, the concentration of magnesium ions is 9.6 mM, and the concentration of manganese ions is 2.9 mM.

[0053] In some embodiments, the transcription reaction mixture also includes 2'-OH GTP.

[0054] In some embodiments, the transcription reaction mixture also includes a polyalkylene glycol. The polyalkylene glycol can be, e.g., polyethylene glycol (PEG).

[0055] In some embodiments, the transcription reaction mixture also includes GMP.

[0056] In some embodiments, the method for identifying nucleic acid ligands to a target molecule further includes repeating steps d) partitioning the nucleic acids having an increased affinity to the target molecule relative to the candidate mixture from the remainder of the candidate mixture; and e) amplifying the increased affinity nucleic acids, in vitro, to yield a ligand-enriched mixture of nucleic acids.

[0057] In some aspects, the invention relates to a nucleic acid ligand to thrombin which was identified according to the method of the invention.

[0058] In some aspects, the invention relates to a nucleic acid ligand to vascular endothelial growth factor (VEGF) which was identified according to the method of the invention.

[0059] In some aspects, the invention relates to a nucleic acid ligand to IgE which was identified according to the method of the invention.

[0060] In some aspects, the invention relates to a nucleic acid ligand to IL-23 which was identified according to the method of the invention.

[0061] In some aspects, the invention relates to a nucleic acid ligand to platelet-derived growth factor-BB (PDGF-BB) which was identified according to the method of the invention.

[0062] In some embodiments, the transcription reaction mixture includes 2'-OH adenosine triphosphate (ATP), 2'-OH guanosine triphosphate (GTP), 2'-O-methyl cytidine triphosphate (CTP) and 2'-O-methyl uridine triphosphate (UTP).

[0063] In some embodiments, the transcription reaction mixture includes 2'-deoxy purine nucleotide triphosphates and 2'-O-methyl pyrimidine nucleotide triphosphates.

[0064] In some embodiments, the transcription reaction mixture includes 2'-O-methyl adenosine triphosphate (ATP), 2'-OH guanosine triphosphate (GTP), 2'-O-methyl cytidine triphosphate (CTP) and 2'-O-methyl uridine triphosphate (UTP).

[0065] In some embodiments, the transcription reaction mixture includes 2'-O-methyl adenosine triphosphate (ATP), 2'-O-methyl cytidine triphosphate (CTP) and 2'-O-methyl uridine triphosphate (UTP), 2'-O-methyl guanosine triphosphate (GTP) and deoxy guanosine triphosphate (GTP), wherein the deoxy guanosine triphosphate comprises a maximum of 10% of the total guanosine triphosphate population.

[0066] In some embodiments, the transcription reaction mixture includes 2'-O-methyl adenosine triphosphate (ATP), 2'-F guanosine triphosphate (GTP), 2'-O-methyl cytidine triphosphate (CTP) and 2'-O-methyl uridine triphosphate (UTP).

[0067] In some embodiments, the transcription reaction mixture includes 2'-deoxy adenosine triphosphate (ATP), 2'-O-methyl guanosine triphosphate (GTP), 2'-O-methyl cytidine triphosphate (CTP) and 2'-O-methyl uridine triphosphate (UTP).

[0068] The invention also relates to a method of preparing a nucleic acid comprising one or more modified nucleotides by: preparing a transcription reaction mixture comprising a mutated polymerase, one or more 2'-modified nucleotide triphosphates (NTPs), magnesium ions and one or more oligonucleotide transcription templates; and contacting the one or more oligonucleotide transcription templates with the mutated polymerase under conditions whereby the mutated polymerase incorporates the one or more 2'-modified nucleotides into a nucleic acid transcription product.

[0069] 2'-position modified pyrimidines and 2'-position modified purines include 2'-OH, 2'-deoxy, 2'-O-methyl, 2'-NH₂, 2'-F, and 2'-methoxy ethyl modifications. Preferably, the 2'-modified nucleotides are 2'-O-methyl or 2'-F nucleotides.

[0070] In some embodiments, the mutated polymerase is a mutated T7 RNA polymerase, such as a T7 RNA polymerase having a mutation at position 639 from a tyrosine residue to a phenylalanine residue (Y639F); a T7 RNA polymerase having a mutation at position 784 from a histidine residue to an alanine residue (H784A); a T7 RNA polymerase having a mutation at position 639 from a tyrosine residue to a phenylalanine residue and a mutation at position 784 from a histidine residue to an alanine residue (Y639F/H784A).

[0071] In some embodiments, the oligonucleotide transcription template includes a leader sequence incorporated into the 5' end of a fixed region at the 5' end of the oligonucleotide transcription template. The leader sequence, for example, is an all-purine leader sequence. The leader sequence, for example, can be at least 6 nucleotides long; at least 8 nucleotides long; at least 10 nucleotides long; at least 12 nucleotides long; or at least 14 nucleotides long.

[0072] In some embodiments, the transcription reaction mixture also includes manganese ions. For example, the concentration of magnesium ions is between 3.0 and 3.5 times greater than the concentration of manganese ions.

[0073] In some embodiments of the transcription reaction mixture, each NTP is present at a concentration of 0.5 mM, the concentration of magnesium ions is 5.0 mM, and the concentration of manganese ions is 1.5 mM. In other embodiments of the transcription reaction mixture each NTP is present at a concentration of 1.0 mM, the concentration of magnesium ions is 6.5 mM, and the concentration of manganese ions is 2.0 mM. In other

embodiments of the transcription reaction mixture each NTP is present at a concentration of 2.0 mM, the concentration of magnesium ions is 9.6 mM, and the concentration of manganese ions is 2.9 mM.

[0074] In some embodiments, the transcription reaction mixture also includes 2'-OH GTP.

[0075] In some embodiments, the transcription reaction mixture also includes a polyalkylene glycol. The polyalkylene glycol can be, *e.g.*, polyethylene glycol (PEG).

[0076] In some embodiments, the transcription reaction mixture also includes GMP.

[0077] The invention also relates to an aptamer composition comprising a sequence where substantially all adenosine nucleotides are 2'-OH adenosine, substantially all guanosine nucleotides are 2'-OH guanosine, substantially all cytidine nucleotides are 2'-O-methyl cytidine, and substantially all uridine nucleotides are 2'-O-methyl uridine. In one embodiment, the aptamer has a sequence composition where at least 80% of all adenosine nucleotides are 2'-OH adenosine, at least 80% of all guanosine nucleotides are 2'-OH guanosine, at least 80% of all cytidine nucleotides are 2'-O-methyl cytidine and at least 80% of all uridine nucleotides are 2'-O-methyl uridine. In another embodiment, the aptamer has a sequence composition where at least 90% of all adenosine nucleotides are 2'-OH adenosine, at least 90% of all guanosine nucleotides are 2'-OH guanosine, at least 90% of all cytidine nucleotides are 2'-O-methyl cytidine and at least 90% of all uridine nucleotides are 2'-O-methyl uridine. In another embodiment, the aptamer has a sequence composition where 100% of all adenosine nucleotides are 2'-OH adenosine, at 100% of all guanosine nucleotides are 2'-OH guanosine, 100% of all cytidine nucleotides are 2'-O-methyl cytidine and 100% of all uridine nucleotides are 2'-O-methyl uridine.

[0078] The invention also relates to an aptamer composition comprising a sequence where substantially all purine nucleotides are 2'-deoxy purines and substantially all pyrimidine nucleotides are 2'-O-methyl pyrimidines. In one embodiment, the aptamer has a sequence composition where at least 80% of all purine nucleotides are 2'-deoxy purines and at least 80% of all pyrimidine nucleotides are 2'-O-methyl pyrimidines. In another embodiment, the aptamer has a sequence composition where at least 90% of all purine nucleotides are 2'-deoxy purines and at least 90% of all pyrimidine nucleotides are 2'-O-methyl pyrimidines. In another embodiment, the aptamer has a sequence composition where 100% of all purine nucleotides are 2'-deoxy purines and 100% of all pyrimidine nucleotides are 2'-O-methyl pyrimidines.

[0079] The invention also relates to an aptamer composition comprising a sequence where substantially all guanosine nucleotides are 2'-OH guanosine, substantially all cytidine nucleotides are 2'-O-methyl cytidine, substantially all uridine nucleotides are 2'-O-methyl uridine, and substantially all adenosine nucleotides are 2'-O-methyl adenosine. In one embodiment, the aptamer has a sequence composition where at least 80% of all guanosine nucleotides are 2'-OH guanosine, at least 80% of all cytidine nucleotides are 2'-O-methyl cytidine, at least 80% of all uridine nucleotides are 2'-O-methyl uridine, and at least 80% of all adenosine nucleotides are 2'-O-methyl adenosine. In another embodiment, the aptamer has a sequence composition where at least 90% of all guanosine nucleotides are 2'-OH guanosine, at least 90% of all cytidine nucleotides are 2'-O-methyl cytidine, at least 90% of all uridine nucleotides are 2'-O-methyl uridine, and at least 90% of all adenosine nucleotides are 2'-O-methyl adenosine. In another embodiment, the aptamer has a sequence composition where 100% of all guanosine nucleotides are 2'-OH guanosine, 100% of all cytidine nucleotides are 2'-O-methyl cytidine, 100% of all uridine nucleotides are 2'-O-methyl uridine, and 100% of all adenosine nucleotides are 2'-O-methyl adenosine.

[0080] The invention also relates to an aptamer composition comprising a sequence where substantially all adenosine nucleotides are 2'-O-methyl adenosine, substantially all cytidine nucleotides are 2'-O-methyl cytidine, substantially all guanosine nucleotides are 2'-O-methyl guanosine or deoxy guanosine, substantially all uridine nucleotides are 2'-O-methyl uridine, where less than about 10% of the guanosine nucleotides are deoxy guanosine. In one embodiment, the aptamer has a sequence composition where at least 80% of all adenosine nucleotides are 2'-O-methyl adenosine, at least 80% of all cytidine nucleotides are 2'-O-methyl cytidine, at least 80% of all guanosine nucleotides are 2'-O-methyl guanosine, at least 80% of all uridine nucleotides are 2'-O-methyl uridine, and no more than about 10% of all guanosine nucleotides are deoxy guanosine. In another embodiment, the aptamer has a sequence composition where at least 90% of all adenosine nucleotides are 2'-O-methyl adenosine, at least 90% of all cytidine nucleotides are 2'-O-methyl cytidine, at least 90% of all guanosine nucleotides are 2'-O-methyl guanosine, at least 90% of all uridine nucleotides are 2'-O-methyl uridine, and no more than about 10% of all guanosine nucleotides are deoxy guanosine. In another embodiment, the aptamer has a sequence composition where 100% of all adenosine nucleotides are 2'-O-methyl adenosine, 100% of all cytidine nucleotides are 2'-O-methyl cytidine, at least 90% of all guanosine nucleotides

are 2'-O-methyl guanosine, 100% of all uridine nucleotides are 2'-O-methyl uridine, and no more than about 10% of all guanosine nucleotides are deoxy guanosine.

[0081] The invention also relates to an aptamer composition comprising a sequence where substantially all adenosine nucleotides are 2'-O-methyl adenosine, substantially all uridine nucleotides are 2'-O-methyl uridine, substantially all cytidine nucleotides are 2'-O-methyl cytidine, and substantially all guanosine nucleotides are 2'-F guanosine sequence. In one embodiment, the aptamer has a sequence composition where at least 80% of all adenosine nucleotides are 2'-O-methyl adenosine, at least 80% of all uridine nucleotides are 2'-O-methyl uridine, at least 80% of all cytidine nucleotides are 2'-O-methyl cytidine, and at least 80% of all guanosine nucleotides are 2'-F guanosine. In another embodiment, the aptamer has a sequence composition where at least 90% of all adenosine nucleotides are 2'-O-methyl adenosine, at least 90% of all uridine nucleotides are 2'-O-methyl uridine, at least 90% of all cytidine nucleotides are 2'-O-methyl cytidine, and at least 90% of all guanosine nucleotides are 2'-F guanosine. In another embodiment, the aptamer has a sequence composition where 100% of all adenosine nucleotides are 2'-O-methyl adenosine, 100% of all uridine nucleotides are 2'-O-methyl uridine, 100% of all cytidine nucleotides are 2'-O-methyl cytidine, and 100% of all guanosine nucleotides are 2'-F guanosine.

[0082] The invention also relates to an aptamer composition comprising a sequence where substantially all adenosine nucleotides are 2'-deoxy adenosine, substantially all cytidine nucleotides are 2'-O-methyl cytidine, substantially all guanosine nucleotides are 2'-O-methyl guanosine, and substantially all uridine nucleotides are 2'-O-methyl uridine. In one embodiment, the aptamer has a sequence composition where at least 80% of all adenosine nucleotides are 2'-deoxy adenosine, at least 80% of all cytidine nucleotides are 2'-O-methyl cytidine, at least 80% of all guanosine nucleotides are 2'-O-methyl guanosine, and at least 80% of all uridine nucleotides are 2'-O-methyl uridine. In another embodiment, the aptamer has a sequence composition where at least 90% of all adenosine nucleotides are 2'-deoxy adenosine, at least 90% of all cytidine nucleotides are 2'-O-methyl cytidine, at least 90% of all guanosine nucleotides are 2'-O-methyl guanosine, and at least 90% of all uridine nucleotides are 2'-O-methyl uridine. In another embodiment, the aptamer has a sequence composition where 100% of all adenosine nucleotides are 2'-deoxy adenosine, 100% of all cytidine nucleotides are 2'-O-methyl cytidine, 100% of all guanosine nucleotides are 2'-O-methyl guanosine, and 100% of all uridine nucleotides are 2'-O-methyl uridine.

[0083] The invention also relates to an aptamer composition comprising a sequence where substantially all adenosine nucleotides are 2'-OH adenosine, substantially all guanosine nucleotides are 2'-OH guanosine, substantially all cytidine nucleotides are 2'-OH cytidine, and substantially all uridine nucleotides are 2'-OH uridine. In one embodiment, the aptamer has a sequence composition where at least 80% of all adenosine nucleotides are 2'-OH adenosine, at least 80% of all cytidine nucleotides are 2'-OH cytidine, at least 80% of all guanosine nucleotides are 2'-OH guanosine, and at least 80% of all uridine nucleotides are 2'-OH uridine. In another embodiment, the aptamer has a sequence composition where at least 90% of all adenosine nucleotides are 2'-OH adenosine, at least 90% of all cytidine nucleotides are 2'-OH cytidine, at least 90% of all guanosine nucleotides are 2'-OH guanosine, and at least 90% of all uridine nucleotides are 2'-OH uridine. In another embodiment, the aptamer has a sequence composition where 100% of all adenosine nucleotides are 2'-OH adenosine, 100% of all cytidine nucleotides are 2'-OH cytidine, 100% of all guanosine nucleotides are 2'-OH guanosine, and 100% of all uridine nucleotides are 2'-OH uridine.

DETAILED DESCRIPTION OF THE INVENTION

[0084] The details of one or more embodiments of the invention are set forth in the accompanying description below. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. Other features, objects, and advantages of the invention will be apparent from the description. In the specification, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In the case of conflict, the present Specification will control.

Modified nucleotide transcription

[0085] The present invention provides materials and methods to produce stabilized oligonucleotides (including, *e.g.*, aptamers) that contain modified nucleotides (*e.g.*, nucleotides which have a modification at the 2' position) which make the oligonucleotide more stable than the unmodified oligonucleotide. The stabilized oligonucleotides produced

by the materials and methods of the present invention are also more stable to enzymatic and chemical degradation as well as thermal and physical degradation.

[0086] In order for an aptamer to be suitable for use as a therapeutic, it is preferably inexpensive to synthesize, safe and stable *in vivo*. Wild-type RNA and DNA aptamers are typically not stable *in vivo* because of their susceptibility to degradation by nucleases. Resistance to nuclease degradation can be greatly increased by the incorporation of modifying groups at the 2'-position. Fluoro and amino groups have been successfully incorporated into oligonucleotide libraries from which aptamers have been subsequently selected. However, these modifications greatly increase the cost of synthesis of the resultant aptamer, and may introduce safety concerns because of the possibility that the modified nucleotides could be recycled into host DNA, by degradation of the modified oligonucleotides and subsequent use of the nucleotides as substrates for DNA synthesis.

[0087] Aptamers that contain 2'-O-methyl (2'-OMe) nucleotides overcome many of these drawbacks. Oligonucleotides containing 2'-O-methyl nucleotides are nuclease-resistant and inexpensive to synthesize. Although 2'-O-methyl nucleotides are ubiquitous in biological systems, natural polymerases do not accept 2'-O-methyl NTPs as substrates under physiological conditions, thus there are no safety concerns over the recycling of 2'-O-methyl nucleotides into host DNA. A generic formula for a 2'-OMe nucleotide is shown in Figure 2.

[0088] There are several examples of 2'-OMe-containing aptamers in the literature, see, for example Green et al., *Current Biology* 2, 683-695, 1995. These were generated by the *in vitro* selection of libraries of modified transcripts in which the C and U residues were 2'-fluoro (2'-F) substituted and the A and G residues were 2'-OH. Once functional sequences were identified then each A and G residue was tested for tolerance to 2'-OMe substitution, and the aptamer was re-synthesized having all A and G residues which tolerated 2'-OMe substitution as 2'-OMe residues. Most of the A and G residues of aptamers generated in this two-step fashion tolerate substitution with 2'-OMe residues, although, on average, approximately 20% do not. Consequently, aptamers generated using this method tend to contain from two to four 2'-OH residues, and stability and cost of synthesis are compromised as a result. By incorporating modified nucleotides into the transcription reaction which generate stabilized oligonucleotides used in oligonucleotide libraries from which aptamers are selected and enriched by SELEX™ (and/or any of its variations and improvements, including those described below), the methods of the current invention

eliminate the need for stabilizing the selected aptamer oligonucleotides (*e.g.*, by resynthesizing the aptamer oligonucleotides with modified nucleotides).

[0089] Furthermore, the modified oligonucleotides of the invention can be further stabilized after the selection process has been completed. (*See* "post-SELEX™ modifications", including truncating, deleting and modification, below.)

The SELEX™ Method

[0090] A suitable method for generating an aptamer is with the process entitled "Systematic Evolution of Ligands by EXponential enrichment" ("SELEX™") depicted generally in Figure 1. The SELEX™ process is a method for the *in vitro* evolution of nucleic acid molecules with highly specific binding to target molecules and is described in, *e.g.*, U.S. patent application Ser. No. 07/536,428, filed Jun. 11, 1990, now abandoned, U.S. Pat. No. 5,475,096 entitled "Nucleic Acid Ligands", and U.S. Pat. No. 5,270,163 (see also WO 91/19813) entitled "Nucleic Acid Ligands". Each SELEX™-identified nucleic acid ligand is a specific ligand of a given target compound or molecule. The SELEX™ process is based on the unique insight that nucleic acids have sufficient capacity for forming a variety of two- and three-dimensional structures and sufficient chemical versatility available within their monomers to act as ligands (form specific binding pairs) with virtually any chemical compound, whether monomeric or polymeric. Molecules of any size or composition can serve as targets.

[0091] SELEX™ relies as a starting point upon a large library of single stranded oligonucleotide templates comprising randomized sequences derived from chemical synthesis on a standard DNA synthesizer. In some examples, a population of 100% random oligonucleotides is screened. In others, each oligonucleotide in the population comprises a random sequence and at least one fixed sequence at its 5' and/or 3' end which comprises a sequence shared by all the molecules of the oligonucleotide population. Fixed sequences include sequences such as hybridization sites for PCR primers, promoter sequences for RNA polymerases (*e.g.*, T3, T4, T7, SP6, and the like), restriction sites, or homopolymeric sequences, such as poly A or poly T tracts, catalytic cores, sites for selective binding to affinity columns, and other sequences to facilitate cloning and/or sequencing of an oligonucleotide of interest.

[0092] The random sequence portion of the oligonucleotide can be of any length and can comprise ribonucleotides and/or deoxyribonucleotides and can include modified or non-

natural nucleotides or nucleotide analogs. See, e.g., U.S. Patent Nos. 5,958,691; 5,660,985; 5,958,691; 5,698,687; 5,817,635; and 5,672,695, and PCT publication WO 92/07065.

Random oligonucleotides can be synthesized from phosphodiester-linked nucleotides using solid phase oligonucleotide synthesis techniques well known in the art (Froehler *et al.*, Nucl. Acid Res. 14:5399-5467 (1986); Froehler *et al.*, Tet. Lett. 27:5575-5578 (1986)).

Oligonucleotides can also be synthesized using solution phase methods such as triester synthesis methods (Sood *et al.*, Nucl. Acid Res. 4:2557 (1977); Hirose *et al.*, Tet. Lett., 28:2449 (1978)). Typical syntheses carried out on automated DNA synthesis equipment yield 10^{15} - 10^{17} molecules. Sufficiently large regions of random sequence in the sequence design increases the likelihood that each synthesized molecule is likely to represent a unique sequence.

[0093] To synthesize randomized sequences, mixtures of all four nucleotides are added at each nucleotide addition step during the synthesis process, allowing for random incorporation of nucleotides. In one embodiment, random oligonucleotides comprise entirely random sequences; however, in other embodiments, random oligonucleotides can comprise stretches of nonrandom or partially random sequences. Partially random sequences can be created by adding the four nucleotides in different molar ratios at each addition step.

[0094] Template molecules typically contain fixed 5' and 3' terminal sequences which flank an internal region of 30 – 50 random nucleotides. A standard (1 μ mole) scale synthesis will yield 10^{15} – 10^{16} individual template molecules, sufficient for most SELEX™ experiments. The RNA library is generated from this starting library by *in vitro* transcription using recombinant T7 RNA polymerase. This library is then mixed with the target under conditions favorable for binding and subjected to step-wise iterations of binding, partitioning and amplification, using the same general selection scheme, to achieve virtually any desired criterion of binding affinity and selectivity. Starting from a mixture of nucleic acids, preferably comprising a segment of randomized sequence, the SELEX™ method includes steps of contacting the mixture with the target under conditions favorable for binding, partitioning unbound nucleic acids from those nucleic acids which have bound specifically to target molecules, dissociating the nucleic acid-target complexes, amplifying the nucleic acids dissociated from the nucleic acid-target complexes to yield a ligand-enriched mixture of nucleic acids, then reiterating the steps of binding, partitioning,

dissociating and amplifying through as many cycles as desired to yield highly specific high affinity nucleic acid ligands to the target molecule.

[0095] Within a nucleic acid mixture containing a large number of possible sequences and structures, there is a wide range of binding affinities for a given target. A nucleic acid mixture comprising, for example a 20 nucleotide randomized segment containing only natural unmodified nucleotides can have 4^{20} candidate possibilities. Those which have the higher affinity constants for the target are most likely to bind to the target. After partitioning, dissociation and amplification, a second nucleic acid mixture is generated, enriched for the higher binding affinity candidates. Additional rounds of selection progressively favor the best ligands until the resulting nucleic acid mixture is predominantly composed of only one or a few sequences. These can then be cloned, sequenced and individually tested for binding affinity as pure ligands.

[0096] Cycles of selection and amplification are repeated until a desired goal is achieved. In the most general case, selection/amplification is continued until no significant improvement in binding strength is achieved on repetition of the cycle. The method may be used to sample as many as about 10^{18} different nucleic acid species. The nucleic acids of the test mixture preferably include a randomized sequence portion as well as conserved sequences necessary for efficient amplification. Nucleic acid sequence variants can be produced in a number of ways including synthesis of randomized nucleic acid sequences and size selection from randomly cleaved cellular nucleic acids. The variable sequence portion may contain fully or partially random sequence; it may also contain subportions of conserved sequence incorporated with randomized sequence. Sequence variation in test nucleic acids can be introduced or increased by mutagenesis before or during the selection/amplification iterations.

[0097] In one embodiment of SELEX™, the selection process is so efficient at isolating those nucleic acid ligands that bind most strongly to the selected target, that only one cycle of selection and amplification is required. Such an efficient selection may occur, for example, in a chromatographic-type process wherein the ability of nucleic acids to associate with targets bound on a column operates in such a manner that the column is sufficiently able to allow separation and isolation of the highest affinity nucleic acid ligands.

[0098] In many cases, it is not necessarily desirable to perform the iterative steps of SELEX™ until a single nucleic acid ligand is identified. The target-specific nucleic acid ligand solution may include a family of nucleic acid structures or motifs that have a number

of conserved sequences and a number of sequences which can be substituted or added without significantly affecting the affinity of the nucleic acid ligands to the target. By terminating the SELEX™ process prior to completion, it is possible to determine the sequence of a number of members of the nucleic acid ligand solution family.

[0099] A variety of nucleic acid primary, secondary and tertiary structures are known to exist. The structures or motifs that have been shown most commonly to be involved in non-Watson-Crick type interactions are referred to as hairpin loops, symmetric and asymmetric bulges, pseudoknots and myriad combinations of the same. Almost all known cases of such motifs suggest that they can be formed in a nucleic acid sequence of no more than 30 nucleotides. For this reason, it is often preferred that SELEX™ procedures with contiguous randomized segments be initiated with nucleic acid sequences containing a randomized segment of between about 20-50 nucleotides.

[00100] The core SELEX™ method has been modified to achieve a number of specific objectives. For example, U.S. Patent No. 5,707,796 describes the use of SELEX™ in conjunction with gel electrophoresis to select nucleic acid molecules with specific structural characteristics, such as bent DNA. U.S. Patent No. 5,763,177 describes SELEX™ based methods for selecting nucleic acid ligands containing photoreactive groups capable of binding and/or photocrosslinking to and/or photoinactivating a target molecule. U.S. Patent No. 5,567,588 and U.S. Application No. 08/792,075, filed January 31, 1997, entitled "Flow Cell SELEX™", describe SELEX™ based methods which achieve highly efficient partitioning between oligonucleotides having high and low affinity for a target molecule. U.S. Patent No. 5,496,938 describes methods for obtaining improved nucleic acid ligands after the SELEX™ process has been performed. U.S. Patent No. 5,705,337 describes methods for covalently linking a ligand to its target.

[00101] SELEX™ can also be used to obtain nucleic acid ligands that bind to more than one site on the target molecule, and to obtain nucleic acid ligands that include non-nucleic acid species that bind to specific sites on the target. SELEX™ provides means for isolating and identifying nucleic acid ligands which bind to any envisioned target, including large and small biomolecules including proteins (including both nucleic acid-binding proteins and proteins not known to bind nucleic acids as part of their biological function) cofactors and other small molecules. For example, see U.S. Patent No. 5,580,737 which discloses nucleic acid sequences identified through SELEX™ which are capable of binding with high affinity to caffeine and the closely related analog, theophylline.

[00102] Counter- SELEX™ is a method for improving the specificity of nucleic acid ligands to a target molecule by eliminating nucleic acid ligand sequences with cross-reactivity to one or more non-target molecules. Counter- SELEX™ is comprised of the steps of a) preparing a candidate mixture of nucleic acids; b) contacting the candidate mixture with the target, wherein nucleic acids having an increased affinity to the target relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; d) contacting the increased affinity nucleic acids with one or more non-target molecules such that nucleic acid ligands with specific affinity for the non-target molecule(s) are removed; and e) amplifying the nucleic acids with specific affinity to the target molecule to yield a mixture of nucleic acids enriched for nucleic acid sequences with a relatively higher affinity and specificity for binding to the target molecule.

[00103] One potential problem encountered in the use of nucleic acids as therapeutics and vaccines is that oligonucleotides in their phosphodiester form may be quickly degraded in body fluids by intracellular and/or extracellular enzymes such as endonucleases and exonucleases before the desired effect is manifest. SELEX™ methods therefore encompass the identification of high-affinity nucleic acid ligands which are altered, after selection, to contain modified nucleotides which confer improved characteristics on the ligand, such as improved *in vivo* stability or improved delivery characteristics. Modifications of nucleic acid ligands include, but are not limited to, those which provide other chemical groups that incorporate additional charge, polarizability, hydrophobicity, hydrogen bonding, electrostatic interaction, and fluxionality to the nucleic acid ligand bases or to the nucleic acid ligand as a whole. Modifications include chemical substitutions at the ribose and/or phosphate and/or base positions, such as 2'-position sugar modifications, 5-position pyrimidine modifications, 8-position purine modifications, modifications at exocyclic amines, substitution of 4-thiouridine, substitution of 5-bromo or 5-iodo-uracil; backbone modifications, phosphorothioate or alkyl phosphate modifications, methylations, unusual base-pairing combinations such as the isobases isocytidine and isoguanidine and the like. Modifications can also include 3' and 5' modifications such as capping.

[00104] In oligonucleotides which comprise modified sugar groups, for example, one or more of the hydroxyl groups is replaced with halogen, aliphatic groups, or functionalized as ethers or amines. Examples of substitution at the 2'-position of the furanose residue include O-alkyl (*e.g.*, O-methyl), O-allyl, S-alkyl, S-allyl, or a halo group. Methods of

synthesis of 2'-modified sugars are described in Sproat, *et al.*, Nucl. Acid Res. 19:733-738 (1991); Cotten, *et al.*, Nucl. Acid Res. 19:2629-2635 (1991); and Hobbs, *et al.*, Biochemistry 12:5138-5145 (1973). Other modifications are known to one of ordinary skill in the art.

[00105] SELEXTM-identified nucleic acid ligands synthesized after selection to contain modified nucleotides are described in U.S. Patent No. 5,660,985, which describes oligonucleotides containing nucleotide derivatives chemically modified at the 5' and 2' positions of pyrimidines. Additionally, U.S. Patent No. 5,756,703 describes oligonucleotides containing various 2'-modified pyrimidines; and U.S. Patent No. 5,580,737 describes highly specific nucleic acid ligands containing one or more nucleotides modified with 2'-amino (2'-NH₂), 2'-fluoro (2'-F), and/or 2'-O-methyl (2'-OMe) substituents.

[00106] The SELEXTM method encompasses combining selected oligonucleotides with other selected oligonucleotides and non-oligonucleotide functional units as described in U.S. Patent No. 5,637,459 and U.S. Patent No. 5,683,867. The SELEXTM method further encompasses combining selected nucleic acid ligands with lipophilic or non-immunogenic high molecular weight compounds in a diagnostic or therapeutic complex, as described in U.S. Patent No. 6,011,020. VEGF nucleic acid ligands that are associated with a lipophilic compound, such as diacyl glycerol or dialkyl glycerol, in a diagnostic or therapeutic complex are described in U.S. Patent No. 5,859,228.

[00107] VEGF nucleic acid ligands that are associated with a lipophilic compound, such as a glycerol lipid, or a non-immunogenic high molecular weight compound, such as polyalkylene glycol are further described in U.S. Patent No. 6,051,698. VEGF nucleic acid ligands that are associated with a non-immunogenic, high molecular weight compound or a lipophilic compound are further described in PCT Publication No. WO 98/18480. These patents and applications describe the combination of a broad array of oligonucleotide shapes and other properties, and the efficient amplification and replication properties, of oligonucleotides with the desirable properties of other molecules.

[00108] The identification of nucleic acid ligands to small, flexible peptides via the SELEXTM method has also been explored. Small peptides have flexible structures and usually exist in solution in an equilibrium of multiple conformers, and thus it was initially thought that binding affinities may be limited by the conformational entropy lost upon binding a flexible peptide. However, the feasibility of identifying nucleic acid ligands to small peptides in solution was demonstrated in U.S. Patent No. 5,648,214. In this patent,

high affinity RNA nucleic acid ligands to substance P, an 11 amino acid peptide, were identified.

[00109] To generate oligonucleotide populations which are resistant to nucleases and hydrolysis, modified oligonucleotides can be used and can include one or more substitute internucleotide linkages, altered sugars, altered bases, or combinations thereof. In one embodiment, oligonucleotides are provided in which the P(O)O group is replaced by P(O)S ("thioate"), P(S)S ("dithioate"), P(O)NR₂ ("amidate"), P(O)R, P(O)OR', CO or CH₂ ("formacetal") or 3'-amine (-NH-CH₂-CH₂-), wherein each R or R' is independently H or substituted or unsubstituted alkyl. Linkage groups can be attached to adjacent nucleotide through an -O-, -N-, or -S- linkage. Not all linkages in the oligonucleotide are required to be identical.

[00110] Nucleic acid aptamer molecules are generally selected in a 5 to 20 cycle procedure. In one embodiment, heterogeneity is introduced only in the initial selection stages and does not occur throughout the replicating process.

[00111] The starting library of DNA sequences is generated by automated chemical synthesis on a DNA synthesizer. This library of sequences is transcribed *in vitro* into RNA using T7 RNA polymerase or a modified T7 RNA polymerase, and purified. In one example, the 5'-fixed:random:3'-fixed sequence includes a random sequence having from 30 to 50 nucleotides.

[00112] Incorporation of modified nucleotides into the aptamers of the invention is accomplished before (pre-) the selection process (e.g., a pre-SELEXTM process modification). Optionally, aptamers of the invention in which modified nucleotides have been incorporated by pre-SELEXTM process modification can be further modified by post-SELEXTM process modification (i.e., a post-SELEXTM process modification after a pre-SELEXTM modification). Pre-SELEXTM process modifications yield modified nucleic acid ligands with specificity for the SELEXTM target and also improved *in vivo* stability. Post-SELEXTM process modifications (e.g., modification of previously identified ligands having nucleotides incorporated by pre-SELEXTM process modification) can result in a further improvement of *in vivo* stability without adversely affecting the binding capacity of the nucleic acid ligand having nucleotides incorporated by pre-SELEXTM process modification.

Modified Polymerases

[00113] A single mutant T7 polymerase (Y639F) in which the tyrosine residue at position 639 has been changed to phenylalanine readily utilizes 2'-deoxy, 2'-amino-, and 2'-fluoro- nucleotide triphosphates (NTPs) as substrates and has been widely used to synthesize modified RNAs for a variety of applications. However, this mutant T7 polymerase reportedly can not readily utilize (*e.g.*, incorporate) NTPs with bulkier 2'-substituents, such as 2'-O-methyl (2'-OMe) or 2'-azido (2'-N₃) substituents. For incorporation of bulky 2' substituents, a double T7 polymerase mutant (Y639F/H784A) having the histidine at position 784 changed to an alanine, or other small amino acid, residue, in addition to the Y639F mutation has been described and has been used to incorporate modified pyrimidine NTPs. A single mutant T7 polymerase (H784A) having the histidine at position 784 changed to an alanine residue has also been described. (Padilla *et al.*, Nucleic Acids Research, 2002, 30: 138). In both the Y639F/H784A double mutant and H784A single mutant T7 polymerases, the change to smaller amino acid residues allows for the incorporation of bulkier nucleotide substrates, *e.g.*, 2'-O methyl substituted nucleotides.

[00114] The present invention provides methods and conditions for using these and other modified T7 polymerases having a higher incorporation rate of modified nucleotides having bulky substituents at the furanose 2' position, than wild-type polymerases. Generally, it has been found that under the conditions disclosed herein, the Y693F single mutant can be used for the incorporation of all 2'-OMe substituted NTPs except GTP and the Y639F/H784A double mutant can be used for the incorporation of all 2'-OMe substituted NTPs including GTP. It is expected that the H784A single mutant possesses similar properties when used under the conditions disclosed herein.

[00115] The present invention provides methods and conditions for modified T7 polymerases to enzymatically incorporate modified nucleotides into oligonucleotides. Such oligonucleotides may be synthesized entirely of modified nucleotides, or with a subset of modified nucleotides. The modifications can be the same or different. All nucleotides may be modified, and all may contain the same modification. All nucleotides may be modified, but contain different modifications, *e.g.*, all nucleotides containing the same base may have one type of modification, while nucleotides containing other bases may have different types of modification. All purine nucleotides may have one type of modification (or are unmodified), while all pyrimidine nucleotides have another, different type of modification

(or are unmodified). In this way, transcripts, or libraries of transcripts are generated using any combination of modifications, for example, ribonucleotides, (2'-OH, "rN"), deoxyribonucleotides (2'-deoxy), 2'-F, and 2'-OMe nucleotides. A mixture containing 2'-OMe C and U and 2'-OH A and G is called "rRmY"; a mixture containing deoxy A and G and 2'-OMe U and C is called "dRmY"; a mixture containing 2'-OMe A, C, and U, and 2'-OH G is called "rGmH"; a mixture alternately containing 2'-OMe A, C, U and G and 2'-OMe A, U and C and 2'-F G is called "toggle"; a mixture containing 2'-OMe A, U, C, and G, where up to 10% of the G's are deoxy is called "r/mGmH"; a mixture containing 2'-OMe A, U, and C, and 2'-F G is called "fGmH"; and a mixture containing deoxy A, and 2'-OMe C, G and U is called "dAmB".

[00116] A preferred embodiment includes any combination of 2'-OH, 2'-deoxy and 2'-OMe nucleotides. A more preferred embodiment includes any combination of 2'-deoxy and 2'-OMe nucleotides. An even more preferred embodiment is with any combination of 2'-deoxy and 2'-OMe nucleotides in which the pyrimidines are 2'-OMe (such as dRmY, mN or dGmH).

2'-Modified SELEX™

[00117] The present invention provides methods to generate libraries of 2'-modified (*e.g.*, 2'-OMe) RNA transcripts in conditions under which a polymerase accepts 2'-modified NTPs. Preferably, the polymerase is the Y693F/H784A double mutant or the Y693F single mutant. Other polymerases, particularly those that exhibit a high tolerance for bulky 2'-substituents, may also be used in the present invention. Such polymerases can be screened for this capability by assaying their ability to incorporate modified nucleotides under the transcription conditions disclosed herein. A number of factors have been determined to be crucial for the transcription conditions useful in the methods disclosed herein. For example, great increases in the yields of modified transcript are observed when a leader sequence is incorporated into the 5' end of a fixed sequence at the 5' end of the DNA transcription template, such that at least about the first 6 residues of the resultant transcript are all purines.

[00118] Another important factor in obtaining transcripts incorporating modified nucleotides is the presence or concentration of 2'-OH GTP. Transcription can be divided into two phases: the first phase is initiation, during which an NTP is added to the 3'-

hydroxyl end of GTP (or another substituted guanosine) to yield a dinucleotide which is then extended by about 10-12 nucleotides, the second phase is elongation, during which transcription proceeds beyond the addition of the first about 10-12 nucleotides. It has been found that small amounts of 2'-OH GTP added to a transcription mixture containing an excess of 2'-OMe GTP are sufficient to enable the polymerase to initiate transcription using 2'-OH GTP, but once transcription enters the elongation phase the reduced discrimination between 2'-OMe and 2'-OH GTP, and the excess of 2'-OMe GTP over 2'-OH GTP allows the incorporation of principally the 2'-OMe GTP.

[00119] Another important factor in the incorporation of 2'-OMe into transcripts is the use of both divalent magnesium and manganese in the transcription mixture. Different combinations of concentrations of magnesium chloride and manganese chloride have been found to affect yields of 2'-O-methylated transcripts, the optimum concentration of the magnesium and manganese chloride being dependent on the concentration in the transcription reaction mixture of NTPs which complex divalent metal ions. To obtain the greatest yields of maximally 2' substituted O-methylated transcripts (*i.e.*, all A, C, and U and about 90% of G nucleotides), concentrations of approximately 5 mM magnesium chloride and 1.5 mM manganese chloride are preferred when each NTP is present at a concentration of 0.5 mM. When the concentration of each NTP is 1.0 mM, concentrations of approximately 6.5 mM magnesium chloride and 2.0 mM manganese chloride are preferred. When the concentration of each NTP is 2.0 mM, concentrations of approximately 9.6 mM magnesium chloride and 2.9 mM manganese chloride are preferred. In any case, departures from these concentrations of up to two-fold still give significant amounts of modified transcripts.

[00120] Priming transcription with GMP or guanosine is also important. This effect results from the specificity of the polymerase for the initiating nucleotide. As a result, the 5'-terminal nucleotide of any transcript generated in this fashion is likely to be 2'-OH G. The preferred concentration of GMP (or guanosine) is 0.5 mM and even more preferably 1 mM. It has also been found that including PEG, preferably PEG-8000, in the transcription reaction is useful to maximize incorporation of modified nucleotides.

[00121] For maximum incorporation of 2'-OMe ATP (100%), UTP(100%), CTP(100%) and GTP (~90%) ("r/mGmH") into transcripts the following conditions are preferred: HEPES buffer 200 mM, DTT 40 mM, spermidine 2 mM, PEG-8000 10% (w/v),

Triton X-100 0.01% (w/v), MgCl_2 5 mM (6.5 mM where the concentration of each 2'-OMe NTP is 1.0 mM), MnCl_2 1.5 mM (2.0 mM where the concentration of each 2'-OMe NTP is 1.0 mM), 2'-OMe NTP (each) 500 μM (more preferably, 1.0 mM), 2'-OH GTP 30 μM , 2'-OH GMP 500 μM , pH 7.5, Y639F/H784A T7 RNA Polymerase 15 units/ml, inorganic pyrophosphatase 5 units/ml, and an all-purine leader sequence of at least 8 nucleotides long. As used herein, one unit of the Y639F/H784A mutant T7 RNA polymerase, or any other mutant T7 RNA polymerase specified herein) is defined as the amount of enzyme required to incorporate 1 nmole of 2'-OMe NTPs into transcripts under the r/mGmH conditions. As used herein, one unit of inorganic pyrophosphatase is defined as the amount of enzyme that will liberate 1.0 mole of inorganic orthophosphate per minute at pH 7.2 and 25 °C.

[00122] For maximum incorporation (100%) of 2'-OMe ATP, UTP and CTP ("rGmH") into transcripts the following conditions are preferred: HEPES buffer 200 mM, DTT 40 mM, spermidine 2 mM, PEG-8000 10% (w/v), Triton X-100 0.01% (w/v), MgCl_2 5 mM (9.6 mM where the concentration of each 2'-OMe NTP is 2.0 mM), MnCl_2 1.5 mM (2.9 mM where the concentration of each 2'-OMe NTP is 2.0 mM), 2'-OMe NTP (each) 500 μM (more preferably, 2.0 mM), pH 7.5, Y639F T7 RNA Polymerase 15 units/ml, inorganic pyrophosphatase 5 units/ml, and an all-purine leader sequence of at least 8 nucleotides long.

[00123] For maximum incorporation (100%) of 2'-OMe UTP and CTP ("rRmY") into transcripts the following conditions are preferred: HEPES buffer 200 mM, DTT 40 mM, spermidine 2 mM, PEG-8000 10% (w/v), Triton X-100 0.01% (w/v), MgCl_2 5 mM (9.6 mM where the concentration of each 2'-OMe NTP is 2.0 mM), MnCl_2 1.5 mM (2.9 mM where the concentration of each 2'-OMe NTP is 2.0 mM), 2'-OMe NTP (each) 500 μM (more preferably, 2.0 mM), pH 7.5, Y639F/H784A T7 RNA Polymerase 15 units/ml, inorganic pyrophosphatase 5 units/ml, and an all-purine leader sequence of at least 8 nucleotides long.

[00124] For maximum incorporation (100%) of deoxy ATP and GTP and 2'-OMe UTP and CTP ("dRmY") into transcripts the following conditions are preferred: HEPES buffer 200 mM, DTT 40 mM, spermidine 2 mM, PEG-8000 10% (w/v), Triton X-100 0.01% (w/v), MgCl_2 9.6 mM, MnCl_2 2.9 mM, 2'-OMe NTP (each) 2.0 mM, pH 7.5, Y639F T7 RNA Polymerase 15 units/ml, inorganic pyrophosphatase 5 units/ml, and an all-purine leader sequence of at least 8 nucleotides long.

[00125] For maximum incorporation (100%) of 2'-OMe ATP, UTP and CTP and 2'-F GTP ("fGmH") into transcripts the following conditions are preferred: HEPES buffer 200 mM, DTT 40 mM, spermidine 2 mM, PEG-8000 10% (w/v), Triton X-100 0.01% (w/v), MgCl₂ 9.6 mM, MnCl₂ 2.9 mM, 2'-OMe NTP (each) 2.0 mM, pH 7.5, Y639F T7 RNA Polymerase 15 units/ml, inorganic pyrophosphatase 5 units/ml, and an all-purine leader sequence of at least 8 nucleotides long.

[00126] For maximum incorporation (100%) of deoxy ATP and 2'-OMe UTP, GTP and CTP ("dAmB") into transcripts the following conditions are preferred: HEPES buffer 200 mM, DTT 40 mM, spermidine 2 mM, PEG-8000 10% (w/v), Triton X-100 0.01% (w/v), MgCl₂ 9.6 mM, MnCl₂ 2.9 mM, 2'-OMe NTP (each) 2.0 mM, pH 7.5, Y639F T7 RNA Polymerase 15 units/ml, inorganic pyrophosphatase 5 units/ml, and an all-purine leader sequence of at least 8 nucleotides long.

[00127] For each of the above, (1) transcription is preferably performed at a temperature of from about 30 °C to about 45 °C and for a period of at least two hours and (2) 50-300 nM of a double stranded DNA transcription template is used (200 nm template was used for round 1 to increase diversity (300 nm template was used for dRmY transcriptions), and for subsequent rounds approximately 50 nM, a 1/10 dilution of an optimized PCR reaction, using conditions described herein, was used). The preferred DNA transcription templates are described below (where ARC254 and ARC256 transcribe under all 2'-OMe conditions and ARC255 transcribes under rRmY conditions).

ARC254:

5'-CATCGATGCTAGTCGTAACGATCCNNCGAGAACGTTCTCTCCTCTCCCTATAGTGAGTCGTATTA-3'
(SEQ ID NO:1)

ARC255:

5'-CATGCATCGCGACTGACTAGCCGNNGTAGAACGTTCTCTCCTCTCCCTATAGTGAGTCGTATTA-3'
(SEQ ID NO:2)

ARC256:

5'-CATCGATCGATCGATCGACAGCGNNGTAGAACGTTCTCTCCTCTCCCTATAGTGAGTCGTATTA-3'
(SEQ ID NO:453)

[00128] Under rN transcription conditions of the present invention, the transcription reaction mixture comprises 2'-OH adenosine triphosphates (ATP), 2'-OH guanosine triphosphates (GTP), 2'-OH cytidine triphosphates (CTP), and 2'-OH uridine triphosphates (UTP). The modified oligonucleotides produced using the rN transcription mixtures of the present invention comprise substantially all 2'-OH adenosine, 2'-OH guanosine, 2'-OH cytidine, and 2'-OH uridine. In a preferred embodiment of rN transcription, the resulting modified oligonucleotides comprise a sequence where at least 80% of all adenosine nucleotides are 2'-OH adenosine, at least 80% of all guanosine nucleotides are 2'-OH guanosine, at least 80% of all cytidine nucleotides are 2'-OH cytidine, and at least 80% of all uridine nucleotides are 2'-OH uridine. In a more preferred embodiment of rN transcription, the resulting modified oligonucleotides of the present invention comprise a sequence where at least 90% of all adenosine nucleotides are 2'-OH adenosine, at least 90% of all guanosine nucleotides are 2'-OH guanosine, at least 90% of all cytidine nucleotides are 2'-OH cytidine, and at least 90% of all uridine nucleotides are 2'-OH uridine. In a most preferred embodiment of rN transcription, the modified oligonucleotides of the present invention comprise 100% of all adenosine nucleotides are 2'-OH adenosine, of all guanosine nucleotides are 2'-OH guanosine, of all cytidine nucleotides are 2'-OH cytidine, and of all uridine nucleotides are 2'-OH uridine.

[00129] Under rRmY transcription conditions of the present invention, the transcription reaction mixture comprises 2'-OH adenosine triphosphates, 2'-OH guanosine triphosphates, 2'-O-methyl cytidine triphosphates, and 2'-O-methyl uridine triphosphates. The modified oligonucleotides produced using the rRmY transcription mixtures of the present invention comprise substantially all 2'-OH adenosine, 2'-OH guanosine, 2'-O-methyl cytidine and 2'-O-methyl uridine. In a preferred embodiment, the resulting modified oligonucleotides comprise a sequence where at least 80% of all adenosine nucleotides are 2'-OH adenosine, at least 80% of all guanosine nucleotides are 2'-OH guanosine, at least 80% of all cytidine nucleotides are 2'-O-methyl cytidine and at least 80% of all uridine nucleotides are 2'-O-methyl uridine. In a more preferred embodiment, the resulting modified oligonucleotides comprise a sequence where at least 90% of all adenosine nucleotides are 2'-OH adenosine, at least 90% of all guanosine nucleotides are 2'-OH guanosine, at least 90% of all cytidine nucleotides are 2'-O-methyl cytidine and at least 90% of all uridine nucleotides are 2'-O-methyl uridine. In a most preferred embodiment, the

resulting modified oligonucleotides comprise a sequence where 100% of all adenosine nucleotides are 2'-OH adenosine, 100% of all guanosine nucleotides are 2'-OH guanosine, 100% of all cytidine nucleotides are 2'-O-methyl cytidine and 100% of all uridine nucleotides are 2'-O-methyl uridine.

[00130] Under dRmY transcription conditions of the present invention, the transcription reaction mixture comprises 2'-deoxy purine triphosphates and 2'-O-methyl pyrimidine triphosphates. The modified oligonucleotides produced using the dRmY transcription conditions of the present invention comprise substantially all 2'-deoxy purines and 2'-O-methyl pyrimidines. In a preferred embodiment, the resulting modified oligonucleotides of the present invention comprise a sequence where at least 80% of all purine nucleotides are 2'-deoxy purines and at least 80% of all pyrimidine nucleotides are 2'-O-methyl pyrimidines. In a more preferred embodiment, the resulting modified oligonucleotides of the present invention comprise a sequence where at least 90% of all purine nucleotides are 2'-deoxy purines and at least 90% of all pyrimidine nucleotides are 2'-O-methyl pyrimidines. In a most preferred embodiment, the resulting modified oligonucleotides of the present invention comprise a sequence where 100% of all purine nucleotides are 2'-deoxy purines and 100% of all pyrimidine nucleotides are 2'-O-methyl pyrimidines.

[00131] Under rGmH transcription conditions of the present invention, the transcription reaction mixture comprises 2'-OH guanosine triphosphates, 2'-O-methyl cytidine triphosphates, 2'-O-methyl uridine triphosphates, and 2'-O-methyl adenosine triphosphates. The modified oligonucleotides produced using the rGmH transcription mixtures of the present invention comprise substantially all 2'-OH guanosine, 2'-O-methyl cytidine, 2'-O-methyl uridine, and 2'-O-methyl adenosine. In a preferred embodiment, the resulting modified oligonucleotides comprise a sequence where at least 80% of all guanosine nucleotides are 2'-OH guanosine, at least 80% of all cytidine nucleotides are 2'-O-methyl cytidine, at least 80% of all uridine nucleotides are 2'-O-methyl uridine, and at least 80% of all adenosine nucleotides are 2'-O-methyl adenosine. In a more preferred embodiment, the resulting modified oligonucleotides comprise a sequence where at least 90% of all guanosine nucleotides are 2'-OH guanosine, at least 90% of all cytidine nucleotides are 2'-O-methyl cytidine, at least 90% of all uridine nucleotides are 2'-O-methyl uridine, and at least 90% of all adenosine nucleotides are 2'-O-methyl adenosine. In a most preferred embodiment, the resulting modified oligonucleotides comprise a sequence where

100% of all guanosine nucleotides are 2'-OH guanosine, 100% of all cytidine nucleotides are 2'-O-methyl cytidine, 100% of all uridine nucleotides are 2'-O-methyl uridine, and 100% of all adenosine nucleotides are 2'-O-methyl adenosine.

[00132] Under r/mGmH transcription conditions of the present invention, the transcription reaction mixture comprises 2'-O-methyl adenosine triphosphate, 2'-O-methyl cytidine triphosphate, 2'-O-methyl guanosine triphosphate, 2'-O-methyl uridine triphosphate and deoxy guanosine triphosphate. The resulting modified oligonucleotides produced using the r/mGmH transcription mixtures of the present invention comprise substantially all 2'-O-methyl adenosine, 2'-O-methyl cytidine, 2'-O-methyl guanosine, and 2'-O-methyl uridine, wherein the population of guanosine nucleotides has a maximum of about 10% deoxy guanosine. In a preferred embodiment, the resulting r/mGmH modified oligonucleotides of the present invention comprise a sequence where at least 80% of all adenosine nucleotides are 2'-O-methyl adenosine, at least 80% of all cytidine nucleotides are 2'-O-methyl cytidine, at least 80% of all guanosine nucleotides are 2'-O-methyl guanosine, at least 80% of all uridine nucleotides are 2'-O-methyl uridine, and no more than about 10% of all guanosine nucleotides are deoxy guanosine. In a more preferred embodiment, the resulting modified oligonucleotides comprise a sequence where at least 90% of all adenosine nucleotides are 2'-O-methyl adenosine, at least 90% of all cytidine nucleotides are 2'-O-methyl cytidine, at least 90% of all guanosine nucleotides are 2'-O-methyl guanosine, at least 90% of all uridine nucleotides are 2'-O-methyl uridine, and no more than about 10% of all guanosine nucleotides are deoxy guanosine. In a most preferred embodiment, the resulting modified oligonucleotides comprise a sequence where 100% of all adenosine nucleotides are 2'-O-methyl adenosine, 100% of all cytidine nucleotides are 2'-O-methyl cytidine, 90% of all guanosine nucleotides are 2'-O-methyl guanosine, and 100% of all uridine nucleotides are 2'-O-methyl uridine, and no more than about 10% of all guanosine nucleotides are deoxy guanosine.

[00133] Under fGmH transcription conditions of the present invention, the transcription reaction mixture comprises 2'-O-methyl adenosine triphosphates (ATP), 2'-O-methyl uridine triphosphates (UTP), 2'-O-methyl cytidine triphosphates (CTP), and 2'-F guanosine triphosphates. The modified oligonucleotides produced using the fGmH transcription conditions of the present invention comprise substantially all 2'-O-methyl adenosine, 2'-O-methyl uridine, 2'-O-methyl cytidine, and 2'-F guanosine. In a preferred

embodiment, the resulting modified oligonucleotides comprise a sequence where at least 80% of all adenosine nucleotides are 2'-O-methyl adenosine, at least 80% of all uridine nucleotides are 2'-O-methyl uridine, at least 80% of all cytidine nucleotides are 2'-O-methyl cytidine, and at least 80% of all guanosine nucleotides are 2'-F guanosine. In a more preferred embodiment, the resulting modified oligonucleotides comprise a sequence where at least 90% of all adenosine nucleotides are 2'-O-methyl adenosine, at least 90% of all uridine nucleotides are 2'-O-methyl uridine, at least 90% of all cytidine nucleotides are 2'-O-methyl cytidine, and at least 90% of all guanosine nucleotides are 2'-F guanosine. The resulting modified oligonucleotides comprise a sequence where 100% of all adenosine nucleotides are 2'-O-methyl adenosine, 100% of all uridine nucleotides are 2'-O-methyl uridine, 100% of all cytidine nucleotides are 2'-O-methyl cytidine, and 100% of all guanosine nucleotides are 2'-F guanosine.

[00134] Under dAmB transcription conditions of the present invention, the transcription reaction mixture comprises 2'-deoxy adenosine triphosphates (dATP), 2'-O-methyl cytidine triphosphates (CTP), 2'-O-methyl guanosine triphosphates (GTP), and 2'-O-methyl uridine triphosphates (UTP). The modified oligonucleotides produced using the dAmB transcription mixtures of the present invention comprise substantially all 2'-deoxy adenosine, 2'-O-methyl cytidine, 2'-O-methyl guanosine, and 2'-O-methyl uridine. In a preferred embodiment, the resulting modified oligonucleotides comprise a sequence where at least 80% of all adenosine nucleotides are 2'-deoxy adenosine, at least 80% of all cytidine nucleotides are 2'-O-methyl cytidine, at least 80% of all guanosine nucleotides are 2'-O-methyl guanosine, and at least 80% of all uridine nucleotides are 2'-O-methyl uridine. In a more preferred embodiment, the resulting modified oligonucleotides comprise a sequence where at least 90% of all adenosine nucleotides are 2'-deoxy adenosine, at least 90% of all cytidine nucleotides are 2'-O-methyl cytidine, at least 90% of all guanosine nucleotides are 2'-O-methyl guanosine, and at least 90% of all uridine nucleotides are 2'-O-methyl uridine. In a most preferred embodiment, the resulting modified oligonucleotides of the present invention comprise a sequence where 100% of all adenosine nucleotides are 2'-deoxy adenosine, 100% of all cytidine nucleotides are 2'-O-methyl cytidine, 100% of all guanosine nucleotides are 2'-O-methyl guanosine, and 100% of all uridine nucleotides are 2'-O-methyl uridine.

[00135] In each case, the transcription products can then be used as the library in the SELEX™ process to identify aptamers and/or to determine a conserved motif of sequences that have binding specificity to a given target. The resulting sequences are already stabilized, eliminating this step from the process to arrive at a stabilized aptamer sequence and giving a more highly stabilized aptamer as a result. Another advantage of the 2'-OMe SELEX™ process is that the resulting sequences are likely to have fewer 2'-OH nucleotides required in the sequence, possibly none.

[00136] As described below, lower but still useful yields of transcripts fully incorporating 2'-OMe substituted nucleotides can be obtained under conditions other than the optimized conditions described above. For example, variations to the above transcription conditions include:

[00137] The HEPES buffer concentration can range from 0 to 1 M. The present invention also contemplates the use of other buffering agents having a pKa between 5 and 10, for example without limitation, Tris(hydroxymethyl)aminomethane.

[00138] The DTT concentration can range from 0 to 400 mM. The methods of the present invention also provide for the use of other reducing agents, for example without limitation, mercaptoethanol.

[00139] The spermidine and/or spermine concentration can range from 0 to 20 mM.

[00140] The PEG-8000 concentration can range from 0 to 50 % (w/v). The methods of the present invention also provide for the use of other hydrophilic polymer, for example without limitation, other molecular weight PEG or other polyalkylene glycols.

[00141] The Triton X-100 concentration can range from 0 to 0.1% (w/v). The methods of the present invention also provide for the use of other non-ionic detergents, for example without limitation, other detergents, including other Triton-X detergents.

[00142] The MgCl_2 concentration can range from 0.5 mM to 50 mM. The MnCl_2 concentration can range from 0.15 mM to 15 mM. Both MgCl_2 and MnCl_2 must be present within the ranges described and in a preferred embodiment are present in about a 10 to about 3 ratio of MgCl_2 : MnCl_2 , preferably, the ratio is about 3-5, more preferably, the ratio is about 3 to about 4.

[00143] The 2'-OMe NTP concentration (each NTP) can range from 5 μM to 5 mM.

[00144] The 2'-OH GTP concentration can range from 0 μM to 300 μM .

[00145] The 2'-OH GMP concentration can range from 0 to 5 mM.

[00146] The pH can range from pH 6 to pH 9. The methods of the present invention can be practiced within the pH range of activity of most polymerases that incorporate modified nucleotides.

[00147] In addition, the methods of the present invention provide for the optional use of chelating agents in the transcription reaction condition, for example without limitation, EDTA, EGTA, and DTT.

Pharmaceutical Compositions

[00148] The invention also includes pharmaceutical compositions containing the aptamer molecules described herein. In some embodiments, the compositions are suitable for internal use and include an effective amount of a pharmacologically active compound of the invention, alone or in combination, with one or more pharmaceutically acceptable carriers. The compounds are especially useful in that they have very low, if any toxicity.

[00149] Compositions of the invention can be used to treat or prevent a pathology, such as a disease or disorder, or alleviate the symptoms of such disease or disorder in a patient. Compositions of the invention are useful for administration to a subject suffering from, or predisposed to, a disease or disorder which is related to or derived from a target to which the aptamers specifically bind.

[00150] For example, the target is a protein involved with a pathology, for example, the target protein causes the pathology.

[00151] Compositions of the invention can be used in a method for treating a patient having a pathology. The method involves administering to the patient a composition comprising aptamers that bind a target (*e.g.*, a protein) involved with the pathology, so that binding of the composition to the target alters the biological function of the target, thereby treating the pathology.

[00152] The patient having a pathology, *e.g.* the patient treated by the methods of this invention can be a mammal, or more particularly, a human.

[00153] In practice, the compounds or their pharmaceutically acceptable salts, are administered in amounts which will be sufficient to exert their desired biological activity.

[00154] For instance, for oral administration in the form of a tablet or capsule (*e.g.*, a gelatin capsule), the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.

Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, starches, agar, alginic acid or its sodium salt, or effervescent mixtures, and the like. Diluents, include, *e.g.*, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine.

[00155] Injectable compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. The compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. The compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1 to 75%, preferably about 1 to 50%, of the active ingredient.

[00156] The compounds of the invention can also be administered in such oral dosage forms as timed release and sustained release tablets or capsules, pills, powders, granules, elixirs, tinctures, suspensions, syrups and emulsions.

[00157] Liquid, particularly injectable compositions can, for example, be prepared by dissolving, dispersing, *etc.* The active compound is dissolved in or mixed with a pharmaceutically pure solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form the injectable solution or suspension. Additionally, solid forms suitable for dissolving in liquid prior to injection can be formulated. Injectable compositions are preferably aqueous isotonic solutions or suspensions. The compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.

[00158] The compounds of the present invention can be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions.

[00159] Parental injectable administration is generally used for subcutaneous, intramuscular or intravenous injections and infusions. Additionally, one approach for parenteral administration employs the implantation of a slow-release or sustained-released systems, which assures that a constant level of dosage is maintained, according to U.S. Pat. No. 3,710,795, incorporated herein by reference.

[00160] Furthermore, preferred compounds for the present invention can be administered in intranasal form *via* topical use of suitable intranasal vehicles, or *via* transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen. Other preferred topical preparations include creams, ointments, lotions, aerosol sprays and gels, wherein the concentration of active ingredient would range from 0.01% to 15%, w/w or w/v.

[00161] For solid compositions, excipients include pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like may be used. The active compound defined above, may be also formulated as suppositories using for example, polyalkylene glycols, for example, propylene glycol, as the carrier. In some embodiments, suppositories are advantageously prepared from fatty emulsions or suspensions.

[00162] The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, containing cholesterol, stearylamine or phosphatidylcholines. In some embodiments, a film of lipid components is hydrated with an aqueous solution of drug to a form lipid layer encapsulating the drug, as described in U.S. Pat. No. 5,262,564. For example, the aptamer molecules described herein can be provided as a complex with a lipophilic compound or non-immunogenic, high molecular weight compound constructed using methods known in the art. An example of nucleic-acid associated complexes is provided in US Patent No. 6,011,020.

[00163] The compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropyl-methacrylamide-phenol, polyhydroxyethylaspanamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polypepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.

[00164] If desired, the pharmaceutical composition to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and other substances such as for example, sodium acetate, triethanolamine, oleate, *etc.*

[00165] The dosage regimen utilizing the compounds is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.

[00166] Oral dosages of the present invention, when used for the indicated effects, will range between about 0.05 to 1000 mg/day orally. The compositions are preferably provided in the form of scored tablets containing 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100.0, 250.0, 500.0 and 1000.0 mg of active ingredient. Effective plasma levels of the compounds of the present invention range from 0.002 mg to 50 mg per kg of body weight per day.

[00167] Compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.

[00168] All publications and patent documents cited herein are incorporated herein by reference as if each such publication or document was specifically and individually indicated to be incorporated herein by reference. Citation of publications and patent documents is not intended as an admission that any is pertinent prior art, nor does it constitute any admission as to the contents or date of the same.

[00169] The invention having now been described by way of written description, those of skill in the art will recognize that the invention can be practiced in a variety of embodiments

and that the foregoing description and examples below are for purposes of illustration and not limitation of the claims that follow.

EXAMPLES

EXAMPLE 1 2'-OMe SELEX™ Against Thrombin and VEGF targets

[00170] A library of approximately 3×10^{14} unique transcription templates, each containing a random region of thirty contiguous nucleotides, was synthesized as described below, and PCR amplified. Cloning and sequencing of this library demonstrated that the composition of the random region in this library was approximately 25% of each nucleotide. The DNA library was purified away from unincorporated dNTPs by gel-filtration and ethanol-precipitation. Modified transcripts were then generated from a mixture containing 500 μ M of each of the four 2'-OMe NTPs, *i.e.*, A, C, U and G, and 30 μ M 2'-OH GTP ("r/mGmH"). In addition, modified transcripts were generated from mixtures containing part modified nucleotides and part ribonucleotides or all ribonucleotides namely, a mixture containing all 2'-OH nucleotides (rN); a mixture containing 2'-OMe C and U and 2'-OH A and G (rRmY); a mixture containing 2'-OMe A, C, and U, and 2'-OH G ("rGmH"); and a mixture alternately containing 2'-OMe A, C, U and G and 2'-OMe A, U and C and 2'-F G ("toggle"). These modified transcripts were then used in SELEX™ against targets – *e.g.*, VEGF and thrombin.

[00171] Generally, after gel-purification and DNase-treatment these modified transcripts were dissolved in PBS for VEGF or 1X ASB (150 mM KCl, 20 mM HEPES, 10 mM MgCl_2 , 1 mM DTT, 0.05 % Tween20, pH 7.4) for thrombin, and incubated for one hour in an empty well on a hydrophobic multiwell plate to subtract plastic-binding sequences. The supernatant was then transferred to a well that had previously been incubated for one hour at room temperature in PBS for VEGF or in ASBND (150 mM KCl, 20 mM HEPES, 10 mM MgCl_2 , 1 mM DTT, pH 7.4) for thrombin. After a one hour incubation the well was washed and bound sequences were reverse-transcribed *in situ* using thermoscript reverse transcriptase (Invitrogen) at 65-°C for one hour. The resultant cDNA was then PCR-amplified, separated from dNTPs by gel-filtration, and used to generate modified transcripts for input into the next round of selection. After 10 rounds of selection and amplification the ability of the resultant library to bind to VEGF or thrombin was assessed by Dot-Blot. At this point, the library was cloned, sequenced and individual clones were assayed for their

ability to bind VEGF or thrombin. Using this combination of sequence and clonal binding data, sequence motifs were identified.

[00172] One VEGF aptamer motif, exemplified by ARC224, which was common to both the r/mGmH and toggle selections, was used to design smaller synthetic constructs which were also assayed for binding to VEGF and ultimately minimized aptamers to VEGF were identified, ARC245 and ARC259, both of which are 23 nucleotides long. Another VEGF aptamer motif, exemplified by ARC226, which was common to all 2'-OMe selections, was also identified. The ARC224 aptamer produced by the methods of the present invention has the sequence

5'-mCmGmAmUmAmUmGmCmAmGmUmUmUmGmAmGmAmAmGmUmCmGmCmGmCmAmUmUmCmG-3' (SEQ ID No. 184) where "m" represents a 2'-O-methyl substitution.

[00173] The ARC226 aptamer has the sequence:

5-mGmAmUmCmAmUmGmCmAmUGmUmGmGmAmUmCmGmCmGmGmAmUmC-[3T]-3' (SEQ ID No. 186).

[00174] The ARC245 aptamer has sequence:

5'-mAmUmGmCmAmGmUmUmUmGmAmGmAmAmGmUmCmGmCmGmCmAmU-[3T]-3' (SEQ ID No. 187).

[00175] The ARC259 aptamer has the sequence:

5'-mAmCmGmCmAmGmUmUmUmGmAmGmAmAmGmUmCmGmCmGmCmGmUm-[3T]-3' (SEQ ID No. 188).

[00176] Figure 3A is a graph of VEGF binding by ARC224, ARC245 and ARC259. A schematic representation of the secondary structure of these aptamers is presented in Figure 3B.

[00177] All residues in ARC224, ARC226 and ARC245 are 2'-OMe and all constructs (initially identified by SELEX™) were generated by solid-phase chemical synthesis. The K_D values of these aptamers, determined by dot-blot in PBS, are as follows: ARC224 3.9 nM, ARC245 2.1 nM, ARC259 1.4 nM.

[00178] **Reagents.** All reagents were acquired from Sigma (St. Louis, MO) except where otherwise stated.

[00179] Oligonucleotide synthesis. DNA syntheses were undertaken according to standard protocols using an Expedite 8909 DNA synthesizer (Applied Biosystems, Foster City, CA). The DNA library used in this study had the following sequence: ARC254: 5'-CATCGATGCTAGTCGTAACGATCCNNCGAGAACGTTCTCTCCTCTCCCTATAGTGAGTCGTATTA-3' (SEQ ID NO:1) in which each N has an equal probability of being each of the four nucleotides. 2'-OMe RNA syntheses, including those containing 2'-OH nucleotides, were undertaken according to standard protocols using a 3900 DNA Synthesizer (Applied Biosystems, Foster City, CA). All oligonucleotides were purified by denaturing PAGE except PCR and RT primers.

[00180] 2'-OMe Library Generation. The synthetic DNA library (1.5 nmol) was amplified by PCR under standard conditions with the following primers: 3'-primer 5'-CATCGATGCTAGTCGTAACGATCC-3' (SEQ ID NO:454) and 5'-primer 5'-TAATACGACTCACTATAGGGAGAGAGAGAAACGTTCTCG-3' (SEQ ID NO:455). The resultant library of double-stranded transcription templates was precipitated and separated from unincorporated nucleotides by gel-filtration. At no point was the library denatured, either by thermal means or by exposure to low-salt conditions. r/mGmH transcription was performed under the following conditions to produce template for the first round of selection: double-stranded DNA template 200 nM, HEPES 200 mM, DTT 40 mM, Triton X-100 0.01%, Spermidine 2 mM, 2'-O-methyl ATP, CTP, GTP and UTP 500 μ M each, 2'-OH GTP 30 μ M, GMP 500 μ M, $MgCl_2$ 5.0 mM, $MnCl_2$ 1.5 mM, inorganic pyrophosphatase 0.5 units per 100 μ L reaction, Y639F/H784A T7 RNA polymerase 1.5 units per 100 μ L reaction pH 7.5 and 10% w/v PEG and were incubated at 37 °C overnight. The resultant transcripts were purified by denaturing 10% PAGE, eluted from the gel, incubated with RQ1 DNase (Promega, Madison WI), phenol-extracted, chloroform-extracted, precipitated and taken up in PBS. For the initiation of selection transcripts were additionally generated by the direct chemical synthesis of 2'-OMe RNA, these were purified by denaturing 10% polyacrylamide gel electrophoresis, eluted from the gel and taken up in PBS.

[00181] For the rN, rRmY and rGmH transcriptions, the transcription conditions were as follows, where 1X Tc buffer is: 200 mM HEPES, 40 mM DTT, 2 mM Spermidine, 0.01% Triton X-100, pH 7.5.

[00182] When 2'-OH A, C, U and G (rN) conditions were used, the transcription reaction conditions were $MgCl_2$ 25 mM, each NTP 5 mM, 1X Tc buffer, 10% w/v PEG, T7 RNA

polymerase 1.5 units, and 50-200 nM double stranded template (200 nM of template was used in Round 1 to increase diversity and for subsequent rounds approximately 50 nM, a 1/10 dilution of an optimized PCR reaction using conditions described herein, was used). [00183] When 2'-OMe C and U and 2'-OH A and G (rRmY) conditions were used, the transcription reaction conditions were 1X Tc buffer, 50-200 nM double stranded template (200 nM of template was used in Round 1 to increase diversity and for subsequent rounds approximately 50 nM, a 1/10 dilution of an optimized PCR reaction using conditions described herein, was used), 5.0 mM MgCl₂, 1.5 mM MnCl₂, 0.5 mM each base, 10% PEG-8000, 0.25 units inorganic pyrophosphatase, and 1.5 units Y639F/H784A T7 RNA polymerase.

[00184] When 2'-OMe A, C, and U and 2'-OH G (rGmH) conditions were used, the transcription reaction conditions were 1X Tc buffer, 50-200 nM double stranded DNA template (200 nM of template was used in Round 1 to increase diversity for subsequent rounds approximately 50 nM, a 1/10 dilution of an optimized PCR reaction using conditions described herein, was used), 5.0 mM MgCl₂, 1.5 mM MnCl₂, 0.5 mM each base, 10% PEG-8000, 0.25 units inorganic pyrophosphatase, and 1.5 units Y639F single mutant T7 RNA polymerase in 100 µl volume.

[00185] When 2'-OMe A, C, U and 2'-F G conditions were used, the transcription reaction conditions were as for rGmH, except 0.5 mM 2'-F GTP is used instead of 2'-OH GTP.

[00186] **Reverse Transcription.** The reverse transcription conditions used during SELEX™ are as follows (100 µL reaction volume): 1X Thermo buffer (Invitrogen), 4 µM primer, 10 mM DTT, 0.2 mM each dNTP, 200 µM Vanadate nucleotide inhibitor, 10 µg/ml tRNA, Thermoscript RT enzyme 1.5 units (Invitrogen). Reverse transcriptase reaction yields are lower for 2'-OMe templates. PCR reaction conditions are as follows 1X ThermoPol buffer (NEB), 0.5 µM 5' primer, 0.5 µM 3' primer 0.2 mM each dNTP, Taq DNA Polymerase 5 units (NEB).

[00187] **2'-OMe SELEX™ Protocol.** As noted above, SELEX™ was performed with the modified transcripts against each of two targets (VEGF and Thrombin) using 5 kinds of transcripts for a total of 10 selections. The five kinds of transcripts were: "rN" (all 2'-OH), "rRmY" (2'-OH A, G, 2'-OMe C, U), "rGmH" (2'-OH G, 2'-OMe C, U, A), "r/mGmH" (2'-OMe A, U, G, C 500 uM, 2'-OH G 30 uM), "toggle" (alternately "r/mGmH" and 2'-OMe A, U, C, 2'-F G).

[00188] All of the selections directed against VEGF generated VEGF specific aptamers

while only the rN and rRmY selections against thrombin generated thrombin specific aptamers. The aptamer sequences identified in these selections are set forth in Tables 1 through 5 (VEGF) and Tables 6 through 10 (thrombin) below.

[00189] The sequences are from SELEX™ round 11 except for Thrombin “rGmH”, “r/mGmH” and “toggle” which are from round 5, VEGF “r/mGmH” which is from round 10 and VEGF “toggle” which is from round 8.

[00190] The selection was performed by initially immobilizing the protein by hydrophobic absorption to “NUNC MAXY” plates, washing away the protein that didn’t bind, incubating the library of 2’-OMe-substituted transcripts with the immobilized protein, washing away the transcripts that didn’t bind, performing RT directly in the plate, then PCR, and then transcribing the resultant double-stranded DNA template under the appropriate transcription conditions.

[00191] Binding assays were performed with trace ³²P-body-labelled transcripts that were incubated with various protein concentrations in silanized wells, these were then passed through a sandwich of a nitrocellulose membrane over a nylon membrane. Protein-bound RNA is visualized on the NC membrane, unbound RNA on the nylon membrane. The proportion binding is then used to calculate affinity (see Figures 4, 5, and 6). For example, the binding characteristics of various 2’-OH G variants of ARC224 (all 2-OMe) are shown in Figure 4. The nomenclature “mGXG” indicates a substitution of 2’-OH G for 2’-OMe G at position “X”, as numbered sequentially from the 5’-terminus. Thus, mG7G ARC224 is ARC224 with a 2’-OH at position 7. ARC225 is ARC224 with 2’-OMe to 2’-OH substitutions at positions 7, 10, 14, 16, 19, 22 and 24. All constructs (initially identified by SELEX™) were generated by solid-phase chemical synthesis. These data were generated by dot-blot in PBS. The fully 2’-OMe aptamer, ARC224, has superior VEGF-binding characteristics when compared to any of the 2’-OH substituted variants studied.

[00192] Figure 5 is a plot of ARC224 and ARC225 binding to VEGF. This graph indicates that ARC224 binds VEGF in a manner which inhibits the biological function of VEGF. ¹²⁵I-labeled VEGF was incubated with the aptamer and this mixture was then incubated with human umbilical cord vascular endothelial cells (HUVEC). The supernatant was removed, the cells were washed, and bound VEGF was counted in a scintillation counter. ARC225 has the same sequence as ARC224 and 2’-OMe to 2’-OH substitutions at positions 7, 10, 14, 16, 19, 22 and 24 numbered from the 5’-terminus. These data indicate that the IC₅₀ of ARC224 is approximately 2 nM.

[00193] Figure 6 is a binding curve plot of ARC224 binding to VEGF before and after autoclaving, with or without EDTA. Figure 6 shows both the proportion of aptamer that is functional and the IC_{50} for binding to VEGF before and after autoclaving for 25 minutes with a peak temperature of 125 °C. These data were determined by the inhibition by unlabeled ARC224 of the binding of 5'-labeled ARC224 to 1 nM VEGF in PBS as measured by dot-blot in PBS. Where indicated, samples contained 1 mM EDTA. All constructs (initially identified by SELEX™) were generated by solid-phase chemical synthesis. No degradation of ARC224 was observed within the limitations of this assay.

[00194] Degradation studies show that incubation in plasma at 37 °C over 4 days induces so little degradation that measuring a half-life is not possible, but is at least in excess of 4 days (see, *e.g.*, Figure 7). Figures 7A and 7B are plots of the stability of ARC224 and ARC226, respectively, when incubated at 37 °C in rat plasma. As indicated in the figure, both ARC224 and ARC226 showed no detectable degradation after for 4 days in rat plasma. In these experiments, 5'-labeled ARC224 and ARC226 were incubated in rat plasma at 37 °C and analyzed by denaturing PAGE. All constructs (initially identified by SELEX™) were generated by solid-phase chemical synthesis. The half-life appears to be in excess of 100 hours.

[00195] Tables 1 through Table 10 below show the DNA sequences of aptamers corresponding to the transcribed aptamers isolated from the various libraries, *i.e.* rN, rRmY, rGmH, and r/mGmH, as indicated. The sequence of the aptamers will have uridine residues instead of thymidine residues in the DNA sequences shown. Table 11 shows the stabilized aptamer sequences obtained by the methods of the present invention. As used herein, "3T" refers to an inverted thymidine nucleotide attached to the oligonucleotide phosphodiester backbone at the 5' position, the resulting oligo having two 5'-OH ends and is thus resistant to 3' nucleases.

[00196] Unless noted otherwise, individual sequences listed in the various tables represent the cDNA clones of the aptamers that were selected under the SELEX conditions provided.

The actual aptamers provided in the invention are those corresponding sequences comprising the rN, mN, rRmY, rGmH, r/mGmH, dRmY and toggle combinations of residues, as indicated in the text.

2'-OMe SELEX™ Results.

[00197] TABLE 1 – Corresponding cDNAs of the VEGF Aptamer Sequences – all 2'-OH (rN)

SEQ ID No. 3 >PB.97.126.F_43-H1
GGGAGAGGAGAGAACGTTCTCGAAATGATGCATGTTTCGTAAATGGCAGTATTGGATCGTTACAACCTAGCATCG
ATG

SEQ ID No. 4 >PB.97.126.F_43-A2
GGGAGAGGAGAGAACGTTCTCGTCCGAGGTCCGGAACCTTGATGATTGGCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 5 >PB.97.126.F_48-A1
GGGAGAGGAGAGAACGTTCTCGCATTGTTGGCTAGTTGTGAAATGGCAGTATTGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 6 >PB.97.126.F_48-B1
GGGAGAGGAGAGAACGTTCTCGAATCGTAGATAGTCGTGAAATGGCAGTATTGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 7 >PB.97.126.F_48-C1
GGGAGAGGAGAGAACGTTCTCGTCTAGTCGGTACGATATGTTGACGAATCCGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 8 >PB.97.126.F_48-D1
GGGAGAGGAGAGAACGTTCTCGTTTGATGAGGCGGACATAATCCGTGCCGAGCGGGATCGTTACGACTAGCATC
GATG

SEQ ID No. 9 >PB.97.126.F_48-E1
GGGAGAGGAGAGAACGTTCTCGAAGGAAAGAGTTTAGTATTGGCCGTCCGTGGGATCGTTACGACTAGCATCG
ATG

SEQ ID No. 10 >PB.97.126.F_48-F1
GGGAGAGGAGAGAACGTTCTCGTGCCGAGGTCCGGAACCTTGATGATTGGCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 11 >PB.97.126.F_48-G1
GGGAGAGGAGAGAACGTTCTCGTACGGTCCATTGAGTTTGAGATGTCGCCATGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 12 >PB.97.126.F_48-B2
GGGAGAGGAGAGAACGTTCTCGAGTTAGTGGTAACTGATATGTTGAATTGTCCGGATCGTTACGACTAGCATCG
ATG

SEQ ID No. 13 >PB.97.126.F_48-C2
GGGAGAGGAGAGAACGTTCTCGCACGGATGGCGAGAACAGAGATTGCTAGGTGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 14 >PB.97.126.F_48-D2
GGGAGAGGAGAGAACGTTCTCGNTANCGNTNCGCCNTGCTAACGCNTANTTGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 15 >PB.97.126.F_48-E2
GGGAGAGGAGAGAACGTTCTCGAAGATGAGTTTGTGTCGTGAAATGGCAGTATTGGATCGTTACGACTAGCATCG
ATG

SEQ ID No. 16 >PB.97.126.F_48-F2
GGGAGAGGAGAGAACGTTCTCGGGATGCCGGATTGATTTCTGATGGGTACTGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 17 >PB.97.126.F_48-G2
GGGAGAGGAGAGAACGTTCTCGAATGGAATGCATGTCCATCGCTAGCATTTGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 18 >PB.97.126.F_48-H2

GGGAGAGGAGAGAACGTTCTCGTGCTGAGGTCCGGAACCTTGATGATTGGCGGGATCGTTNCNACTAGCATCGA
TG

SEQ ID No. 19 >PB.97.126.F_48-A3
GGGAGAGGAGAGAACGTTCTCGCTAATTGCTGAGTCGTGAAGTGGCAGTATTGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 20 >PB.97.126.F_48-B3
GGGAGAGGAGAGAACGTTCTCGTAACGATGTCCGGGGCGAAAGGCTAGCATGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 21 >PB.97.126.F_48-C3
GGGAGAGGAGAGAACGTTCTCGATGCGATTGTGCGAGATTGTGAAGATAGCTGTGGATCGTTACGACTAGCATCG
ATG

**[00198] TABLE 2 – Corresponding cDNAs of the VEGF Aptamer Sequences – 2'-OH
AG, 2'-OMe CU (rRmY)**

SEQ ID No. 22 >PB.97.126.G_43-D3
GGGAGAGGAGAGAACGTTCTCGCAGAAAACATCTTTGCGGTTGAATACATGTGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 23 >PB.97.126.G_43-G3
GGGAGAGGAGAGAACGTTCTCGAAAAAGANANCNNCCTTCNGAATACATGCGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 24 >PB.97.126.G_48-E3
GGGAGAGGAGAGAACGTTCTCGAGAGTGATTCGATGCTTCANGAATACATGTGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 25 >PB.97.126.G_48-F3
GGGAGAGGAGAGAACGTTCTCGACANNNCNTNGCTNGGTTGANTACATGTGNNTNTCNNNANCNNTNNTCTNTN
ANAGGGG

SEQ ID No. 26 >PB.97.126.G_48-H3
GGGAGAGGAGAGAACGTTCTCGAAGAAGGAAAGCTGCAAGTCAATACACGCGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 27 >PB.97.126.G_48-A4
GGGAGAGGAGAGAACGTTCTCGCAAAAACATCGATTACAGTTGAGTACATGTGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 28 >PB.97.126.G_48-B4
GGGAGAGGAGAGAACGTTCTCGAGACATCATTGCTCGTTGAATACATGTGGATCGTTACGACTAGCATCGATG

SEQ ID No. 29 >PB.97.126.G_48-C4
GGGAGAGGAGAGAACGTTCTCGCCAAAGTAGCTTCGACAGTCAATACATGTGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 30 >PB.97.126.G_48-D4
GGGAGAGGAGAGAACGTTCTCGAAAATCAGTACTGTGCAGTCAATACATGCGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 31 >PB.97.126.G_48-E4
GGGAGAGGAGAGAACGTTCTCGTAATGACATCAATGCTTCTTGAATACAGGTGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 32 >PB.97.126.G_48-F4
GGGAGAGGAGAGAACGTTCTCGAGAAAAACGATCTGTGACGTGTAATCCGCGGATCGTTACGACTAGCATCGAT
G

SEQ ID No. 33 >PB.97.126.G_48-G4
GGGAGAGGAGAGAACGTTCTCGCAACAAACGTGACGCTTCTGAATACATGTGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 34 >PB.97.126.G_48-H4
GGGAGAGGAGAGAACGTTCTCGTGATCATAGAAATGCTAGCTGAATACATGTGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 35 >PB.97.126.G_48-A5
GGGAGAGGAGAGAACGTTCTCGCAGCGTAAATGCTTTTCGAAGTACATGTGGATCGTTACGACTAGCATCGAT
G

SEQ ID No. 36 SEQ ID No. >PB.97.126.G_48-B5
GGGAGAGGAGAGAACGTTCTCGCCAAGAATCAATCGCTTGTCGAATACATGCGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 37 >PB.97.126.G_48-C5
GGGAGAGGAGAGAACGTTCTCGTGATCATAGAAATGCTAGCTGAGTACATGTGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 38 >PB.97.126.G_48-D5
GGGAGAGGAGAGAACGTTCTCGCAGAAAACATCTTTGCGGTTGAATACATGTGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 39 >PB.97.126.G_48-E5
GGGAGAGGAGAGAACGTTCTCGNAAACANNCATCTATTGNAGTTGAATACATGTGGATCGTTACGACTAGCATC
GATG

SEQ ID No. 40 >PB.97.126.G_48-F5
GGGAGAGGAGAGAACGTTCTCGCTAAAGATTGCTGCTTGCCGAATACATGTGGATCGTTACGACTAGCATCGA
TG

[00199] TABLE 3 – Corresponding cDNAs of the VEGF Aptamer Sequences – 2'-OH G,
2'-OMe CUA (rGmH)

SEQ ID No. 41 >PB.97.126.H_43-H6
GGGAGAGGAGAGAACGTTCTCGGGTTTTGTCTGCGTTTGTGCGTTGAACCCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 42 >PB.97.126.H_43-F7
GGGAGAGGAGAGAACGTTCTCGTGATTACGTGATGAGGATCCGCGTTTTCTCGGGATCGTTACGACTAGCATCG
ATG

SEQ ID No. 43 >PB.97.126.H_43-H7
GGGAGAGGAGAGAACGTTCTCGTTAGTGAACGATCATGCATGTGGATCGCGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 44 >PB.97.126.H_48-H5
GGGAGAGGAGAGAACGTTCTCGTGTTTCATTGCTTTGCTTATCGTTGCATGTGGATCGTTACGACTAGCATCGAT
G

SEQ ID No. 45 >PB.97.126.H_48-A6
AGGAGAGGAGAGAACGTTCTCGGCAGAGTGTGATGTGCATCCGCACGTGCCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 46 >PB.97.126.H_48-B6
GGGAGAGGAGAGAACGTTCTCGTTAGTAAATACGATCGTGCATGTGGATCGCGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 47 >PB.97.126.H_48-C6
GGGAGAGGAGAGAACGCCCCCTGATTNCGTGAAGAGGATCCGCANTTTCNCGGGATCGTTACGACTAGCATCG
ATG

SEQ ID No. 48 >PB.97.126.H_48-D6
GGGAGAGGAGAGAACGTTCTCGTGGCTTTGGAACGGGTACGGATTTGGCACGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 49 >PB.97.126.H_48-E6

GGGAGAGGAGAGAACGTTCTCGTGATTACGTGATGAGGATCCGCGTTTCTCGGGATCGTTACGACTAGCATCG
ATG

SEQ ID No. 50 >PB.97.126.H_48-F6
GGGAGAGGAGAGAACGTTCTCGTCATTGGTGACNGCGTTGCATGTGGATCGCGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 51 >PB.97.126.H_48-G6
GGGAGAGGAGAGAACGTTCTCGNTGGTNNANGCTTTTGTNGGGNTANNTGTGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 52 SEQ ID No. >PB.97.126.H_48-A7
GGGAGAGGAGAGAACGTTCTCGTGGCTTTGGAACGAATTCGGATTGGCACGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 53 >PB.97.126.H_48-B7
GGGAGAGGAGAGAACGTTCTCGTGCATGTCGTGGATTTCGGTTTCGCAAGGGATCGTTACGACTAGCATCGAT
G

SEQ ID No. 54 >PB.97.126.H_48-C7
GGGAGAGGAGAGAACGTTCTCGTGAAGCAGATGTCGTGGCGACTTAGAGGGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 55 >PB.97.126.H_48-D7
GGGAGAGGAGAGAACGTTCTCGTGATTTCGTGATGAGGATCCGCGTTTCTCGGGATCGTTACGACTAGCATCG
ATG

SEQ ID No. 56 >PB.97.126.H_48-E7
GGGAGAGGAGAGAACGTTCTCGCTAGTAACGATGACTTGATGAGCATCCGAGGATCGTTACGACTAGCATCGAT
G

SEQ ID No. 57 >PB.97.126.H_48-G7
GGGAGAGGAGAGAACGTTCTCGTCATAAGTAACGACGTTGCATGTGGATCGCGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 58 >PB.97.126.H_48-A8
GGGAGAGGAGAGAACGTTCTCGCAAGGAGATGGTTGCTAGCTGAGTACATGTGGATCGTTACGACTAGCATCGA
TG

**[00200] TABLE 4 – Corresponding cDNAs of the VEGF Aptamer Sequences – 2'-OMe
AUGC (r/mGmH, each G has a 90% probability of having a 2'-OMe group incorporated
therein)**

SEQ ID No. 59 PB.97.126.I_43-B8
GGGAGAGGAGAGAACGTTCTCGCGATATGCAGTTGAGAAGTCGCGCATTGGGGGATCGTTACGACTAGCATC
GATG

SEQ ID No. 60 >PB.97.126.I_48-C8
GGGAGAGGAGAGAACGTTCTCGTGCACGGGCTTCTTGTGTCATTGCGATGGGATCGTTACGACTAGCATCGAT
G

SEQ ID No. 61 >PB.97.126.I_48-D8
GGGAGAGGAGAGAACGTTCTCGGCATTGCAGTTGATAGGTCGCGCAGTGCTGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 62 >PB.97.126.I_48-E8
GGGAGAGGAGAGAACGTTCTCGCGATATGCAGTCTGAGAAGTCGCGCATTGAGGGATCGTTACGACTAGCATC
GATG

SEQ ID No. 63 >PB.97.126.I_48-F8
GGGAGAGGAGAGAACGTTCTCGTGTAGCAAGCATGTGGATCGCGACTGCACGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 64 >PB.97.126.I_48-G8

GGGAGAGGAGAGAACGTTCTCGGATAAGCAGTTGAGATGTCGCGCTTTGACGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 65 >PB.97.126.I_48-H8
GGGAGAGGAGAGAACGTTCTCGATGANCANTTTGAGAAGTCGCGCTTGTCGGGATCGTTACGACTAGCATCGAT
G

SEQ ID No. 66 >PB.97.126.I_48-A9
GGGAGAGGAGAGAACGTTCTCGAGTAATGCAGTGGAAGTCGCGCATTACCTGGGATCGTTACGACTAGCATCAT
G

SEQ ID No. 67 >PB.97.126.I_48-B9
GGGAGAGGAGAGAACGTTCTCGGATATGCAGTTTGAGAAGTCGCGCATTCTGGGGATCGTTACGACTAGCATC
GATG

SEQ ID No. 68 >PB.97.126.I_48-C9
GGGAGAGGAGAGAACGTTCTCGTGATNCAGTTGANAAGTCNCGCATAACAGGATCGTTACGACTAGCATCGATG

SEQ ID No. 69 >PB.97.126.I_48-D9
GGGAGAGGAGAGAACGTTCTCGAGTAATGCTGTGGAAGTCGCGCATTTCTGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 70 >PB.97.126.I_48-D8
GGGAGAGGAGAGAACGTTCTCGGCATTGCAGTTGATAGGTCGCGCAGTGCTGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 71 >PB.97.126.I_48-F9
GGGAGAGGAGAGAACGTTCTCGGATATGCAGTTTGGAAGTCGCGCATTCTGAGGGATCGTTACGACTAGCATC
GATG

SEQ ID No. 72 >PB.97.126.I_48-G9
GGGAGAGGAGAGAACGTTCTCGCNATATGCTGTTTGANAANTCGCGCATTCTGGGGATCGTTACGACTAGCATC
GATG

SEQ ID No. 73 >PB.97.126.I_48-H9
GGGAGAGGAGAGAACGTTCTCGCGTAGATTGGGCTGAATGGGATATCTTTAGCGGGATCGTTACGACTAGCATC
GATG

SEQ ID No. 74 >PB.97.126.I_48-B10
GGGAGAGGAGAGAACGTTCTCGGATATGCAGTTTGAGAAGTCGCGCTTTCTGAGGGATCGTTACGACTAGCATC
GATG

SEQ ID No. 75 >PB.97.126.I_48-D10
GGGAGAGGAGAGAACGTTCTCGTCAATCTGATGTAGCCTCACGTGGGCGGAGTCGGATCGTTACGACTAGCATC
GATG

**[00201] TABLE 5 – Corresponding cDNAs of the VEGF Aptamer Sequences – alternately
“r/mGmH” and 2’-OMe AUC, 2’-F G (toggle)**

SEQ ID No. 76 >PB.97.126.J_48-F10
GGGAGAGGAGAGAACGTTCTCGGATCGTTACGACTAGCATCGATG

SEQ ID No. 77 >PB.97.126.J_48-G10
GGGAGAGGAGAGAACGTTCTCGGATCGTTACGACTAGCATCGATG

SEQ ID No. 78 >PB.97.126.J_48-H10
GGGAGAGGAGAGAACGTTCTCGGTGGTGTGCTGAAGTGTGCGGTTTCGCCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 79 >PB.97.126.J_48-A11
GGGAGAGGAGAGAACGTTCTCGTCGCGATTGCATATTTCCGCCTTGCTGTGAGGATCGTTACGACTAGCATCG
ATG

SEQ ID No. 80 >PB.97.126.J_48-B11

GGGAGAGGAGAGAACGTTCTCGCGATTTGCAGTTTGAGATGTCGCGCATTTCGAGGGATCGTTACGACTAGCATC
GATG

SEQ ID No. 81 >PB.97.126.J_48-C11
GGGAGAGGAGAGAACGTTCTCGCGATATGCAGTTTGAGAAGTCGCGCATTTCGGGGGATCGTTACGACTAGCATC
GATG

SEQ ID No. 82 >PB.97.126.J_48-D11
GGGAGAGGAGAGAACGTTCTCGTTGGTGCAGTTTGAGATGTCGCGCACCTTGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 83 >PB.97.126.J_48-E11
GGGAGAGGAGAGAACGTTCTCGGTATTGGTTCCATTAAAGCTGGACACTCTGCTCCGGGATCGTTACGACTAGCA
TCGATG

SEQ ID No. 84 >PB.97.126.J_48-F11
GGGAGAGGAGAGAACGTTCTCGTTGGTGCAGTTTGAGATGTCGCGCGCCTTGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 85 >PB.97.126.J_48-G11
GGGAGAGGAGAGAACGTTCTCGCGATATGCAGTTTGAGAAGTCGCGCATTTCGAGGGATCGTTACNACTAGCATC
GATG

SEQ ID No. 86 >PB.97.126.J_48-A12
GGGAGAGGAGAGAACGTTCTCGCGATATGCAGTTTGAGAAGTCGCGCATTTCGGGGGATCGTTACGACTAGCATC
GATG

SEQ ID No. 87 >PB.97.126.J_48-B12
GGGAGAGGAGAGAACGTTCTCGGGGACNNAAANNCGAATTGNCGCGTGNGTCCGGGGGAGCGCCCGACTAGTCA
TCGATG

SEQ ID No. 88 >PB.97.126.J_48-C12
GGGAGAGGAGAGAACGTTCTCGCGATATGNANTTTGAGAAGTCGCGCATTTCGGGGGATCGTTACGACTAGCATC
GATG

SEQ ID No. 89 >PB.97.126.J_48-D12
GGGAGAGGAGAGAACGTTCTCGGTGTACAGCTTGAGATGTCGCGTACTCCGGGATCGTTACGACTAGCATCGAT
G

SEQ ID No. 90 >PB.97.126.J_48-E12
GGGAGAGGAGAGAACGTTCTCGCGATATGCAGTTTGAGAAGTCGCGCATTTCGGGGGATCGTTACGACTAGCATC
GATG

SEQ ID No. 91 >PB.97.126.J_48-F12
GGGAGAGGAGAGAACGTTCTCGAGTAAGAAAGCTGAATGGTCGCACTTCTCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 92 >PB.97.126.J_48-G12
AGGGAGAGGAAGAACGTTCTCGCGATGTGCAGTTTGAGAAGTCGCGCATTTCGAGGGATCGTTACGACTAGCATC
GATG

SEQ ID No. 93 >PB.97.126.J_48-H12
GGGAGAGGAGAGAACGTTCTCGAAAGAATCAGCATGCGGATCGCGGCTTTCGGGATCGTTACGACTAGCATCGA
TG

[00202] TABLE 6 – Corresponding cDNAs of the Thrombin Aptamer Sequences – all 2'-
OH (rN)

SEQ ID No. 94 >PB.97.126.A_44-A1
GGGAGAGGAGAGAACGTTCTCGANTCCANTNTNCNTGGAGGAGTAAGTACCTGAGGGATCGTTACGACTAGCAT
CGATG

SEQ ID No. 95 >PB.97.126.A_44-B1

GGGAGAGGAGAGAACGTTCTCGGGAAACAAGGAACCTTAGAGTTANTTGACCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 96 >PB.97.126.A_44-C1
GGGAGAGGAGAGAACGTTCTCGTACCATGCAAGGAACATAATAGTTAGCGTGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 97 >PB.97.126.A_44-D1
GGGAGAGGAGAGAACGTTCTCGGGACACAAGGAACACAATAGTTAGTGTACGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 98 >PB.97.126.A_44-E1
GGGAGAGGAGAGAACGTTCTCGTCTGCAAGGAACACAATAGTTAGCATTGCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 99 >PB.97.126.A_44-F1
GGGAGAGGAGAGAACGTTCTCGCGCCAACAAGCTGGAGTACTTAGAGCGCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 100 >PB.97.126.A_44-G1
GGGAGAGGAGAGAACGTTCTCGATTGCAAAATAGCTGTAGAATAAGCAATCGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 101 >PB.97.126.A_44-H1
GGGAGAGGAGAGAACGTTCTCGTGAGATGACTATGTTAAGATGACGCTGTTGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 102 >PB.97.126.A_44-A2
GGGAGAGGAGAGAACGTTCTCGGGANACAAGGAACNCAATATTTAGTGAACGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 103 >PB.97.126.A_44-B2
GGGAGAGGAGAGAACGTTCTCGCCAAGGAACACAATAGTTAGGTGAGAATCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 104 >PB.97.126.A_44-C2
GGGAGAGGAGAGAACGTTCTCGGTACAAGGAACACAATAGTTAGTGCCGTGGGATCGTTACGACTAGCATCGAT
G

SEQ ID No. 105 >PB.97.126.A_44-D2
GGGAGAGGAGAGAACGTTCTCGATTCAACGGTCCAAAAAGCTGTAGTACTTAGGATCGTTACGACTAGCATCG
ATG

SEQ ID No. 106 >PB.97.126.A_44-E2
GGGAGAGGAGAGAACGTTCTCGCAATGCAAGGAACACAATAGTTAGCAGCCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 107 >PB.97.126.A_44-F2
GGGAGAGGAGAGAACGTTCTCGAAAGGAGAAAGCTGAAGTACTTACTATGCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 108 >PB.97.126.A_44-G2
GGGAGAGGAGAGAACGTTCTCGCACAAAGGAACACAATAGTTAGTGCAAGACGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 109 >PB.97.126.A_44-A3
GGGAGAGGAGAGAACGTTCTCGCACAAAGGAACACAATAGTTAGTGTGGGAGTGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 110 >PB.97.126.A_44-B3
GGGAGAGGAGAGAACGTTCTCGCACAAAGGAACACAATAGTTAGTGCAAGACGGGATCGTTACGACTAGCATCGA
TA

SEQ ID No. 111 >PB.97.126.A_44-C3
GGGAGAGGAGAGAACGTTCTCGGCGGGAAAATAGCTGTAGTACTAACCACGGGATCGTTACGACTAGCATCGAT
G

[00203] TABLE 7 – Corresponding cDNAs of the Thrombin Aptamer Sequences – 2'-OH
AG, 2'-OMe CU (rRmY)

SEQ ID No. 112 >PB.97.126.B_44-E3
GGGAGAGGAGAGAACGTTCTCGGCCTCAAGGAAAAGAAAATTTAGAGGCCCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 113 >PB.97.126.B_44-F3
GGGAGAGGAGAGAACGTTCTCGGAACAAGATAGCTGAAGGACTAAGTTTACGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 114 >PB.97.126.B_44-G3
GGGAGAGGAGAGAACGTTCTCGGAACAAGATAGCTGAAGGACTAAGTTTACGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 115 >PB.97.126.B_44-H3
GGGAGAGGAGAGAACGTTCTCGGAGCCAAGGAAACGAAGATTTAGGCTCATTGGGATCGTTACGACTAGCATCG
ATG

SEQ ID No. 116 >PB.97.126.B_44-A4
GGGAGAGGAGAGAACGTTCTCGATCACAAGAAATGTGGGANGGTAGTGATNCNNNTCGTTNCGACTAGCATCGA
TG

SEQ ID No. 117 >PB.97.126.B_44-B4
GGGAGAGGAGAGAACGTTCTCGTCGAAAGGGAGCTTTGTCTCGGGACAGAACGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 118 >PB.97.126.B_44-C4
GGGAGAGGAGAGAACGNTCTCGTGCAAAGATAGCTGGAGGACTAATGCGGCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 119 >PB.97.126.B_44-D4
GGGAGAGGAGAGAACGTTCTCGTCGAAAGGGAGCTTTGTCTCGGGACAGAACGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 120 >PB.97.126.B_44-E4
GGGAGAGGAGAGAACGTTCTCGNCNAAGNGAGCTTTGTCCNGGACANAANGNATCGTTACAAGTACGACTAGCATCGA
TG

SEQ ID No. 121 >PB.97.126.B_44-F4
GGGAGAGGAGAGAACGTTCTCGGAACAAGATAGCTGAAGGACTAAGTTTACGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 122 >PB.97.126.B_44-G4
GGGAGAGGAGAGAACGTTCTCGGAACAAGATAGCTGAAGGACTAAGTTTACGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 123 >PB.97.126.B_44-H4
GGGAGAGGAGAGAACGTTCTCGGCGCAAAAAAGCTGGAGTACTTAGTGTCGAGGGATCGTTACGACTAGCATC
GATG

SEQ ID No. 124 >PB.97.126.B_44-A5
GGGAGAGGAGAGAACGTTCTCGTCGAAAGGGAGCTTTGTCTCGGGACAGAACGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 125 >PB.97.126.B_44-B5
GGGAGAGGAGAGAACGTTCTCGACACAAGAAAGCTGCAGAACTTAGGGTCGTGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 126 >PB.97.126.B_44-C5
GGGAGAGGAGAGAACGTTCTCGGAACNGGATTGTTGAAGGACTAANTTTACGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 127 >PB.97.126.B_44-D5

GGGAGAGGAGAGAACGTTCTCGGCCTCAAGGGAAAGAAAATTTAGAGGCCCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 128 >PB.97.126.B_44-E5
GGGAGAGGAGAGAACGTTCTCGGAAACAAGCTTAGAAATTCGCACCCTTGCCGGGATCGTTACGACTAGCATCG
ATG

SEQ ID No. 129 >PB.97.126.B_44-F5
GGGAGAGGAGAGAACGTTCTCGAAAGAAAAAGCTGGAGAACTTACTTCCGGGATCGTTACGACTAGCATCGAT
G

SEQ ID No. 130 >PB.97.126.B_44-G5
GGGAGAGGAGAGAACGTTCTCGGTGATTGTACTCACATAGAAATGGCAACACTGGGATCGTTACGACTAGCATC
GATG

[00204] TABLE 8 – Corresponding cDNAs of the Thrombin Aptamer Sequences – 2'-OH
G, 2'-OMe CUA (rGmH)

SEQ ID No. 131 >PB.97.126.C_44-H5
GGGAGAGGAGAGAACGTTCTCGGGTTCAAGGAACATGATAGTTAGAACCCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 132 >PB.97.126.C_44-A6
GGGAGAGGAGAGAACGTTCTCGTTCGGAAGGAACACAATAGTTATCGGATTGGGATCGTTACGACTAGCATCG
ATG

SEQ ID No. 133 >PB.97.126.C_44-B6
GGGAGAGGAGAGAACGTTCTCGTCTGCAAGGAACACAATAGTTAGCATTGCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 134 >PB.97.126.C_44-C6
GGGAGAGGAGAGAACGTTCTCGGTACAAGGAACACAATAGTTAGTGCCGGGGATCGTTACGACTAGCATCGATG

SEQ ID No. 135 >PB.97.126.C_44-D6
GGGAGAGGAGAGAACGTTCTCGGAACTCAGAGATCCTATGTGGACCAGAGAGGATCGTTACGACTAGCATCGAT
G

SEQ ID No. 136 >PB.97.126.C_44-E6
GGGAGAGGAGAGAACGTTCTCGCTGAGCAAGGAACGTAATAGTTAGCCTGCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 137 >PB.97.126.C_44-F6
GGGAGAGGAGAGAACGTTCTCGNANNNATAAATGATGGATCNCCTTATTGTNNAGGATCGTTACGACTAGCATCG
ATG

SEQ ID No. 138 >PB.97.126.C_44-G6
GGGAGAGGAGAGAACGTTCTCGGCTTGGAAAAATAGCTTTTGGGCATCCGGGATCGTTACGACTAGCATCGATG

SEQ ID No. 139 >PB.97.126.C_44-H6
GGGAGAGGAGAGAACGTTCTCGGGTTCAAGGAACATGATAGCTAGAACCCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 140 >PB.97.126.C_44-A7
GGGAGAGGAGAGAACGTTCTCGGGTTCAAGGAACATGATAGTTAGAACCCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 141 >PB.97.126.C_44-B7
GGGAGAGGAGAGAACGTTCTCGTGGGCAGGGAACACAATAGTTAGCCTACGCGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 142 >PB.97.126.C_44-C7
GGGAGAGGAGAGAACGTTCTCGCGTGAAAGGAACACAATAGTTATCGTGCGGGATCGTTACGACTAGCATCGAT
G

SEQ ID No. 143 >PB.97.126.C_44-D7

GGGAGAGGAGAGAACGTTCTCGCGAGGTTTATCCTAGACGACTAACCGCCTGGGGATCGTTACGACTAGCATCG
ATG

SEQ ID No. 144 >PB.97.126.C_44-F7
GGGAGAGGAGAGAACGTTCTCGTCTGCTAGGAACACAATAGTTAGCATTGCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 145 >PB.97.126.C_44-G7
GGGAGAGGAGAGAACGTTCTCGCACAAAGGAACACTACGAGTTAGTGTGGGAGTGGGGATCGTTACGACTAGCATCG
ATG

SEQ ID No. 146 >PB.97.126.C_44-H7
GGGAGAGGAGAGAACGTTCTCGTGACACGAGGAACCTTAGAGTTAGTAGCAGGAGATCGTTACGACTAGCATCG
ATG

SEQ ID No. 147 >PB.97.126.C_44-A8
GGGAGAGGAGAGAACGTTCTCGGCGGCGAAGGAACACAATAGTTACGTCCCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 148 >PB.97.126.C_44-B8
GGGAGAGGAGAGAACGTTCTCGAGCCCCAAAAGCTGAAGTACTTTGGGCAGGGATCGTTACGACTAGCATCGA
TG

[00205] TABLE 9 – Corresponding cDNAs of the Thrombin Aptamer Sequences – 2'-
OMe AUGC (r/mGmH, each G has a 90% probability of having a 2'-OMe group
incorporated therein)

SEQ ID No. 149 >PB.97.126.D_44-D8
GGGAGAGGAGAGAACGTTCTCGGTACAAGGAACACAATAGTTAGTGCCGTGGGATCGTTACGACTAGCATCGAT
G

SEQ ID No. 150 >PB.97.126.D_44-E8
GGGAGAGGAGAGAACGTTCTCGGATCGTTACGACTAGCATCGATG

SEQ ID No. 151 >PB.97.126.D_44-G8
GGGAGAGGAGAGAACGTTCTCGTGCGCAAGGAACACAATAGTTAGGGCGCGAGGATCGTTACGACTAGCATTGA
TG

SEQ ID No. 152 >PB.97.126.D_44-H8
GGGAGAGGAGAGAACGTTCTCGGAATGGAAGGAACACAATAGTTACCAGACGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 153 >PB.97.126.D_44-A9
GGGAGAGGAGAGAACGTTCTCGTCTGCAAGGAACACAATAGTTAGCATTGCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 154 >PB.97.126.D_44-B9
GGGAGAGGAGAGAACGTTCTCGAGACAAGACAGCTGGAGGACTAAGTCACGAGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 155 >PB.97.126.D_44-C9
GGGAGAGGAGAGAACGTTCTCGATGCCCGCAAAGGAACACGATAGTTATGCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 156 >PB.97.126.D_44-D9
GGGAGAGGAGAGAACGTTCTCGTCTGNNAAGGAACACAATATTTAGCATTGCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 157 >PB.97.126.D_44-E9
GGGAGAGGAGAGAACGTTCTCGAATGTGCGGAGCAGTATTGGTACACTTTGCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 158 >PB.97.126.D_44-F9

GGGAGAGGAGAGAACGTTCTCGCCAAGGAACACAATAGTTAGGTGAGAATCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 159 >PB.97.126.D_44-G9
GGGAGAGGAGAGAACGTTCTCGCCAAGGAACACAATAGTTAGGTGAGAATCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 160 >PB.97.126.D_44-H9
GGGAGAGGAGAGAACGTTCTCGGGAAGCAAGGAACCTAGAGTTAGTTGACCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 161 >PB.97.126.D_44-A10
GGGAGAGGAGAGAACGTTCTCGTGGGCAAGGAACACAATAGTTAGCCTACGCGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 162 >PB.97.126.D_44-B10
GGGAGAGGAGAGAACGTTCTCGTGGGCAAGGAACACAATAGTTAGACCGCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 163 >PB.97.126.D_44-C10
GGGAGAGGAGAGAACGTTCTCGGTGCAAGGAACATAATAGTTAGCGGAGGGGATCGTTACGACTAGCATCGAT
G

SEQ ID No. 164 >PB.97.126.D_44-D10
GGGAGAGGAGAGAACGTTCTCGTCTGCAAGGAACACAATAGTTAGCATTGCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 165 >PB.97.126.D_44-E10
GGGAGAGGAGAGAACGTTCTCGCCGACAATCAGCTCGGATCGTGTGCTACGCTGGATCGTTACGACTAGCATCG
ATG

[00206] TABLE 10 – Corresponding cDNAs of the Thrombin Aptamer Sequences – alternately “r/mGmH” and 2'-OMe AUC, 2'-F G (toggle).

SEQ ID No. 166 >PB.97.126.E_44-F10
GGGAGAGGAGAGAACGTTCTCGAGACAAGATAGCTGAAGGACTAAGTCACGAGGGATCGTTACGACTAGCATCG
ATG

SEQ ID No. 167 >PB.97.126.E_44-G10
GGGAGAGGAGAGAACGTTCTCGGAACAAGATAGCTGAAGGACTAAGTTTTCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 168 >PB.97.126.E_44-H10
GGGAGAGGAGAGAACGTTCTCGGAGNCAAGGAAACNAATATTTAGGCTCANTGGNNNCNTTNCANCTAGCNNCN
NTA

SEQ ID No. 169 >PB.97.126.E_44-A11
GGGAGAGGAGAGAACGTTCTCGTCTGCAAGGAACACAATAGTTAGCATTGCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 170 >PB.97.126.E_44-B11
GGGAGAGGAGAGAACGTTCTCGGAACAAGATAGCTGAAGGACTAAGTTTACGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 171 >PB.97.126.E_44-C11
GGGAGAGGAGAGAACGTTCTCGGATCGTTACGACTAGCATCGATG

SEQ ID No. 172 >PB.97.126.E_44-D11
GGGAGAGGAGAGAACGTTCTCGGTGATAGTACTACATAGAAATGGCTACACTGGGATCGTTACGACTAGCATC
GATG

SEQ ID No. 173 >PB.97.126.E_44-E11
GGGAGAGGAGAGAACGTTCTCGCCTGGGCAAGGAACAGAAAAGTTAGCGCCAGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 174 >PB.97.126.E_44-F11
GGGAGAGGAGAGAACGTTCTCGTAACGGACAAAAGGAACCGGGAAGTTATCTGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 175 >PB.97.126.E_44-G11
GGGAGAGGAGAGAACGTTCTCGCGCACAAAGATAGAGAAGACTAAGTCCGCGGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 176 >PB.97.126.E_44-H11
GGGAGAGGAGAGAACGTTCTCGCGCACAAAGATAGAGAAGACTAAGTTCGCGGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 177 >PB.97.126.E_44-A12
GGGAGAGGAGAGAACGTTCTCGCGCCAATAAAGCTGGAGTACTTAGAGCGCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 178 >PB.97.126.E_44-B12
GGGAGAGGAGAGAACGTTCTCGGGAACAAGGAAGTTAGAGTTAGTTGACCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 179 >PB.97.126.E_44-C12
GGGAGAGGAGAGAACGTTCTCGCTAGCAAGATAGGTGGGACTAAGCTAGTGAGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 180 >PB.97.126.E_44-D12
GGGAGAGGAGAGAACGTTCTCGTCGAAGGGGAGCTTTGTCTCGGGACAGAACGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 181 >PB.97.126.E_44-E12
GGGAGAGGAGAGAACGTTCTCGGAACAAGATAGCTGAAGGACTAAGTTTACGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 182 >PB.97.126.E_44-G12
GGGAGAGGAGAGAACGTTCTCGGAACAAGATAGCTGAAGGACTAAGTTTGCGGGATCGTTACGACTAGCATCGA
TG

SEQ ID No. 183 >PB.97.126.E_44-H12
GGGAGAGGAGANNTCCCNCCNCGGAAAAANAAAAAGAAGAANTANGTTNGGGGGATCGTTACGACTAGCATCG
ATG

[00207] Table 11 – Stabilized Aptamer Sequences (each G residue has 90% probability of being substituted with a 2'-OMe group, "3T" refers to an inverted thymidine nucleotide attached to the phosphodiester backbone at the 5' position, the resulting oligo having two 5'-OH ends and is thus resistant to 3' nucleases).

SEQ ID No. 184 ARC224 -Stabilized VEGF Aptamer
5' mCmGmAmUmAmUmGmCmAmGmUmUmUmGmAmGmAmAmGmUmCmGmCmGmCmAmUmUmCmG-3T

SEQ ID No. 185 ARC225 - Stabilized VEGF Aptamer
5' mCmGmAmUmAmUmGmCmAmGmUmUmUmGmAmAmAmGmUmCmGmCmAmUmUmCmG-3T

SEQ ID No. 186 ARC226 Single-hydroxy VEGF aptamer
5' mGmAmUmCmAmUmGmCmAmUmUmGmGmAmUmCmGmCmGmAmUmC-3T

SEQ ID No. 187 ARC245 VEGF Aptamer
5' mAmUmGmCmAmGmUmUmUmGmAmGmAmAmGmUmCmGmCmGmCmAmU-3T

SEQ ID No. 188 ARC259 hVEGF Aptamer- C-G base pair swap of ARC245 (2nd base pair in) which has improved binding over ARC245.
5' mAmCmGmCmAmGmUmUmUmGmAmGmAmAmGmUmCmGmCmGmCmGmU-3'

Example 2 2'-OMe SELEX™

[00208] Libraries of transcription templates were used to generate pools of RNA oligonucleotides incorporating 2'-O-methyl NTPs under various transcription conditions. The transcription template (ARC256) and the transcription conditions are described below as rRmY (SEQ ID NO:456), rGmH (SEQ ID NO:462), r/mGmH (SEQ ID NO:463), and dRmY (SEQ ID NO:464). The unmodified RNA transcript is represented by SEQ ID NO:468.

ARC256: DNA transcription template

5'-CATCGATCGATCGATCGACAGCGNNNGTAGAACGTTCTCTCCTCTCCCTATAGTGAGTCGTATTA-3'
(SEQ ID NO:453)

The ARC256 RNA transcription product is:

5'-GGGAGAGGAGAGAACGUUCUACNNNCGUCGUCGAUCGAUCGAUCGAUG-3' (SEQ ID NO:468)

[00209] The transcription conditions were varied as follows where 1X Tc buffer is 200 mM HEPES, 40 mM DTT, 2 mM Spermidine, 0.01% Triton X-100, pH 7.5.

[00210] When 2'-OMe C and U and 2'-OH A and G (rRmY) conditions were used, the transcription reaction conditions were 1X Tc buffer, 50-200 nM double stranded template (200 nm template was used for round 1, and for subsequent rounds approximately 50 nM, a 1/10 dilution of an optimized PCR reaction, using conditions described herein, was used), 9.6 mM MgCl₂, 2.9 mM MnCl₂, 2 mM each base, 10% PEG-8000, 0.25 units inorganic pyrophosphatase, and 1.5 units Y639F/H784A T7 RNA polymerase. One unit of the Y639F/H784A mutant T7 RNA polymerase is defined as the amount of enzyme required to incorporate 1 nmole of 2'-OMe NTPs into transcripts under the r/mGmH conditions. One unit of inorganic pyrophosphatase is defined as the amount of enzyme that will liberate 1.0 mole of inorganic orthophosphate per minute at pH 7.2 and 25 °C.

[00211] When 2'-OMe A, C, and U and 2'-OH G (rGmH) conditions were used, the transcription reaction conditions were 1X Tc buffer, 50-200 nM double stranded DNA template (200 nm template was used for round 1, and for subsequent rounds approximately 50 nM, a 1/10 dilution of an optimized PCR reaction, using conditions described herein was used), 9.6 mM MgCl₂, 2.9 mM MnCl₂, 2 mM each base, 10% PEG-8000, 0.25 units inorganic pyrophosphatase, and 1.5 units Y639F single mutant T7 RNA polymerase. One

unit of the Y639F mutant T7 RNA polymerase is defined as the amount of enzyme required to incorporate 1 nmole of 2'-OMe NTPs into transcripts under the r/mGmH conditions.

[00212] When all 2'-OMe nucleotides (r/mGmH) conditions were used, the reaction conditions were 1X Tc buffer, 50-200 nM double stranded template (200 nm template was used for round 1, and for subsequent rounds approximately 50 nM, a 1/10 dilution of an optimized PCR reaction, using conditions described herein was used), 6.5 mM MgCl₂, 2 mM MnCl₂, 1 mM each base, 30 μM GTP, 1 mM GMP, 10% PEG-8000, 0.25 units inorganic pyrophosphatase, and 1.5 units Y639F/H784A T7 RNA polymerase.

[00213] When deoxy purines, A and G, and 2'-OMe pyrimidines (dRmY) conditions were used, the reaction conditions were 1X Tc buffer, 50-300 nM double stranded template (300 nm template was used for round 1, and for subsequent rounds approximately 50 nM, a 1/10 dilution of an optimized PCR reaction, using conditions described herein was used), 9.6 mM MgCl₂, 2.9 mM MnCl₂, 2 mM each base, 30 μM GTP, 2 mM Spermine, 10% PEG-8000, 0.25 units inorganic pyrophosphatase, and 1.5 units Y639F single mutant RNA polymerase.

[00214] These pools were then used in SELEX™ to select for aptamers against the following targets: IgE, IL-23, PDGF-BB, thrombin and VEGF. A plot of dRmY Round 6, 7, 8, and unselected sequences binding to target IL-23 is shown in Figure 14, and a plot of dRmY Round 6, 7, and unselected sequences binding to target PDGF-BB is shown in Figure 14.

Example 3 dRmY SELEX™ of Aptamers against IgE

[00215] While fully 2'-OMe substituted oligonucleotides are the most stable modified aptamers, substituting the purines with deoxy purine nucleotides also results in stable transcripts. When dRmY (deoxy purines, A and G, and 2'-OMe pyrimidines) transcription conditions are used, the products are very DNase-resistant and useful as stable therapeutics.

This result is surprising since the composition of the dRmY transcripts is approximately 50% DNA, which is notoriously easily degraded by nucleases. Also, when dRmY transcription conditions are used, there is no requirement for a 2'-OH GTP spike. Studies have shown that approximately the same amount of dRmY transcripts having modified nucleotides are produced with 2'-OH GTP doping as without 2'-OH GTP doping. Accordingly, under dRmY transcription conditions, 2'-OH GTP doping is optional. Libraries of transcription templates were used to generate pools of oligonucleotides

incorporating 2'-O-methyl pyrimidine NTPs (U and C) and deoxy purines (A and G) NTPs under various transcription conditions. The transcription template (ARC256) and the transcription conditions are described below as dRmY.

ARC256: DNA transcription template

5'-CATCGATCGATCGATCGACAGCGNNNGTAGAACGTTCTCTCCTCTCCCTATAGTGAGTCGTATTA-3'
(SEQ ID NO:453)

The ARC256 dRmY RNA transcription product is:

**5'-GGGAGAGGAGAGAACGUUCUACNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNCGCUGUCGAUCGAUCGAUCGAUC-3' (SEQ ID NO:464)**

[00216] When deoxy purines, A and G, and 2'-OMe pyrimidines (dRmY) conditions were used, the reaction conditions were 1X Tc buffer, 50-300 nM double stranded template (300 nm template was used for round 1, and for subsequent rounds approximately 50 nM, a 1/10 dilution of an optimized PCR reaction, using conditions described herein, was used), 9.6 mM MgCl₂, 2.9 mM MnCl₂, 2 mM each base, 30 μM GTP, 2 mM Spermine, 10% PEG-8000, 0.25 units inorganic pyrophosphatase, and 1.5 units Y639F single mutant RNA polymerase.

[00217] These pools were then used in SELEX™ to select for aptamers against IgE as a target. The sequences obtained after round 6 of SELEX™ as described above are listed in Table 12 below. A plot of Round 6 sequences bound with increasing target IgE concentration is shown in Figure 8.

[00218] Table 12 – Corresponding cDNAs of the Round 6 sequences of dRmY SELEX™ against IgE.

SEQ ID No.190 IgE A5

GGGAGAGGAGAGAA CGTTCTACAGGCAGTTCTGGGGACCCATGGGGGAAGTGC GCTGTTCGATCGATCGATCGATCG

SEQ ID No.191 IgE A6

GGGAGAGGAGAGAACGTTCTACGATTAGCAGGGAGGGAGAGTGCGAAGAGGACGCTGTCGATCGATCGATCGATCG

SEQ ID No.192 IgE A7

GGGAGAGGAGAGAGAACGTTCTACACTCTGGGGACCGTGGGGGAGTGCAGCAACCGTGTGGATCGATCGATCGATCGATCG

SEO ID No.193 IqE A8

GGGAGAGGAGAGAA CGTTCTACAAGCAGTTCTGGGGACCCATGGGGGAAGTGCCTGTCGATCGATCGATCGATCGATG

SEO ID No.194 IqE B5

GGGAGAGGAGAGAACGTTCTACGAGGTGAGGGTCTACAATGGAGGGATGGTGGCTGTCGATCGATCGATCGATCGATG

SEQ ID No.195 IgE B6

GGGAGAGGAGAGAACGTTCTACCCGAGCATAGCCTGNGGACCCATGNGGGGCGCTGTCGATCGATCGATCGATG

SEQ ID No.196 IgE B7

GGGAGAGGAGAGAACGTTCTACTGGGGGCGTGTTATTAGCAGCGTCGTGTCGATCGATCGATCGATG

SEQ ID No.197 IgE B8

GGGAGAGGAGAGAACGTTCTACAGGCAGTTCTGGGGACCCATGGGGGAAGTGCCTGTCGATCGATCGATCGATG

SEQ ID No.198 IgE C5

GGGAGAGGAGAGAACGTTCTACGAGCGCATCTGGGGACCCAGAGGGGATTGCTGTCGATCGATCGATCGATG

SEQ ID No.199 IgE C6

GGGAGAGGAGAGAACGTTCTACAGGCAGTTCTGGGGACCCATGGGGGAAGTGCCTGTCGATCGATCGATCGATG

SEQ ID No.200 IgE C7

GGGAGAGGAGAGAACGTTCTACGGGATGGGTAGTTGGATGGAATGGGAACGCTGTCGATCGATCGATCGATG

SEQ ID No.201 IgE C8

GGGAGAGGAGAGAACGTTCTACGAGGTGTAGGGATAGAGGGGTGTAGGTAACGCTGTCGATCGATCGATCGATG

SEQ ID No.202 IgE D5

GGGAGAGGAGAGAACGTTCTACAGGAGTGGAGCTACAGAGAGGGTTAGGGGTGCTGTCGATCGATCGATCGATG

SEQ ID No.203 IgE D6

GGGAGAGGAGAGAACGTTCTACGGATGTTGGGAGTGATAGAAGGAAGGGAGCGCTGTCGATCGATCGATCGATG

SEQ ID No.204 IgE D7

GGGAGAGGAGAGAACGTTCTACAGGCAGTTCTGGGGACCCATGGGGGAAGTGCCTGTCGATCGATCGATCGATG

SEQ ID No.205 IgE D8

GGGAGAGGAGAGAACGTTCTACAGGCAGTTCTGGGGACCCATGGGGGAAGTGCCTGTCGATCGATCGATCGATG

SEQ ID No.206 IgE E5

GGGAGAGGAGAGAACGTTCTACAGGCAGTTCTGGGGACCCATGGGGGAAGTGCCTGTCGATCGATCGATCGATG

SEQ ID No.207 IgE E6

GGGAGAGGAGAGAACGTTCTACTTGGGTGGAAGGAGTAAGGGAGGTGCTGATCGCTGTCGATCGATCGATCGATG

SEQ ID No.208 IgE E7

GGGAGAGGAGAGAACGTTCTACGTATTAGGGGGGAAGGGGAGGAATAGATCACGCTGTCGATCGATCGATCGATG

SEQ ID No.209 IgE E8

GGGAGAGGAGAGAACGTTCTACAGGAGAGAGTGTGAGTGAAGAGGAGGAGTCGCTGTCGATCGATCGATCGATG

SEQ ID No.210 IgE F5

GGGAGAGGAGAGAACGTTCTACATTGTGCTCCTGGGGCCAGTGGGGAGCCACGCTGTCGATCGATCGATCGATG

SEQ ID No.211 IgE F6

GGGAGAGGAGAGAACGTTCTACGAGCAGCCCTGGGGCCCGAGGGGGATGGTCGCTGTCGATCGATCGATCGATG

SEQ ID No.212 IgE F7

GGGAGAGGAGAGAACGTTCTACAGGCAGTTCTGGGGACCCATGGGGGAAGTGCCTGTCGATCGATCGATCGATG

SEQ ID No.213 IgE F8

5'-GGGAGAGGAGAGAACGUUCUACNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNCGCUGUCAUCGAUCGAUCGAUG-3' (SEQ ID NO:464)

[00220] When deoxy purines, A and G, and 2'-OMe pyrimidines (dRmY) conditions were used, the reaction conditions were 1X Tc buffer, 50-300 nM double stranded template (300 nm template was used for round 1, and for subsequent rounds a 1/10 dilution of an optimized PCR reaction, using conditions described herein, was used), 9.6 mM MgCl₂, 2.9 mM MnCl₂, 2 mM each base, 30 μM GTP, 2 mM Spermine, 10% PEG-8000, 0.25 units inorganic pyrophosphatase, and 1.5 units Y639F single mutant RNA polymerase.

[00221] These pools were then used in SELEX™ to select for aptamers against thrombin as a target. The sequences obtained after round 6 of SELEX™ as described above are listed in Table 13 below. A plot of Round 6 sequences bound to target thrombin is shown in Figure 9.

[00222] Table 13 – Corresponding cDNAs of the Round 6 sequences of dRmY SELEX™ against thrombin.

SEQ ID No.221 Thrombin A1

GGGAGAGGAGAGAACGTTCTACGTGTGATGGGGTGAGAGGATGAGTTAGTGA CGCTGTCGATCGATCGATCGATG

SEQ ID No.222 Thrombin A2

GGGAGAGGAGAGAAACGTTCTACAATGGGAGGGTAATAGTGTATGAGGAGAGGCGCTGTCGATCGATCGATCGATG

SEQ ID No.223 Thrombin A3

GGGAGAGGAGAGAAACGTTCTACGGGTCGTGAGATAATGGCTCCCGTATTCAGCGCTGTCGATCGATCGATCGATG

SEQ ID No.224 Thrombin A4

GGGAGAGGAGAGAACGTTCTACGGGTCGTGAGATAATGGCTCCCGTATTTCAGCGCTGTCGATCGATCGATCGATG

SEQ ID No.225 Thrombin B1

GGGAGAGGAGAGAAACGTTCTACAGGTAGCGTGAGGGGGTGTTAATAGAGGGGCGCTGTCGATCGATCGATCGATG

SEQ ID No.226 Thrombin B2

GGGAGAGGAGAGAAACGTTCTACGATAGGATGGGTGGGACAGGAGAGGGAGTGCCTGTCCATCGATCGATCGATG

SEQ ID No.227 Thrombin B3

GGGAGAGGAGACGACGTTCTACCACTGAGGGCAGTGTCAGATTGAGAGGAGGCGCTGTCGATCGATCGATCGATG

SEQ ID No.228 Thrombin B4

GGGAGAGGAGAGAACGTTCTACCTTGCCTAACAGGAGGTGGAGTATTGGACCCGCTGTCGATCGATCGATCGATG

SEQ ID No.229 Thrombin C1

GGGAGAGGAGAGAACGTTCTACCTTGCCTAACAGGAGGTGGAGTATTGGACCCGCTGTCGATCGATCGATCGATG

SEQ ID No.230 Thrombin C2

GGGAGAGGAGAGAACGTTCTACGTCGTGAGTAATGGCTCGTAGATGAGGTCGCTGTCGATCGATCGATCGATG

SEQ ID No.231 Thrombin C3

GGGAGAGGAGAGAACGTTCTACGGGATTAAGAGGGGAGAGGAGCAGTTGAGCGCTGTCGATCGATCGATCGATG

SEQ ID No.232 Thrombin C4

GGGAGAGGAGAGAACGTTCTACTCCGGTTGGGGTATCAGGTCTACGGACTGACGCTGTCGATCGATCGATCGATG

SEQ ID No.233 Thrombin D1

GGGAGAGGAGAGAACGTTCTACGGGTCGTGAGATAATGGCTCCCGTATTGAGCGCTGTCGATCGATCGATCGATG

SEQ ID No.234 Thrombin D2

GGGAGAGGAGAGAACGTTCTACGGGTCGTGAGATAATGGCTCCCGTATTGAGCGCTGTCGATCGATCGATCGATG

SEQ ID No.235 Thrombin D3

GGGAGAGGAGAGAACGTTCTACATGACAAGAGGGGGTTGTGTGGGATGGCAGCGCTGTCGATCGATCGATCGATG

SEQ ID No.236 Thrombin D4

GGGAGAGGAGAGAACGTTCTACACAGGGAGGGGAGCGGAGAGGAGAGAGGGTACGCTGTCGATCGATCGATCGATG

SEQ ID No.237 Thrombin E1

GGGAGAGGAGAGAACGTTCTACGGGTCGTGAGATAATGGCTCCCGTATTGAGCGCTGTCGATCGATCGATCGATG

SEQ ID No.238 Thrombin E2

GGGAGAGGAGAGAACGTTCTACGTCGTGAGTAATGGCTCGTAGATGAGGTCGCTGTCGATCGATCGATCGATG

SEQ ID No.239 Thrombin E4

GGGAGAGGAGAGAACGTTCTACGGGTCGTGAGATAATGGCTCCCGTATTGAGCGCTGTCGATCGATCGATCGATG

SEQ ID No.240 Thrombin F1

GGGAGAGGAGAGAACGTTCTACGGGTCGTGAGATAATGGCTCCCGTATTGAGCGCTGTCGATCGATCGATCGATG

SEQ ID No.241 Thrombin F2

GGGAGAGGAGAGAACGTTCTACCTTGCCTAACAGGAGGTGGAGTATTGGACCCGCTGTCGATCGATCGATCGATG

SEQ ID No.242 Thrombin F3

GGGAGAGGAGAGAACGTTCTACGGCTATGCGTCGTGAGTCAATGGCCCGCATCGCTGTCGATCGATCGATCGATG

SEQ ID No.243 Thrombin F4

GGGAGAGGAGAGAACGTTCTACGGGTCGTGAGATAGTGGCTCCCGTATTGAGCGCTGTCGATCGATCGATCGATG

SEQ ID No.244 Thrombin G1

GGGAGAGGAGAGAACGTTCTACGGGTCGTGAGATAATGGCTCCCGTATTGAGCGCTGTCGATCGATCGATCGATG

SEQ ID No.245 Thrombin G2

GGGAGAGGAGAGAACGTTCTACGGGTCGTGAGATAATGGCTCCCGTATTGAGCGCTGTCGATCGATCGATCGATG

SEQ ID No.246 Thrombin G3

GGGAGAGGAGAGAACGTTCTACCTTGTCTAACAGGAGGTGGAGTATTGGACCCGCTGTCGATCGATCGATCGATG

SEQ ID No.247 Thrombin G4

GGGAGAGGAGAGAACGTTCTACGACTTTGAGGGTGGTGAGAGTGGAAGAGAGCGCTGTCGATCGATCGATCGATG

SEQ ID No.248 Thrombin H1

GGGAGAGGAGAGAACGTTCTACGGTAGGGTATGACCAGGAGGTATTGGAGGCGCTGTCGATCGATCGATCGATG

SEQ ID No.249 Thrombin H2

GGGAGAGGAGAGAACGTTCTACGGGTCGTGAGATAATGGCTCCCGTATTGAGCGCTGTCGATCGATCGATCGATG

SEQ ID No.250 Thrombin H3

GGGAGAGGAGAGAACGTTCTACGGGTCGTGAGATAATGGCTCCCGTATTGAGCGCTGTCGATCGATCGATCGATG

SEQ ID No.251 Thrombin H4

GGGAGAGGAGAGAACGTTCTACGTTATGTCATGTGGAGAGTGAGAGAGGGCGCTGTCGATCGATCGATCGATG

Example 5 dRmY SELEX™ of Aptamers against VEGF

[00223] While fully 2'-OMe substituted oligonucleotides are the most stable modified aptamers, substituting the purines with deoxy purine nucleotides also results in stable transcripts. When dRmY (deoxy purines, A and G, and 2'-OMe pyrimidines) transcription conditions are used, the products are very DNase-resistant and useful as stable therapeutics. This result is surprising since the composition of the dRmY transcripts is approximately 50% DNA RNA, which is notoriously easily degraded by nucleases. Also, when dRmY transcription conditions are used, there is no requirement for a 2'-OH GTP spike. Libraries of transcription templates were used to generate pools of oligonucleotides incorporating 2'-O-methyl pyrimidine NTPs (U and C) and deoxy purines (A and G) NTPs under various transcription conditions. The transcription template (ARC256) and the transcription conditions are described below as dRmY.

ARC256: DNA transcription template

5'-CATCGATCGATCGATCGACAGCGNNNGTAGAACGTTCTCTCCTCTCCCTATAGTGAGTCGTATTA-3'
(SEQ ID NO:453)

ARC256 dRmY transcription product is:

5'-GGGAGAGGAGAGAACGUUCUACNNNCGCUGUCGAUCGAUCGAUCGAUG-3' (SEQ ID NO:464)

[00224] When deoxy purines, A and G, and 2'-OMe pyrimidines (dRmY) conditions were used, the reaction conditions were 1X Tc buffer, 50-300 nM double stranded template (300 nm template was used for round 1, and for subsequent rounds a 1/10 dilution of an optimized PCR reaction, using conditions described herein, was used), 9.6 mM MgCl₂, 2.9 mM MnCl₂, 2 mM each base, 30 μM GTP, 2 mM Spermine, 10% PEG-8000, 0.25 units inorganic pyrophosphatase, and 1.5 units Y639F single mutant RNA polymerase.

[00225] These pools were then used in SELEX™ to select for aptamers against VEGF as a target. The sequences obtained after round 6 of SELEX™ as described above are listed in an alignment show in Table 14 below. A plot of Round 6 sequences bound to target VEGF is shown in Figure 10.

[00226] Table 14 – Corresponding cDNAs of the Round 6 sequences of dRmY SELEX™ against VEGF.

```

SEQ ID No.252  VEGF A9
GGGAGAGGAGAGAACGTTCTACCATGTCTGCGGGAGGTGAGTAGTGATCCTGCGCTGTCGATCGATCGATCGATG

SEQ ID No.253  VEGF A10
GGGAGAGGAGAGAACGTTCTACAGAGTGGGAGGGATGTGTGACACAGGTAGGCGCTGTCGATCGATCGATCGATG

SEQ ID No.254  VEGF A11
GGGAGAGGAGAGAACGTTCTACGCTCCATGACAGTGAGGTGAGTAGTGATCCTGTCGATCGATCGATCGATG

SEQ ID No.255  VEGF A12
GGGAGAGGAGAGAACGTTCT CGATGCTGACAGGGTGTGTTTCAAGTAATGGCTCGCTGTCGATCGATCGATCGATG

SEQ ID No.256  VEGF B9
GGGAGAGGAGAGAACGTTCTACAGCAACAGGGTCAGGTGAGTAGTGATGACGCTGTCGATCGATCGATCGATG

SEQ ID No.257  VEGF B10
GGGAGAGGAGAGAACGTTCTACGACAAGCCGGGGTGTTCAGTAGTGGCAACCGCTGTCGATCGATCGATCGATG

SEQ ID No.258  VEGF B11
GGGAGAGGAGAGAACGTTCTACATATGGCGCTGGAGGTGAGTAATGATCGTGCCTGTCGATCGATCGATCGATG

SEQ ID No.259  VEGF B12
GGGAGAGGAGAGAACGTTCTACGGGGCGATAGCGTTCAGTAGTGGCGCCGGTGCCTGTCGATCGATCGATCGATG

SEQ ID No.260  VEGF C9
GGGAGAGGAGAGAACGTTCTACATAGCGGACTGGGTGCATGGAGCGGCGCACGCTGTCGATCGATCGATCGATG

SEQ ID No.261  VEGF C10
GGGAGAGGAGAGAACGTTCTACGGGTCAACAGGGGCGTTCAGTAGTGGCGGCGCTGTCGATCGATCGATCGATG

SEQ ID No.262  VEGF C11
GGGAGAGGAGAGAACGTTCTACGCATGCGAGCTGAGGTGAGTAGTGATCAGTCGCTGTCGATCGATCGATCGATG

SEQ ID No.263  VEGF C12
GGGAGAGGAGAGAACGTTCTACATGCGACAGGGGAGTGTTCAGTAGTGGCACGCTGTCGATCGATCGATCGATG

. . . . .
SEQ ID No.264  VEGF D9
GGGAGAGGAGAGAACGTTCTACCCCATCGTATGGAGTGGGAACGGGGCATACGCTGTCGATCGATCGATCGATG

SEQ ID No.265  VEGF D10
GGGAGAGGAGAGAACGTTCTACAGTGAGGCGGGAGCGTTTCAGTAATGGCGCTGTCGATCGATCGATCGATG

SEQ ID No.266  VEGF D12
GGGAGAGGAGAGAACGTTCTACACAGCGTCGGGTGTTTCAAGTAATGGCGCAGCGCTGTCGATCGATCGATCGATG

```

SEQ ID No.267 VEGF E9

GGGAGAGGAGAGAACGTTCTACGGTGTTCAGTAGTGGCACAGGAGGAAGGGATGCTGTCGATCGATCGATCGATG

SEQ ID No.268 VEGF E10

GGGAGAGGAGAGAACGTTCTACAGTTCAGGCGTTAGGCATGGGTGTGCTTTTCGCTGTGTCGATCGATCGATCGATG

SEQ ID No.269 VEGF E11

GGGAGAGGAGAGAACGTTCTACATGCGACATGCGAGTGTTCAGTAGCGGCAGCGCTGTCGATCGATCGATCGATG

SEQ ID No.270 VEGF E12

GGGAGAGGAGAGAACGTTCTACCTATGGCGTTACAGCGAGGTGAGTAGTGATCGCTGTCGATCGATCGATCGATG

SEQ ID No.271 VEGF F9

GGGAGAGGAGAGAACGTTCTACAGCCGATCCAGCCAGGCGTTTCAGTAGTGGCGCTGTCGATCGATCGATCGATG

SEQ ID No.272 VEGF F10

GGGAGAGGAGAGAACGTTCTACGGCACAGGCACGGCGAGGTGAGTAATGATCGCTGTCGATCGATCGATCGATG

SEQ ID No.273 VEGF G9

GGGAGAGGAGAGAACGTTCTACTGTGGACAGCGGAGTGCAGAACGGGTGCTGTCGATCGATCGATCGATG

SEQ ID No.274 VEGF G10

GGGAGAGGAGAGAACGTTCTACTGATGCTGCGAGTGTCATGGGGCAGGCGCTTCGCTGTCGATCGATCGATCGATG

SEQ ID No.275 VEGF G11

GGGAGAGGAGAGAACGTTCTACGGTACAATGGGAATGACAGTGATGGGTAGCCGCTGTCGATCGATCGATCGATG

SEQ ID No.276 VEGF G12

GGGAGAGGAGAGAACGTTCTACATGGACAGCGAAGCATGGGGAGGCGCACGCTGTCGATCGATCGATCGATG

SEQ ID No.277 VEGF H9

GGGAGAGGAGAGAACGTTCTACTGGGAGCGACAGTGAGCATGGGGTAGGCGCGCTGTCGATCGATCGATCGATG

SEQ ID No.278 VEGF H11

GGGAGAGGAGAGAACGTTCTACCGGCGAGCAGGTGTTTCAGTAGTGGCTTTGCGCTGTCGATCGATCGATCGATG

SEQ ID No.279 VEGF H12

GGGAGAGGAGAGAACGTTCTACGATCAGTGAGGGAGTGCACTAGTGGCTCGTCTGTCGATCGATCGATCGATG

Example 6 Plasma stability of 2'-OMe NTPs (mN) and dRmY oligonucleotides

[00227] An oligonucleotide of two sequences linked by a polyethylene glycol polymer (PEG) was synthesized in two versions: (1) with all 2'-OMe NTPs (mN): 5'-GGAGCAGCACC-3' (SEQ ID NO:457) -[PEG]- GGUGCCAAGUCGUUGCUC-3' (SEQ ID NO:458) and (2) with 2'-OH purine NTPs and 2'-OMe pyrimidines (dRmY) GGAGCAGCACC-3' (SEQ ID NO:465) -[PEG]- GGUGCCAAGUCGUUGCUC-3' (SEQ ID NO:466). These oligonucleotides were evaluated for full length stability. Figure 11A shows a degradation plot of the all 2'-OMe oligonucleotide with 3'idT and Figure 11B shows a degradation plot of the dRmY oligonucleotide. The oligonucleotides were

incubated at 50 nM in 95% rat plasma at 37 °C and show a plasma half-life of much greater than 48 hours for each, and that they have very similar plasma stability profiles.

Example 7 rRmY and rGmH 2'-OMe SELEX™ against Human IL-23

[00228] Selections were performed to identify aptamers containing 2'-OMe C, U and 2'-OH G, A (rRmY), and 2'-O-Methyl A, C, and U and 2'-OH G (rGmH). All selections were direct selections against human IL-23 protein target which had been immobilized on a hydrophobic plate. Selections yielded pools significantly enriched for h-IL-23 binding versus naïve, unselected pool. Individual clone sequences for h-IL-23 are reported herein, but h-IL-23 binding data for the individual clones are not shown.

[00229] Pool Preparation. A DNA template with the sequence 5'–

GGGAGAGGAGAGAACGTTCTACNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
CGCTGTCGATCGATCGATCGATG-3' (SEQ ID NO:459) was synthesized using an ABI EXPEDITE™ DNA synthesizer, and deprotected by standard methods. The templates were amplified with the primers PB.118.95.G: 5'-GGGAGAGGAGAGAACGTTCTAC-3' (SEQ ID NO:460) and STC.104.102.A (5'-CATCGATCGATCGATCGACAGC-3' (SEQ ID NO:461) and then used as a template (200 nM template was used for round 1, and for subsequent rounds approximately 50 nM, a 1/10 dilution of an optimized PCR reaction, using conditions described herein, was used) for in vitro transcription with Y639F single mutant T7 RNA polymerase. Transcriptions were done using 200 mM HEPES, 40 mM DTT, 2 mM spermidine, 0.01% TritonX-100, 10% PEG-8000, 5 mM MgCl₂, 1.5 mM MnCl₂, 500 μM NTPs, 500 μM GMP, 0.01 units/μl inorganic pyrophosphatase, and Y639F single mutant T7 polymerase. Two different compositions were transcribed rRmY and rGmH.

[00230] Selection. Each round of selection was initiated by immobilizing 20 pmoles of h-IL-23 to the surface Nunc Maxisorp hydrophobic plates for 2 hours at room temperature in 100 μ L of 1X Dulbecco's PBS. The supernatant was then removed and the wells were washed 4 times with 120 μ L wash buffer (1X DPBS, 0.2% BSA, and 0.05% Tween-20). Pool RNA was heated to 90 $^{\circ}$ C for 3 minutes and cooled to room temperature for 10 minutes to refold. In round 1, a positive selection step was conducted. Briefly, 1×10^{14} molecules (0.2 nmoles) of pool RNA were incubated in 100 μ L binding buffer (1X DPBS and 0.05% Tween-20) in the wells with immobilized protein target for 1 hour. The supernatant was then removed and the wells were washed 4X with 120 μ L wash buffer. In

subsequent rounds a negative selection step was included. The pool RNA was also incubated for 30 minutes at room temperature in empty wells to remove any plastic binding sequences from the pool before the positive selection step. The number of washes was increased after round 4 to increase stringency. In all cases, the pool RNA bound to immobilized h-IL-23 was reverse transcribed directly in the selection plate after by the addition of RT mix (3' primer, STC.104.102.A, and Thermoscript RT, Invitrogen) followed by incubated at 65 °C for 1 hour. The resulting cDNA was used as a template for PCR (Taq polymerase, New England Biolabs) "Hot start" PCR conditions coupled with a 60 °C annealing temperature were used to minimize primer-dimer formation. Amplified pool template DNA was desalted with a Centriscap column according to the manufacturer's recommended conditions and used to program transcription of the pool RNA for the next round of selection. The transcribed pool was gel purified on a 10 % polyacrylamide gel every round. Table 15 shows the RNA pool concentrations used per round of selection.

[00231] Table 15. RNA pool concentrations per round of selection.

pmoles Pool used	rRmY 2OMe				rGmH 3OMe			
Round	IL23	hIgE	mIgE	PDGF- BB	IL23	hIgE	mIgE	PDGF- BB
1	200	200	200	200	200	200	200	200
2	110	140	130	135	40	50	40	60
3	65	115	60	160	100	190	90	160
4	50	40	40	30	170	120	40	240
5	80	130	130	110	100	60	40	70
6	100	80	90	39	110	140	90	90
7	50	90	130	170	70	80	130	90
8	120		190	150	60	90	110	130
9	120		210	170	80	80	100	100
10	130		210	180				
11	110			210				

[00232] The selection progress was monitored using a sandwich filter binding assay. The 5'-³²P-labeled pool RNA was refolded at 90 °C for 3 minutes and cooled to room temperature for 10 minutes. Next, pool RNA (trace concentration) was incubated with h-IL-23 DPBS plus 0.1 mg/ml tRNA for 30 minutes at room temperature and then applied to a nitrocellulose and nylon filter sandwich in a dot blot apparatus (Schleicher and Schuell). The percentage of pool RNA bound to the nitrocellulose was calculated and monitored

approximately every 3 rounds with a single point screen (\pm 250 nM h-IL-23). Pool K_D measurements were measured using a titration of protein and the dot blot apparatus as described above.

[00233] **Selection.** The rRmY h-IL-23 selection was enriched for h-IL-23 binding vs. the naïve pool after 4 rounds of selection. The selection stringency was increased and the selection was continued for 8 more rounds. At round 9 the pool K_D was approximately 500 nM or higher. The rGmH selection was enriched over the naïve pool binding at round 10. The pool K_D is also approximately 500 nM or higher. The pools were cloned using TOPO TA cloning kit (Invitrogen) and individual sequences were generated. Figure 12 shows pool binding data to h-IL-23 for the rGmH round 10 and rRmY round 12 pools. Dissociation constants were estimated fitting data to the equation: fraction RNA bound = $\text{amplitude} \cdot K_D / (K_D + [\text{h-IL-23}])$. Table 16 shows the individual clone sequences for round 12 of the rRmY selection. There is one group of 6 duplicate sequences and 4 pairs of 2 duplicate sequences out of 48 clones. All 48 clones will be labeled and tested for binding to 200 mM h-IL-23. Table 17 shows the individual clone sequences for round 10 of the rGmH selection. Binding data is shown in Figure 14.

[00234] Table 16. Corresponding cDNAs of the Individual Clone Sequences for Round 12 of the rRmY Selection.

```

SEQ ID No. 280   ARX34P2.G01
GGGAGAGGAGAGAACGTTCTACAAATGAGAGCAGGCCGAAAAGGAGTCGCTCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No. 281   ARX34P2.A06
GGGAGAGGAGAGAACGTTCTACAAAGGATCAATCTTCGGCGTATGTGTGAGCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No. 282   ARX34P2.E02
GGGAGAGGAGAGAACGTTCTACGTAAGCAGGCTGACTGAAAGGTTGAAGTCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No. 283   ARX34P2.H05
GGGAGAGGAGAGAACGTTCTACAGGTTAAAGCAGGCTCAGGAATGGAAGTCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No. 284   ARX34P2.G04
GGGAGAGGAGAGAACGTTCTACAAAGCAGGCTCATAGTAATATGGAAGTCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No. 285   ARX34P2.G03
GGGAGAGGAGAGAACGTTCTACAAAGAGAGCAGGCCGAAAAGGAGTCGCTCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No. 286   ARX34P2.H06
GGGAGAGGAGAGAACGTTCTACAAAGGAGGCTCAGGGGATCACTGGAAGTCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No. 287   ARX34P2.B01
GGGAGAGGAGAGAACGTTCTACAAAGAGAGCAGGCCGTAATGATATAAGGAGTCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No. 288   ARX34P2.B03
GGGAGAGGAGAGAACGTTCTACAAAGTGACAGGCTGCAGACATATGCGAAGTCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No. 289   ARX34P2.D05
GGGAGAGGAGAGAACGTTCTACAAAGAGAGCAGGCCGAAAAGGAGTCGCTCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No. 290   ARX34P2.C05
GGGAGAGGAGAGAACGTTCTACAAAGATATAATTAAGGATAAGTGCAAGAGAGAGCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No. 291   ARX34P2.C04
GGGAGAGGAGAGAACGTTCTACAGACAAACAGCNAGAGGGAATCNCANACAAAGACGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No. 292   ARX34P2.E06
GGGAGAGGAGAGAACGTTCTACAGATTCTAAGCGCAGGAATAAGTCACCGAGACGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No. 293   ARX34P2.A01
GGGAGAGGAGAGAACGTTCTACGAAATGAGCATGGAAGTGGGAGTACGTCCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No. 294   ARX34P2.C06
GGGAGAGGAGAGAACGTTCTACGAAAGAGGCGCCGGAAGTGAGAGTAAGTGCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No. 295   ARX34P2.B04
GGGAGAGGAGAGAACGTTCTACGAAGTGAGTTTCCGAAGTGAGAGTACGAAACGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No. 296   ARX34P2.E04
GGGAGAGGAGAGAACGTTCTACGAATGAGAGCAGGCCGAAAAGGAGTCGCTCGCTGTCGATCGATCGATCGATGAAGGGCG

```

SEQ ID No. 297 ARX34P2.H04
 GGGAGAGGAGAGAACGTTCTACGAGAGGCAAGAGAGAGTCGCATAAAAAAGACGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 298 ARX34P2.B06
 GGGAGAGGAGAGAACGTTCTACGAGAGGCTGTCTAGACAAACGATGAAGTCGCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 299 ARX34P2.F05
 GGGAGAGGAGAGAACGTTCTACGAAAAAGATATGAAAGAAAGGATTAAAGAGACGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 300 ARX34P2.H02
 GGGAGAGGAGAGAACGTTCTACGAGAGCATANGGCGTGAAGTGAAGAGTAAACGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 301 ARX34P2.C03
 GGGAGAGGAGAGAACGTTCTACGAGAGCATANGGCGTGAAGTGAAGAGTAAACGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 302 ARX34P2.D01
 GGGAGAGGAGAGAACGTTCTACGAAAAAGGATATGAGAGAAAGGATTAAAGAGACGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 303 ARX34P2.A03
 GGGAGAGGAGAGAACGTTCTACATACATAGGCGCGCGAATGGGAAAGAAAGCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 304 ARX34P2.B02
 GGGAGAGGAGAGAACGTTCTACTCATGAAGCCATGGTTGTAATTCGTTTGGCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 305 ARX34P2.C01
 GGGAGAGGAGAGAACGTTCTACTAATCGAGGCTCAGTTACTACTGGAAGTCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 306 ARX34P2.D06
 GGGAGAGGAGAGAACGTTCTACTTTCATAGGCGGGATTATGGAGGAGTATTCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 307 ARX34P2.G05
 AGGAGAGGAGAGAACGTTCTACTAGAACGAGGCTCGAATCAATTCGGAAGTCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 308 ARX34P2.F06
 GGGAGAGGAGAGAACGTTCTACTTAGCGATGTCGGAAGAGAGAGTACGAGGACGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 309 ARX34P2.F02
 GGGAGAGGAGAGAACGTTCTACTTGCAGAACCGTGGAGAGGAGTACTGGTCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 310 ARX34P2.B05
 GGGAGAGGAGAGAACGTTCTACTTTTGGTGAAGGTGTAAGAGTGGCACTACACGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 311 ARX34P2.A05
 GGGAGAGGAGAGAACGTTCTACCATCAGTTGTGGCGATTATGTGGGAGTATGCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 312 ARX34P2.E03
 GGGAGAGGAGAGAACGTTCTACANAANAACATGCGATTAAAGATCATGAACAGCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 313 ARX34P2.F04
 GGGAGAGGAGAGAACGTTCTACATAAGCAGGCTCCGATAGTATTCGGGAAGTCGCTGTCGATCGATCGATCGATGAAGGGCG

[00235] Table 17. Corresponding cDNAs of the Individual Clone Sequences for Round 10 of the rGmH Selection.

SEQ ID No. 314 ARX34P2.E10
 GGGAGAGGAGAGAACGTTCTACTTTCGGAATGCGATGGGGTGATTGCTGGTCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 315 ARX34P2.H09
 GGGAGAGGAGAGAACGTTCTACCTGTTGAGGCTAAGTGGATGATTGAGGGCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 316 ARX34P2.A07
 GGGAGAGGAGAGAACGTTCTACCTGGGTCGGTGGAGATGTCGTTGCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 317 ARX34P2.A12
 GGGAGAGGAGAGAACGTTCTACCTGATGTCAGGTTGTTTGGAGATTATCTGACNCTGTCNATCGATCGATCGATGAAGGGCG
 SEQ ID No. 318 ARX34P2.A08
 GGGAGAGGAGAGAACGTTCTACCTCGCGCAGCAGCGAATTTCCGGATGCGGCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 319 ARX34P2.D12
 GGGAGAGGAGAGAACGTTCTACCATGAATGATTGCGATCGTTGTTGTCGTGTCGCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 320 ARX34P2.E11
 GGGAGAGGAGAGAACGTTCTACTCCGACACCGCTGGGTGATTCTACNACGACGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 321 ARX34P2.E12
 GGGAGAGGAGAGAACGTTCTACTACTTTTGGGGATTCACTCCGCGCTGATGTCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 322 ARX34P2.D08
 GGGAGAGGAGAGAACGTTCTANTAGTGCTTGCAGATAGTGATAGGATTATCTGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 323 ARX34P2.F07
 GGGAGAGGAGAGAACGTTCTACTAGTGCTCTTCTCCACGTGGTTGTAATTTGTCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 324 ARX34P2.B11
 GGGAGAGGAGAGAACGTTCTACTATGTGGCGCTTGTGGACTAACTGACTACGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 325 ARX34P2.F12
 GGGAGAGGAGAGAACGTTCTACTTCGATTGTGATCTTGTGGCGGCTGTGAGCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 326 ARX34P2.A09
 GGGAGAGGAGAGAACGTTCTACTTGGCGATGTCGGAAGAGAGTACGAGGGCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 467 ARX34P2.B07
 GGGAGAGGAGAGAACGTTCTACTTGTGACGGACGGGCTTGAGAGGCTCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 327 ARX34P2.D07
 GGGAGAGGAGAGAACGTTCTACTTGAANCTGCGTGAATTGANAGTAACGAGCGCTGTCAATCGATCNATCAATNAAGGGCG
 SEQ ID No. 328 ARX34P2.H10
 GGGAGAGGAGAGAACGTTCTACTCGAGAGGACATGTGGATCCGTTTCCGCTGCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 329 ARX34P2.H07
 GGGAGAGGAGAGAACGTTCTACTGTGATGCGGTTTTCGTCGACCGGATTGTCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 330 ARX34P2.F11
 GGGAGAGGAGAGAACGTTCTACTGTGTGATTGGGCGCATGTCGAGGCGACACGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 331 ARX34P2.G07
 GGGAGAGGAGAGAACGTTCTACTGATTAAAGATGCGCTGGTAGAGCGGTGGGCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No. 332 ARX34P2.A10

GGGAGAGGAGAGAAACGTTCTACTGGTTAAITTGCAATGCGCGANTAACNTGTCGCTGTCGATCGATCGATCGATCGATCGAAGGGCG
SEQ ID No. 333 ARX34P2.G10
GGGAGAGGAGAGAAACGTTCTACTGGGAAGCGGTAACTTGGATTGACCGATCCGCTGTCGATCGATCGATCGATCGATCGAAGGGCG
SEQ ID No. 334 ARX34P2.H11
GGGAGAGGAGAGAAACGTTCTACTGTTACCGGATGATGGGTTTGGCTTGGCTTGGCGCTGTCGATCGATCGATCGATCGAAGGGCG
SEQ ID No. 335 ARX34P2.C07
GGGAGAGGAGAGAAACGTTCTACTGTGTGACTGAGATACGATTCGGAGCTGGCGCTGTCGATCGATCGATCGATCGATCGAAGGGCG
SEQ ID No. 336 ARX34P2.E08
GGGAGAGGAGAGAAACGTTCTACTTGTGAGTTTCTTGGGCGCTTGGCGCTGGCGCTGTCGATCGATCGATCGATCGAAGGGCG
SEQ ID No. 337 ARX34P2.A11
GGGAGAGGAGAGAAACGTTCTACAGGTGATGTGAGCCGATTGTGAAGTTTTGTTCGCTGTCGATCGATCGATCGATCGAAGGGCG
SEQ ID No. 338 ARX34P2.B08
GGGAGAGGAGAGAAACGTTCTACAGCGGATGTTTGGGGGTGTGTGTTGGTTTGCCTGTCGATCGATCGATCGATCGAAGGGCG
SEQ ID No. 339 ARX34P2.B09
GGGAGAGGAGAGAAACGTTCTACATGCGGTGGTGGTCTTCGATGGGTGGAAGTCGCTGTCGATCGATCGATCGATCGAAGGGCG
SEQ ID No. 340 ARX34P2.B12
GGGAGAGGAGAGAAACGTTCTACATTGGAAGGGCGCATGTGGTCTGTGTTGATGCGCTGTCGATCGATCGATCGATCGAAGGGCG
SEQ ID No. 341 ARX34P2.F10
GGGAGAGGAGAGAAACGTTCTACGTGTTTCGCGGATTTGGAAGAGGAGTAAATTCGCTGTCGATCGATCGATCGATCGAAGGGCG
SEQ ID No. 342 ARX34P2.B10
GGGAGAGGAGAGAAACGTTCTACGTGTGCGTGTTCGGGAAGGGAGAGTCCGAGGCTGTCGATCGATCGATCGATCGAAGGGCG
SEQ ID No. 343 ARX34P2.G08
GGGAGAGGAGAGAAACGTTCTACGTGTGGTGTGCGATGCTTGGCTGTTTGTTCGCTGTCGATCGATCGATCGATCGAAGGGCG
SEQ ID No. 344 ARX34P2.C08
GGGAGAGGAGAGAAACGTTCTACGTTTGTGTGGCTTGGATCTGAAGACTAAGCGCTGTCGATCGATCGATCGATCGAAGGGCG
SEQ ID No. 345 ARX34P2.F09
GGGAGAGGAGAGAAACGTTCTACGTTTCGGGCTTGTGTGTGAGGATTGACGGCGCTGTCGATCGATCGATCGATCGAAGGGCG
SEQ ID No. 346 ARX34P2.C10
GGGAGAGGAGAGAAACGTTCTACGATGATGAAGGCGAAAAGACGAGGCTGTCGATCGATCGATCGATCGAAGGGCG
SEQ ID No. 347 ARX34P2.C11
GGGAGAGGAGAGAAACGTTCTACGAGTGTGATGCGTGTCTGGGATGGAATTCGCTGTCGATCGATCGATCGATCGAAGGGCG
SEQ ID No. 348 ARX34P2.D09
GGGAGAGGAGAGAAACGTTCTACGCGTTTATACGATCGATGATGATATAGGCCGCTGTCGATCGATCGATCGATCGAAGGGCG
SEQ ID No. 349 ARX34P2.D10
GGGAGAGGAGAGAAACGTTCTACGCGTTCAAATGGGATAGAATTGGCTGCGGCGCTGTCGATCGATCGATCGATCGAAGGGCG
SEQ ID No. 350 ARX34P2.D11
GGGAGAGGAGAGAAACGTTCTACGAAATGTGCGTCAGTGTGAGGCGGTTTGTCTGTCGATCGATCGATCGATCGAAGGGCG
SEQ ID No. 351 ARX34P2.E07
GGGAGAGGAGAGAAACGTTCTACGTTGCAAAATGAGGGTCTGGAGTTCGACGACGCTGTCGATCGATCGATCGATCGAAGGGCG
SEQ ID No. 352 ARX34P2.E09
GGGAGAGGAGAGAAACGTTCTACGAAATTTGGTAAATCTGGGTGACTTAGGATGTGCTGTCGATCGATCGATCGATCGAAGGGCG
SEQ ID No. 353 ARX34P2.G12
GGGAGAGGAGAGAAACGTTCTACGATTTTTTGTGCCGAAGTAAGAGTACGCGCGCTGTCGATCGATCGATCGATCGAAGGGCG
SEQ ID No. 354 ARX34P2.H08
AGGAGAGGAGAGAAACGTTCTACGGAGGTGCGCGGATGAAAAACAGAAAGTTGTGCTGTCGATCGATCGATCGATCGAAGGGCG

Example 8 rRmY 2'-OMe SELEX™ against Human IgE

[00236] Selections were performed to identify aptamers containing 2'-OMe C, U and 2'-OH G, A (rRmY). All selections were direct selections against human IgE protein target which had been immobilized on a hydrophobic plate. Selections yielded pools significantly enriched for h-IgE binding versus naïve, unselected pool. Individual clone sequences for h-IgE are reported herein, but h-IgE binding data for the individual clones are not shown.

[00237] Pool Preparation. A DNA template with the sequence 5'—

GGGAGAGGAGAGAACGTTCTACNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
CGCTGTCGATCGATCGATCGATG-3' (SEQ ID NO:459) was synthesized using an ABI EXPEDITE™ DNA synthesizer, and deprotected by standard methods. The templates were amplified with the primers PB.118.95.G 5'-GGGAGAGGAGAGAACGTTCTAC-3'(SEQ ID NO:460) and STC.104.102.A 5'-CATCGATCGATCGATCGACAGC-3'(SEQ ID NO:461) and then used as a template (200 nM template was used for round 1, and for subsequent rounds approximately 50 nM, a 1/10 dilution of an optimized PCR reaction,

using conditions described herein, was used) for *in vitro* transcription with Y639F single mutant T7 RNA polymerase. Transcriptions were done using 200 mM HEPES, 40 mM DTT, 2 mM spermidine, 0.01% TritonX-100, 10% PEG-8000, 5 mM MgCl₂, 1.5 mM MnCl₂, 500 μ M NTPs, 500 μ M GMP, 0.01 units/ μ l inorganic pyrophosphatase, and Y639F single mutant T7 polymerase.

Selection. Each round of selection was initiated by immobilizing 20 pmoles of h-IgE to the surface Nunc Maxisorp hydrophobic plates for 2 hours at room temperature in 100 μ L of 1X Dulbecco's PBS. The supernatant was then removed and the wells were washed 4 times with 120 μ L wash buffer (1X DPBS, 0.2% BSA, and 0.05% Tween-20). Pool RNA was heated to 90 °C for 3 minutes and cooled to room temperature for 10 minutes to refold. In round 1, a positive selection step was conducted. Briefly, 1×10^{14} molecules (0.2 nmoles) of pool RNA were incubated in 100 μ L binding buffer (1X DPBS and 0.05% Tween-20) in the wells with immobilized protein target for 1 hour. The supernatant was then removed and the wells were washed 4X with 120 μ L wash buffer. In subsequent rounds a negative selection step was included. The pool RNA was also incubated for 30 minutes at room temperature in empty wells to remove any plastic binding sequences from the pool before the positive selection step. The number of washes was increased after round 4 to increase stringency. In all cases, the pool RNA bound to immobilized h-IgE was reverse transcribed directly in the selection plate after by the addition of RT mix (3' primer, STC.104.102.A, and Thermoscript RT, Invitrogen) followed by incubated at 65 °C for 1 hour. The resulting cDNA was used as a template for PCR (Taq polymerase, New England Biolabs) "Hot start" PCR conditions coupled with a 60 °C annealing temperature were used to minimize primer-dimer formation. Amplified pool template DNA was desalted with a Centriscap column according to the manufacturer's recommended conditions and used to program transcription of the pool RNA for the next round of selection. The transcribed pool was gel purified on a 10 % polyacrylamide gel every round.

[00238] rRmY pool selection against h-IgE was enriched after 4 rounds over the naïve pool. The selection stringency was increased and the selection was continued for 2 more rounds. At round 6 the pool K_D is approximately 500 nM or higher. The pools were cloned using TOPO TA cloning kit (Invitrogen) and submitted for sequencing. The pool contained one dominant clone (AMX(123).A1)- which made up 71% of the clones sequenced. Three additional clones were tested and showed a higher extent of binding than the dominant clone. The K_Ds for the pools were calculated to be approximately 500 nM. The

dissociations constants were also calculated as described above. Table 18 shows the rRmY pool clones after Round 6 of selection to h-IgE where the dominant clone was AMX(123).A1 making up 40% of the 96 clones, along with 8 other sequence families.

[00239] Table 18. Corresponding cDNAs of the Individual Clone Sequence of rRmY Pool Clones After Round 6 of Selection to h-IgE.

```

SEQ ID No.355   AMX(123).A1
GGGAGAGGAGAGAACGTTCTACGATCTGGCGGAGCCAGTCTGACTGAGGAAGCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.356   ARX34P1.B07
GGGAGAGGAGAGAACGTTCTACGAGAAGATATGAGAGAAAGGATTAAGAGACGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.357   ARX34P1.A07
GGGAGAGGAGAGAACGTTCTACGAAAAAGATATGAGAGAAAGGATTAAGAGACGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.358   ARX34P1.A01
GGGAGAGGAGAGAACGTTCTACGAAAAAGATATGAGAGAAAGGATTAAGAGGCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.359   -ARX34P1.G05
GGGAGAGGAGAGAACGTTCTACGAAAAAGACATGAGAGAAAGGATTAAGAGACGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.360   ARX34P1.F09
GGGAGAGGAGAGAACGTTCTACNAAAAAGTATATGAGAGAAAGGATTAANAGACGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.361   ARX34P1.B02
GGGAGAGGAGAGAACGTTCTACGAAAAAGATATGAGAGAAAGGATTAAGAGATGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.362   ARX34P1.G02
GGGAGAGGAGAGAACGTTCTACGAAAAAGATATGAGAGAAAGGATTAAGAGACGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.363   ARX34P1.A04
GGGAGAGGAGAGAACGTTCTACGAAAAAGATATGAGAGAAAGGATTAAGAGACGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.364   ARX34P1.G06
GGGAGAGGAGAGAACGTTCTACGAANAAGATACATAGTAGAAGGATTAATAAGACGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.365   ARX34P1.B05
GGGAGAGGAGAGAACGTTCTACGAGCGGTGTTGGTAGGGTACGACGAGGCATGCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.366   ARX34P1.B11
GGGAGAGGAGAGAACGTTCTACGCAAAATGTGATGCGAGGTAATGGAACGCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.367   ARX34P1.B01
GGGAGAGGAGAGAACGTTCTACGACCTCAGCGATAGGGGTGAAACCGACACGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.368   ARX34P1.H06
GGGAGAGGAGAGAACGTTCTACATGGTCGGATGCTGGGGAGTAGGCAAGGTTGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.369   ARX34P1.C12
GGGAGAGGAGAGAACGTTCTACGTATCGGCGAGCGAAGCATCCGGGAGCGTTGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.370   ARX34P1.C09
GGGAGAGGAGAGAACGTTCTACGTATTGGCGCGCAAGCATCCGGGAGCGTTGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.371   ARX34P1.A11
GGGAGAGGAGAGAACGTTCTACTTATACCTGACGCGCGGAGGCGCATAGGTGCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.372   ARX34P1.H09
GGGAGAGGAGAGAACGTTCTACATGGTCGGATGCTGGGGAGTAGGCAAGGTTGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.373   ARX34P1.B05
GGGAGAGGAGAGAACGTTCTACAGAGAGTACTGAGGCGCTTGGTACAGAGTGCCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.374   ARX34P1.B10
GGGAGAGGAGAGAACGTTCTACAGAAAGGTAGAAAAAGGATAGCTGTGAGAAGCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.375   ARX34P1.C01
GGGAGAGGAGAGAACGTTCTACTGAGGGATAATAACGGGTGGGATTGTTCTTCCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.376   ARX34P1.D04
GGGAGAGGAGAGAACGTTCTACATTGAGCGTTGAAGTTGGGGAAGCTCCGAGGCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.377   ARX34P1.E02
GGGAGAGGAGAGAACGTTCTACGCGAGATATACAGCGAGGTAATGGAACGCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.378   ARX34P1.F01
GGGAGAGGAGAGAACGTTCTACGAAGACAGCCCAATAGCGGCACGGAACCTTGCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.379   ARX34P1.G03
GGGAGAGGAGAGAACGTTCTACCGTTGAGGGCTCGCGTGGAAAGGGCCAAACGCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.380   ARX34P1.H01
GGGAGAGGAGAGAACGTTCTACATATCAATAGACTCTTGACGTTTGGGTTTGGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.381   ARX34P1.H02
GGGAGAGGAGAGAACGTTCTACAGTGAAGGAAAAAGTAAAGTGAAGGTGTCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.382   ARX34P1.H03
GGGAGAGGAGAGAACGTTCTACGGATGAAATGAGTGTCTGCGATAGGTTAAGCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.383   ARX34P1.H10
GGGAGAGGAGAGAACGTTCTACGGAAGGAAATGTGTGTCTGCGATAGGTTAAGCGCTGTCGATCGATCGATCGATGAAGGGCG

```

Example 9 rRmY and rGmH 2'-OMe SELEX™ against PDGF-BB

[00240] Selections were performed to identify aptamers containing 2'-OMe C, U and 2'-OH G, A (rRmY), and the other 2'-O-Methyl A, C, and U and 2'-OH G (rGmH). All selections were direct selections against human PDGF-BB protein target which had been immobilized on a hydrophobic plate. Selections yielded pools significantly enriched for h-PDGF-BB binding versus naïve, unselected pool. Individual clone sequences for PDGF-BB are reported herein.

[00241] **Pool Preparation.** A DNA template with the sequence

5'-GGGAGAGGAGAGAACGTTCTACNNCGCTGTCGATCGATCGATCGATG-3' (SEQ ID NO:459) was synthesized using an ABI EXPEDITE™ DNA synthesizer, and deprotected by standard methods. The templates were amplified with the primers PB.118.95.G 5'-GGGAGAGGAGAGAACGTTCTAC-3' (SEQ ID NO:460) and STC.104.102.A 5'-CATCGATCGATCGATCGACAGC-3' (SEQ ID NO:461) and then used as a template (200 nM template was used for round 1, and for subsequent rounds approximately 50 nM, a 1/10 dilution of an optimized PCR reaction, using conditions described herein, was used) for *in vitro* transcription with Y639F single mutant T7 RNA polymerase. Transcriptions were done using 200 mM HEPES, 40 mM DTT, 2 mM spermidine, 0.01% TritonX-100, 10% PEG-8000, 5 mM MgCl₂, 1.5 mM MnCl₂, 500 μM NTPs, 500 μM GMP, 0.01 units/μl inorganic pyrophosphatase, and Y639F single mutant T7 polymerase. Two different compositions were transcribed rRmY and rGmH.

Selection. Each round of selection was initiated by immobilizing 20 pmoles of PDGF-BB to the surface Nunc Maxisorp hydrophobic plates for 2 hours at room temperature in 100 μL of 1X Dulbecco's PBS. The supernatant was then removed and the wells were washed 4 times with 120 μL wash buffer (1X DPBS, 0.2% BSA, and 0.05% Tween-20). Pool RNA was heated to 90 °C for 3 minutes and cooled to room temperature for 10 minutes to refold. In round 1, a positive selection step was conducted. Briefly, 1 X 10¹⁴ molecules (0.2 nmoles) of pool RNA were incubated in 100 μL binding buffer (1X DPBS and 0.05% Tween-20) in the wells with immobilized protein target for 1 hour. The supernatant was then removed and the wells were washed 4X with 120 μL wash buffer. In subsequent rounds a negative selection step was included. The pool RNA was also incubated for 30 minutes at room temperature in empty wells to remove any plastic binding sequences from the pool before the positive selection step. The number of washes was increased after round 4 to increase

stringency. In all cases, the pool RNA bound to immobilized PDGF-BB was reverse transcribed directly in the selection plate after by the addition of RT mix (3' primer, STC.104.102.A, and Thermoscript RT, Invitrogen) followed by incubated at 65 °C for 1 hour. The resulting cDNA was used as a template for PCR (Taq polymerase, New England Biolabs) "Hot start" PCR conditions coupled with a 60 °C annealing temperature were used to minimize primer-dimer formation. Amplified pool template DNA was desalted with a Centriscp column according to the manufacturer's recommended conditions and used to program transcription of the pool RNA for the next round of selection. The transcribed pool was gel purified on a 10 % polyacrylamide gel every round.

[00242] Although the naïve pool does bind to PDGF-BB, the rRmY PDGF-BB selection was enriched after 4 rounds over the naïve pool. The selection stringency was increased and the selection was continued for 8 more rounds. At round 12 the pool is enriched over the naïve pool, but the K_D is very high. The rGmH selection was enriched over the naïve pool binding at round 10. The pool K_D is also approximately 950 nM or higher. The pools were cloned using TOPO TA cloning kit (Invitrogen) and submitted for sequencing. After 12 rounds of PDGF-BB pool selection clones were transcribed and sequenced. Table 19 shows the clone sequences. Figure 13(A) shows a binding plot of round 12 pools for rRmY pool PDGF-BB selection and Figure 13(B) shows a binding plot of round 10 pools for rGmH pool PDGF-BB selection. Dissociation constants were again measured using the sandwich filter binding technique. Dissociation constants (K_D s) were estimated fitting the data to the equation: fraction RNA bound = amplitude* $K_D/(K_D + [PDGF-BB])$.

[00243] Table 19. Corresponding cDNAs of the Individual Clone Sequence of rRmY Pool Clones After Round 12 of Selection to PDGF-BB.

```

SEQ ID No.384 PDGF-BB ARX36.SCK.E05
GGGAGAGGAGAGAACGTTCTACATCCTTGCATATGATCGGCATCGTAAGACACGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.385 PDGF-BB ARX36.SCK.F05
GGGAGAGGAGAGAACGTTCTACATCCTTGCATATGATCGGCATCGTAAGACACGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.386 PDGF-BB ARX36.SCK.E01
GGGAGAGGAGAGAACGTTCTACGATCGAAGTCGTGACAGAAACCACTCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.387 PDGF-BB ARX36.SCK.F01
GGGAGAGGAGAGAACGTTCTACGATCGAAGTCGTGACAGAAACCACTCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.388 PDGF-BB ARX36.SCK.G01
GGGAGAGGAGAGAACGTTCTACGAAAGGTTGGCGAAACGAAGAAGAAATTTGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.389 PDGF-BB ARX36.SCK.G02
GGGAGAGGAGAGAACGTTCTACGAAAGGTTGGCGAAACGAAGAANAATTTGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.390 PDGF-BB ARX36.SCK.F04
GGGAGAGGAGAGAACGTTCTACTGGAGTTGCGGTGTTTTGCGGTGGATTGACGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.391 PDGF-BB ARX36.SCK.E04
GGGAGAGGAGAGAACGTTCTACTGGAGTTGCGGTGTTTTGCGGTGGATTGACGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.392 PDGF-BB ARX36.SCK.F02
GGGAGAGGAGAGAACGCTCTACAAGATTGTAGATCAACAGCGAAGGCGTGGGCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.393 PDGF-BB ARX36.SCK.E02
GGGAGAGGAGAGAACGCTCTACAAGATTGTAGATCAACAGCGAAGGCGTGGGCGCTGTCGATCGATCGATCGATGAAGGGCG
SEQ ID No.394 PDGF-BB ARX36.SCK.A02
GGGAGAGGAGAGAACGTTCTACAAANAAGATNNCCANCNNGAGANAAGGAGCGCTGTCGATCGATCGATCGATGAAGGGCG

```

SEQ ID No.395 PDGF-BB ARX36.SCK.A03
 GGGAGAGGAGAGAACGTTCTACAAACATCGAAGATCGAACTGAAAAGGAGGGCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.396 PDGF-BB ARX36.SCK.A06
 GGGAGAGGAGAGAACGTTCTACATGTGCATGCAAGGTGGGGTGACACGAGCCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.397 PDGF-BB ARX36.SCK.B01
 GGGAGAGGAGAGAACGTTCTACAAGGAGTAGATCGACAGAATAGAAAAATCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.398 PDGF-BB ARX36.SCK.B02
 GGGAGAGGAGAGAACGTTCTACAAAGGTAAGGTCAAAAAAGCGCAACGTTGACGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.399 PDGF-BB ARX36.SCK.D04
 GGGAGAGGAGAGAACGTTCTACAAAGGAGGGCGAAATAGTGAGACAATGTGCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.400 PDGF-BB ARX36.SCK.B04
 GGGAGAGGAGAGAACGTTCTACAAATCCACAAACATAGCTGTAATTGCTGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.401 PDGF-BB ARX36.SCK.B05
 GGGAGAGGAGAGAACGTTCTACAAAGACATATAACATTTTGGTTGAGAGCAACGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.402 PDGF-BB ARX36.SCK.D03
 GGGAGAGGAGAGAACGTTCTACAAGAGTCNACGATTCNATCACAATGTGGCTGCTGTCNATCGATCGATCGATGAAGGGCG
 SEQ ID No.403 PDGF-BB ARX36.SCK.C01
 GGGAGAGGAGAGAACGTTCTACAAGCAAGCAAAAAAGTATCGACAGAAGTGGCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.404 PDGF-BB ARX36.SCK.D06
 GGGAGAGGAGAGAACGTTCTACAAGTAATATCAGAGCAATCGGAATAAGAGTGGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.405 PDGF-BB ARX36.SCK.D02
 GGGAGAGGAGAGAACGTTCTACAGACTTCGATGCGATGGATTGGAATGTGCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.406 PDGF-BB ARX36.SCK.C03
 GGGAGAGGAGAGAACGTTCTACAGAAAGATACAGGAACAAATACACGTGCGGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.407 PDGF-BB ARX36.SCK.F06
 GGGAGAGGAGAGAACGTTCTACAGAAATCAATCGAGGTGATCGTTATATAGGCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.408 PDGF-BB ARX36.SCK.C04
 GGGAGAGGAGAGAACGTTCTACAGATTTGGATCGACAATCTCGTAGAAGAGACGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.409 PDGF-BB ARX36.SCK.C06
 GGGAGAGGAGAGAACGTTCTACAATGCAAGTTTAAGTGTGGTGTCAAACGCAACGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.410 PDGF-BB ARX36.SCK.G03
 GGGAGAGGAGAGAACGTTCTACAAATAAGACACGAGATCGACGGAGACTCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.411 PDGF-BB ARX36.SCK.F03
 GGGAGAGGAGAGAACGTTCTACGAAGATGTGTTAAGAAATCGAGGTTTTTCGACGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.412 PDGF-BB ARX36.SCK.C02
 GGGAGAGGAGAGAACGTTCTACGAGTTGGCAGCATGTATAGTATTTTGGCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.413 PDGF-BB ARX36.SCK.B03
 GGGAGAGGAGAGAACGTTCTACGAAAAAAGAGATGAGAGAAAGGATTAAGAGACGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.414 PDGF-BB ARX36.SCK.B06
 GGGAGAGGAGAGAACGTTCTACGAAAGGAAAAAAGATCGGACAGATCCCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.415 PDGF-BB ARX36.SCK.C05
 GGGAGAGGAGAGAACGTTCTACGATTAAGGAAACATTACGCGAATACATGACGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.416 PDGF-BB ARX36.SCK.D01
 GGGAGAGGAGAGAACGTTCTACGACGTTTGTCTGAAATAGGACAGAAGGCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.417 PDGF-BB ARX36.SCK.B03
 GGGAGAGGAGAGAACGTTCTACGAAGATGTGTTAAGAAATCGAGGTTTTTCGACGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.418 PDGF-BB ARX36.SCK.A04
 GGGAGAGGAGAGAACGTTCTACGAGATCGAAAGGTAAGAGAAAAATTCATGCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.419 PDGF-BB ARX36.SCK.A05
 GGGAGAGGAGAGAACGTTCTACTAAGATTCGCTTCAGACAGAGAAAGCGACGCTGTCGATCGATCGATCGATGAAGGGCG

[00244] Table 20. Corresponding cDNAs of the Individual Clone Sequence of rGmH Pool
 Clones After Round 10 of Selection to PDGF-BB.

SEQ ID No.420 PDGF-BB ARX36.SCK.E08.M13F
 GGGAGAGGAGAGAACGTTCTACCTTGGCGACGATCTGTGACCTGAATTTTGTCCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.421 PDGF-BB ARX36.SCK.F08.M13F
 GGGAGAGGAGAGAACGTTCTACCTTGGCGACGATCTGTGACCTGAATTTTGTCCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.422 PDGF-BB ARX36.SCK.E09.M13F
 GGGAGAGGAGAGAACGTTCTACCTTGGCTCTCAGCAGCTTTTAACAAAGTATCCCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.423 PDGF-BB ARX36.SCK.F09.M13F
 GGGAGAGGAGAGAACGTTCTACCTTGGCTCTCAGCAGCTTTTAACAAAGTATCCCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.424 PDGF-BB ARX36.SCK.F07.M13F
 GGGAGAGGAGAGAACGTTCTACCGCTATTTTGTTCATTGAAGGACTTGTACGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.425 PDGF-BB ARX36.SCK.E07.M13F
 GGGAGAGGAGAGAACGTTCTACCGCTATTTTGTTCATTGAAGGACTTGTACGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.426 PDGF-BB ARX36.SCK.E11.M13F
 GGGAGAGGAGAGAACGTTCTACCTATTTGAGGTTGATTGGAAGTGCCTATGTGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.427 PDGF-BB ARX36.SCK.F11.M13F
 GGGAGAGGAGAGAACGTTCTACCTATTTGAGGTTGATTGGAAGTGCCTATGTGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.428 PDGF-BB ARX36.SCK.F10.M13F
 GGGAGAGGAGAGAACGTTCTACTGAAGATGTTATGATGATTGACGAGGAGGCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.429 PDGF-BB ARX36.SCK.E10.M13F
 GGGAGAGGAGAGAACGTTCTACTGAAGATGTTATGATGATTGACGAGGAGGCGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.430 PDGF-BB ARX36.SCK.E12.M13F
 GGGAGAGGAGAGAACGTTCTACTGCTGAGTGTGCGCCCTTGTGTGATGTTGCTGTCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.431 PDGF-BB ARX36.SCK.F12.M13F

GGGAGAGGAGAGAACGTTCTACTGTCGAGTGTGCGCCCTTGTGTGATGTTGCGTGTGCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.432 PDGF-BB ARX36.SCK.A07.M13F
 GGGAGAGGAGAGAACGTTCTACGTGATGGCTGTGAATGAGGTAGTTTGAATACGCTGTGCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.433 PDGF-BB ARX36.SCK.C12.M13F
 GGGAGAGGAGAGAACGTTCTACGTGAAATCAAGGTTGTTAATTTGGGAATCGCTGTGCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.434 PDGF-BB ARX36.SCK.B07.M13F
 GGGAGAGGAGAGAACGTTCTACGTATAAGGCCGTAAACCGGTAGCGAGTGGTGGTGTGCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.435 PDGF-BB ARX36.SCK.A09.M13F
 GGGAGAGGAGAGAACGTTTACGTGGGCGAAGGAGCTGCGGGCGTTGNAGTTTGTGCTGTGCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.436 PDGF-BB ARX36.SCK.A11.M13F
 GGGAGAGGAGAGAACGTTCTACGTATCCTAGTCTGAGATCGGATTTTCTGCGCTGTGCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.437 PDGF-BB ARX36.SCK.C09.M13F
 GGGAGAGGAGAGAACGTTCTACGTTTGCAGTGTGGTGCAGCTGAATGCGGCGCTGTGCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.438 PDGF-BB ARX36.SCK.A08.M13F
 GGGAGAGGAGAGAACGTTCTACGGATTGATAGGGATTGAGATGAGGTCCTGTGCGCTGTGCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.439 PDGF-BB ARX36.SCK.D07.M13F
 GGGAGAGGAGAGAACGTTCTACGTGTGCTGTGCTAGATTACTTATGCTATCTGCTGTGCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.440 PDGF-BB ARX36.SCK.D08.M13F
 GGGAGAGGAGAGAACGTTCTACGATGCGCTGCGGAAACGAGCCTGGGATTTGCGTGTGCTGATCGATCGATCGATGAAGGGCG
 SEQ ID No.441 PDGF-BB ARX36.SCK.B11.M13F
 GGGAGAGGAGAGAACGTTCTACGAGGATTGACGTTGTGTGCTAGAGTACGCTGTGCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.442 PDGF-BB ARX36.SCK.D09.M13F
 GGGAGAGGAGAGAACGTTCTACGATATTATGCGTCCCTTGAGGATACACGCGCTGTGCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.443 PDGF-BB ARX36.SCK.B10.M13F
 GGGAGAGGAGAGAACGTTCTACAGGATACTGTAGCGATGAAAGTAAACGATGCTGTGCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.444 PDGF-BB ARX36.SCK.C10.M13F
 GGGAGAGGAGAGAACGTTCTACAAGAAGTGTGCGCGCAGAGACGAAATGCACGCTGTGCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.445 PDGF-BB ARX36.SCK.A10.M13F
 GGGAGAGGAGAGAACGTTCTACCCATATCTTCCCTTTTATTCGGTTAGTTGCGCTGTGCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.446 PDGF-BB ARX36.SCK.B09.M13F
 GGGAGAGGAGAGAACGTTCTACCTGTGTGATGCTTCGTTTGAGATTGCCCCGCTGTGCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.447 PDGF-BB ARX36.SCK.B12.M13F
 GGGAGAGGAGAGAACGTTCTACCGTAAAGANAANCTATTTAGCCCTTGNCTGCGCTGTGCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.448 PDGF-BB ARX36.SCK.C08.M13F
 GGGAGAGGAGAGAACGTTCTACCCCTTGTCTCCTCAATCCTCTTTGACTCTTGCCTGTGCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.449 PDGF-BB ARX36.SCK.D12.M13F
 GGGAGAGGAGAGAACGTTCTACCTGATTTTGTCACTGGATTCCGATGGCTTTCGCTGTGCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.450 PDGF-BB ARX36.SCK.C11.M13F
 GGGAGAGGAGAGAACGTTCTACTGTAATAAGGATGCGTCAGGAACCTGTGTTGCGCTGTGCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.451 PDGF-BB ARX36.SCK.D11.M13F
 GGGAGAGGAGAGAACGTTCTACTGCTTCCGGGAATTTGTTTGTGCTTCCGCTGTGCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.452 PDGF-BB ARX36.SCK.C07.M13F
 GGGAGAGGAGAGAACGTTCTACTCGTGGTTGACTTTCTTCGTGTAGTGTGCTGTGCGATCGATCGATCGATGAAGGGCG
 SEQ ID No.189 PDGF-BB ARX36.SCK.A12.M13F
 GGGAGAGGAGAGAACGTTCTACTATGAAGGTTTTAAAGTAGACACATTAGCCGCTGTGCGATCGATCGATCGATGAAGGGCG

[00245] The present invention having been described by detailed description and the foregoing non-limiting examples, is now defined by the spirit and scope of the following claims.

What is claimed is:

1. A method for identifying nucleic acid ligands comprising a modified nucleotide to a target molecule comprising:

- a) preparing a transcription reaction mixture comprising a mutated polymerase, one or more 2'-modified nucleotide triphosphates (NTPs), magnesium ions and one or more oligonucleotide transcription templates;
- b) preparing a candidate mixture of single-stranded nucleic acids by transcribing the one or more oligonucleotide transcription templates under conditions whereby the mutated polymerase incorporates at least one of the one or more modified nucleotides into each nucleic acid of said candidate mixture, wherein each nucleic acid of said candidate mixture comprises a 2'-modified nucleotide selected from the group consisting of a 2'-position modified pyrimidine and a 2'-position modified purine;
- c) contacting the candidate mixture with said target molecule;
- d) partitioning the nucleic acids having an increased affinity to the target molecule relative to the candidate mixture from the remainder of the candidate mixture; and
- e) amplifying the increased affinity nucleic acids, in vitro, to yield a ligand-enriched mixture of nucleic acids, whereby nucleic acid ligands of the target molecule are identified.

2. The method of claim 1, wherein the one or more 2'-modified nucleotides are selected from the group consisting of 2'-OH, 2'-deoxy, 2'-O-methyl, 2'-NH₂, 2'-F, and 2'-methoxy ethyl modifications.

3. The method of claim 1, wherein the one or more 2'-modified nucleotides are a 2'-O-methyl modification.

4. The method of claim 1, wherein the one or more 2'-modified nucleotides are a 2'-F modification.

5. The method of claim 1, wherein the mutated polymerase is a mutated T7 RNA polymerase.

6. The method of claim 5, wherein the mutated T7 RNA polymerase comprises a mutation at position 639 from a tyrosine residue to a phenylalanine residue (Y639F).

7. The method of claim 5, wherein the mutated T7 RNA polymerase comprises a mutation at position 784 from a histidine residue to an alanine residue (H784A).
8. The method of claim 5, wherein the mutated T7 RNA polymerase comprises a mutation at position 639 from a tyrosine residue to a phenylalanine residue and a mutation at position 784 from a histidine residue to an alanine residue (Y639F/H784A).
9. The method of claim 1, wherein the oligonucleotide transcription template further comprises a leader sequence incorporated into a fixed region at the 5' end of the oligonucleotide transcription template.
10. The method of claim 9, wherein the leader sequence comprises an all-purine leader sequence.
11. The method of claim 10, wherein the all-purine leader sequence has a length selected from the group consisting of at least 6 nucleotides long; at least 8 nucleotides long; at least 10 nucleotides long; at least 12 nucleotides long; and at least 14 nucleotides long.
12. The method of claim 1, wherein the transcription reaction mixture further comprises manganese ions.
13. The method of claim 12, wherein the concentration of magnesium ions is between 3.0 and 3.5 times greater than the concentration of manganese ions.
14. The method of claim 1, wherein each NTP is present at a concentration of 0.5 mM, the concentration of magnesium ions is 5.0 mM, and the concentration of manganese ions is 1.5 mM.
15. The method of claim 1, wherein each NTP is present at a concentration of 1.0 mM, the concentration of magnesium ions is 6.5 mM, and the concentration of manganese ions is 2.0 mM.

16. The method of claim 1, wherein each NTP is present at a concentration of 2.0 mM, the concentration of magnesium ions is 9.6 mM, and the concentration of manganese ions is 2.9 mM.
17. The method of claim 1, wherein the transcription reaction mixture further comprises 2'-OH GTP.
18. The method of claim 1, wherein the transcription reaction mixture further comprises a polyalkylene glycol.
19. The method of claim 18, wherein the polyalkylene glycol is polyethylene glycol (PEG).
20. The method of claim 1, wherein the transcription reaction mixture further comprises GMP.
21. The method of claim 1 further comprising
 - f) repeating steps d) and e).
22. A nucleic acid ligand to thrombin identified according to the method of claim 1.
23. A nucleic acid ligand to vascular endothelial growth factor (VEGF) identified according to the method of claim 1.
24. A nucleic acid ligand to IgE identified according to the method of claim 1.
25. A nucleic acid ligand to IL-23 identified according to the method of claim 1.
26. A nucleic acid ligand to platelet-derived growth factor-BB (PDGF-BB) identified according to the method of claim 1.

27. The method of claim 1, wherein the 2' modified nucleotide triphosphates comprise a mixture of 2'-OH adenosine triphosphate (ATP), 2'-OH guanosine triphosphate (GTP), 2'-O-methyl cytidine triphosphate (CTP) and 2'-O-methyl uridine triphosphate (UTP).

28. The method of claim 1, wherein the 2' modified nucleotide triphosphates comprise a mixture of 2'-deoxy purine nucleotide triphosphates and 2'-O-methyl pyrimidine nucleotide triphosphates.

29. The method of claim 1, wherein the 2' modified nucleotide triphosphates comprise a mixture of 2'-O-methyl adenosine triphosphate (ATP), 2'-OH guanosine triphosphate (GTP), 2'-O-methyl cytidine triphosphate (CTP) and 2'-O-methyl uridine triphosphate (UTP).

30. The method of claim 1, wherein the 2' modified nucleotide triphosphates comprise a mixture of 2'-O-methyl adenosine triphosphate (ATP), 2'-O-methyl cytidine triphosphate (CTP) and 2'-O-methyl uridine triphosphate (UTP), 2'-O-methyl guanosine triphosphate (GTP) and deoxy guanosine triphosphate (GTP), wherein the deoxy guanosine triphosphate comprises a maximum of 10% of the total guanosine triphosphate population.

31. The method of claim 1, wherein the 2' modified nucleotide triphosphates comprise a mixture of 2'-O-methyl adenosine triphosphate (ATP), 2'-F guanosine triphosphate (GTP), 2'-O-methyl cytidine triphosphate (CTP) and 2'-O-methyl uridine triphosphate (UTP).

32. The method of claim 1, wherein the 2' modified nucleotide triphosphates comprise a mixture of 2'-deoxy adenosine triphosphate (ATP), 2'-O-methyl guanosine triphosphate (GTP), 2'-O-methyl cytidine triphosphate (CTP) and 2'-O-methyl uridine triphosphate (UTP).

33. A method of preparing a nucleic acid comprising one or more modified nucleotides comprising:

(a) preparing a transcription reaction mixture comprising a mutated polymerase, one or more 2'-modified nucleotide triphosphates (NTPs), magnesium ions and one or more oligonucleotide transcription templates; and

(b) contacting the one or more oligonucleotide transcription templates with the mutated polymerase under conditions whereby the mutated polymerase incorporates the one or more 2'-modified nucleotides into a nucleic acid transcription product.

34. The method of claim 33, wherein the one or more 2'-modified nucleotides are selected from the group consisting of 2'-OH, 2'-deoxy, 2'-O-methyl, 2'-NH₂, 2'-F, and 2'-methoxy ethyl modifications.

35. The method of claim 33, wherein the one or more 2'-modified nucleotides are a 2'-O-methyl modification.

36. The method of claim 33, wherein the one or more 2'-modified nucleotides are a 2'-F modification.

37. The method of claim 33, wherein the mutated polymerase is a mutated T7 RNA polymerase.

38. The method of claim 37, wherein the mutated T7 RNA polymerase comprises a mutation at position 639 from a tyrosine residue to a phenylalanine residue (Y639F).

39. The method of claim 37, wherein the mutated T7 RNA polymerase comprises a mutation at position 784 from a histidine residue to an alanine residue (H784A).

40. The method of claim 37, wherein the mutated T7 RNA polymerase comprises a mutation at position 639 from a tyrosine residue to a phenylalanine residue and a mutation at position 784 from a histidine residue to an alanine residue (Y639F/H784A).

41. The method of claim 33, wherein the oligonucleotide transcription template further comprises a leader sequence incorporated into a fixed region at the 5' end of the oligonucleotide transcription template.

42. The method of claim 41, wherein the leader sequence comprises an all-purine leader sequence.

43. The method of claim 42, wherein the all-purine leader sequence has a length selected from the group consisting of at least 6 nucleotides long; at least 8 nucleotides long; at least 10 nucleotides long; at least 12 nucleotides long; and at least 14 nucleotides long.
44. The method of claim 33, wherein the transcription reaction mixture further comprises manganese ions.
45. The method of claim 44, wherein the concentration of magnesium ions is between 3.0 and 3.5 times greater than the concentration of manganese ions.
46. The method of claim 33, wherein each NTP is present at a concentration of 0.5 mM each, the concentration of magnesium ions is 5.0 mM, and the concentration of manganese ions is 1.5 mM.
47. The method of claim 33, wherein each NTP is present at a concentration of 1.0 mM each, the concentration of magnesium ions is 6.5 mM, and the concentration of manganese ions is 2.0 mM.
48. The method of claim 33, wherein each NTP is present at a concentration of 2.0 mM each, the concentration of magnesium ions is 9.6 mM, and the concentration of manganese ions is 2.9 mM.
49. The method of claim 33, wherein the transcription reaction mixture further comprises 2'-OH GTP.
50. The method of claim 33, wherein the transcription reaction mixture further comprises a polyalkylene glycol.
51. The method of claim 50, wherein the polyalkylene glycol is polyethylene glycol (PEG).

52. The method of claim 33, wherein the transcription reaction mixture further comprises GMP.
53. An aptamer composition comprising a sequence where substantially all adenosine nucleotides are 2'-OH adenosine, substantially all guanosine nucleotides are 2'-OH guanosine, substantially all cytidine nucleotides are 2'-O-methyl cytidine, and substantially all uridine nucleotides are 2'-O-methyl uridine.
54. The aptamer composition of claim 53 wherein said aptamer comprises a sequence composition where at least 80% of all adenosine nucleotides are 2'-OH adenosine, at least 80% of all guanosine nucleotides are 2'-OH guanosine, at least 80% of all cytidine nucleotides are 2'-O-methyl cytidine and at least 80% of all uridine nucleotides are 2'-O-methyl uridine.
55. The aptamer composition of claim 53 wherein said aptamer comprises a sequence composition where at least 90% of all adenosine nucleotides are 2'-OH adenosine, at least 90% of all guanosine nucleotides are 2'-OH guanosine, at least 90% of all cytidine nucleotides are 2'-O-methyl cytidine and at least 90% of all uridine nucleotides are 2'-O-methyl uridine.
56. The aptamer composition of claim 53 wherein said aptamer comprises a sequence composition where 100% of all adenosine nucleotides are 2'-OH adenosine, at 100% of all guanosine nucleotides are 2'-OH guanosine, 100% of all cytidine nucleotides are 2'-O-methyl cytidine and 100% of all uridine nucleotides are 2'-O-methyl uridine.
57. An aptamer composition comprising a sequence where substantially all purine nucleotides are 2'-deoxy purines and substantially all pyrimidine nucleotides are 2'-O-methyl pyrimidines.
58. The aptamer composition of claim 57 wherein said aptamer comprises a sequence composition where at least 80% of all purine nucleotides are 2'-deoxy purines and at least 80% of all pyrimidine nucleotides are 2'-O-methyl pyrimidines.

59. The aptamer composition of claim 57 wherein said aptamer comprises a sequence composition where at least 90% of all purine nucleotides are 2'-deoxy purines and at least 90% of all pyrimidine nucleotides are 2'-O-methyl pyrimidines.

60. The aptamer composition of claim 57 wherein said aptamer comprises a sequence composition where 100% of all purine nucleotides are 2'-deoxy purines and 100% of all pyrimidine nucleotides are 2'-O-methyl pyrimidines

61. An aptamer composition comprising a sequence composition where substantially all guanosine nucleotides are 2'-OH guanosine, substantially all cytidine nucleotides are 2'-O-methyl cytidine, substantially all uridine nucleotides are 2'-O-methyl uridine, and substantially all adenosine nucleotides are 2'-O-methyl adenosine.

62. The aptamer composition of claim 61 wherein said aptamer comprises a sequence composition where at least 80% of all guanosine nucleotides are 2'-OH guanosine, at least 80% of all cytidine nucleotides are 2'-O-methyl cytidine, at least 80% of all uridine nucleotides are 2'-O-methyl uridine, and at least 80% of all adenosine nucleotides are 2'-O-methyl adenosine.

63. The aptamer composition of claim 61 wherein said aptamer comprises a sequence composition where at least 90% of all guanosine nucleotides are 2'-OH guanosine, at least 90% of all cytidine nucleotides are 2'-O-methyl cytidine, at least 90% of all uridine nucleotides are 2'-O-methyl uridine, and at least 90% of all adenosine nucleotides are 2'-O-methyl adenosine.

64. The aptamer composition of claim 61 wherein said aptamer comprises a sequence composition where 100% of all guanosine nucleotides are 2'-OH guanosine, 100% of all cytidine nucleotides are 2'-O-methyl cytidine, 100% of all uridine nucleotides are 2'-O-methyl uridine, and 100% of all adenosine nucleotides are 2'-O-methyl adenosine.

65. An aptamer composition comprising a sequence where substantially all adenosine nucleotides are 2'-O-methyl adenosine, substantially all cytidine nucleotides are 2'-O-methyl cytidine, substantially all guanosine nucleotides are 2'-O-methyl guanosine or deoxy

guanosine, substantially all uridine nucleotides are 2'-O-methyl uridine, wherein less than about 10% of the guanosine nucleotides are deoxy guanosine.

66. The aptamer composition of claim 65 wherein said aptamer comprises a sequence composition where at least 80% of all adenosine nucleotides are 2'-O-methyl adenosine, at least 80% of all cytidine nucleotides are 2'-O-methyl cytidine, at least 80% of all guanosine nucleotides are 2'-O-methyl guanosine, at least 80% of all uridine nucleotides are 2'-O-methyl uridine, and no more than about 10% of all guanosine nucleotides are deoxy guanosine.

67. The aptamer composition of claim 65 wherein said aptamer comprises a sequence composition where at least 90% of all adenosine nucleotides are 2'-O-methyl adenosine, at least 90% of all cytidine nucleotides are 2'-O-methyl cytidine, at least 90% of all guanosine nucleotides are 2'-O-methyl guanosine, at least 90% of all uridine nucleotides are 2'-O-methyl uridine, and no more than about 10% of all guanosine nucleotides are deoxy guanosine.

68. The aptamer composition of claim 65 wherein said aptamer comprises a sequence composition where 100% of all adenosine nucleotides are 2'-O-methyl adenosine, 100% of all cytidine nucleotides are 2'-O-methyl cytidine, 90% of all guanosine nucleotides are 2'-O-methyl guanosine, and 100% of all uridine nucleotides are 2'-O-methyl uridine and no more than about 10% of all guanosine nucleotides are deoxy guanosine.

69. An aptamer composition comprising a sequence where substantially all adenosine nucleotides are 2'-O-methyl adenosine, substantially all uridine nucleotides are 2'-O-methyl uridine, substantially all cytidine nucleotides are 2'-O-methyl cytidine, and substantially all guanosine nucleotides are 2'-F guanosine sequence.

70. The aptamer composition of claim 69 wherein said aptamer comprises a sequence composition where at least 80% of all adenosine nucleotides are 2'-O-methyl adenosine, at least 80% of all uridine nucleotides are 2'-O-methyl uridine, at least 80% of all cytidine nucleotides are 2'-O-methyl cytidine, and at least 80% of all guanosine nucleotides are 2'-F guanosine.

71. The aptamer composition of claim 69 wherein said aptamer comprises a sequence composition where at least 90% of all adenosine nucleotides are 2'-O-methyl adenosine, at least 90% of all uridine nucleotides are 2'-O-methyl uridine, at least 90% of all cytidine nucleotides are 2'-O-methyl cytidine, and at least 90% of all guanosine nucleotides are 2'-F guanosine

72. The aptamer composition of claim 69 wherein said aptamer comprises a sequence composition where 100% of all adenosine nucleotides are 2'-O-methyl adenosine, 100% of all uridine nucleotides are 2'-O-methyl uridine, 100% of all cytidine nucleotides are 2'-O-methyl cytidine, and 100% of all guanosine nucleotides are 2'-F guanosine.

73. An aptamer composition comprising a sequence where substantially all adenosine nucleotides are 2'-deoxy adenosine, substantially all cytidine nucleotides are 2'-O-methyl cytidine, substantially all guanosine nucleotides are 2'-O-methyl guanosine, and substantially all uridine nucleotides are 2'-O-methyl uridine.

74. The aptamer composition of claim 73 wherein said aptamer comprises a sequence composition where at least 80% of all adenosine nucleotides are 2'-deoxy adenosine, at least 80% of all cytidine nucleotides are 2'-O-methyl cytidine, at least 80% of all guanosine nucleotides are 2'-O-methyl guanosine, and at least 80% of all uridine nucleotides are 2'-O-methyl uridine.

75. The aptamer composition of claim 73 wherein said aptamer comprises a sequence composition where at least 90% of all adenosine nucleotides are 2'-deoxy adenosine, at least 90% of all cytidine nucleotides are 2'-O-methyl cytidine, at least 90% of all guanosine nucleotides are 2'-O-methyl guanosine, and at least 90% of all uridine nucleotides are 2'-O-methyl uridine.

76. The aptamer composition of claim 73 wherein said aptamer comprises a sequence composition where 100% of all adenosine nucleotides are 2'-deoxy adenosine, 100% of all cytidine nucleotides are 2'-O-methyl cytidine, 100% of all guanosine nucleotides are 2'-O-methyl guanosine, and 100% of all uridine nucleotides are 2'-O-methyl uridine.




Figure 1





Figure 2

(A)



(B)




Figure 3

Figure 3




Figure 4




Figure 5





Figure 6

7/15

A

ARC224



B

ARC226




Figure 7




Figure 8




Figure 9





Figure 10

(A)



(B)





Figure 11




$y = m3 + m1 / (1 + m2 / m0)$			$y = m3 + m1 / (1 + m2 / m0)$		
	Value	Error		Value	Error
m1	0.98779	0.28549	m1	0.66137	0.14883
m2	906.89	393.33	m2	455.42	180.42
m3	0.015219	0.0061697	m3	-0.0013715	0.0096011
Chisc	0.0017798	NA	Chisc	0.0029399	NA
R	0.99326	NA	R	0.98847	NA

$y = m3 + m1 / (1 + m2 / m0)$		
	Value	Error
m1	0.1179	0.092470
m2	453.7	655.26
m3	-0.0010367	0.005515
Chisc	0.0013325	NA
R	0.87169	NA

$y = m3 + m1 / (1 + m2 / m0)$			$y = m3 + m1 / (1 + m2 / m0)$		
	Value	Error		Value	Error
m1	0.88546	0.25576	m1	0.062477	0.040667
m2	1099.6	441.48	m2	359.44	472.88
m3	0.004482	0.003878	m3	0.0060492	0.0033376
Chisc	0.00071376	NA	Chisc	0.00047328	NA
R	0.99551	NA	R	0.87134	NA

Figure 12

(A)



(B)




Figure 13




Figure 14




Figure 15

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.